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Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of 
the metabolic syndrome and is defined as the accumulation of fat in the liver of 
patients who do not consume excessive alcohol. NAFLD has the potential to 
progress through the inflammatory phase of non-alcoholic steatohepatitis 
(NASH) to fibrosis, cirrhosis, and in some cases to liver failure or hepatocellular 
carcinoma (HCC). The pathogenesis of NAFLD was described as a two-hit 
model. The first hit consisting of hepatic lipid accumulation, from sedentary 
lifestyle, high fat diet, obesity, and insulin resistance. The second hit activates 
inflammatory pathways, oxidative stress, mitochondrial dysfunction with 
associated fibrogenesis. High fat diet (HFD)-induced model was used for our 
studies as NAFLD model which also mimics to human NAFLD. Apart from the 
nutritional factors, several lifestyle activities such as alcohol consumption, 
smoking and physical inactivity were implicated in the pathogenesis of metabolic 
disorders. Notably, heavy alcohol consumption (>50 g/day) was implicated in the 
pathogenesis of metabolic disorders leading to late-stage complications, 
including atherosclerosis and fatty liver disease. Heavy alcohol consumption 
leads to alcoholic fatty liver disease, but in contrast to the alcoholic fatty liver, 
evidence shows that moderate alcohol has beneficial effects on protection from 
type 2 diabetes, protection against the risk of major cardiovascular disease 








Starting from this background, the primary aim of the present study was 
to determine the effects of low, moderate and high alcohol (1 g/kg/day, 2 
g/kg/day, 6 g/kg/day) doses on the development of NAFLD in Sprague Dawley 
(SD) rats. It was hypothesized that low and moderate alcohol intake may protect 





The proposed research project is based on the hypothesis that long-term 
low and moderate alcohol protects the liver from progression to NAFLD. The 
general objective of this thesis is to investigate the in vivo and in vitro effects of 
alcohol on NAFLD induced by HFD-fed rat model. The specific objectives of this 
thesis are (i) To elucidate the serum and histopathological changes observed by 
alcohol treatments on in vivo model, (ii) To elucidate the possible mechanism(s) 
of action of low and moderate alcohol on controlling HFD-induced NAFLD in the 
liver, (iii) elucidate the possible mechanism(s) of action of low and moderate 
alcohol on controlling FFA-induced NAFLD in HepG2 cells, (iv) evaluating the 
effect of alcohol on FFA-induced NAFLD in HeLa cells (LKB1-deficient cells) (v) 
evaluating the effect of alcohol on FFA-induced NAFLD in HepG2 cells in 
absence of AMPK, (vi) evaluating the effects of alcohol on FFA-induced NAFLD 





In the present study, the protective effect of low and moderate alcohol on 
NAFLD were investigated in HFD-induced NAFLD rat model. The rats were 
weight matched and divided into six groups, each consisting of five to six rats. 
Treatment to the groups were done as following, standard diet to normal control, 
XVII 
 
and HFD to disease control and HFD with alcohol doses of 1 g/kg/day, 2 
g/kg/day and 6 g/kg/day for 15 weeks. At the end of the treatment, blood was 
collected from cardiac puncture and serum was extracted for serum biochemical 
estimations and liver tissue was collected for histopathological studies and 
various protein estimations involved in the lipid metabolism pathways. 
 
An in vitro model for finding the protective effect of low and moderate 
alcohol in FFA-treated HepG2 cells. HepG2 cells were treated with low (10 mM) 
and moderate alcohol (20 mM) with free fatty acids (FFA) 1 mM (Oleic acid 0.66 
mM and palmitic acid 0.33 mM) with final concentration of 1% serum-free BSA. 
Followed by some in vitro studies by inhibiting the AMPK, SIRT1 and LKB1 in 
separate studies for evaluating the individual role of AMPK, SIRT1 and LKB1 in 
protecting the HepG2 cells from FFA-induced NAFLD. The underlying molecular 
mechanism(s) were further investigated by focusing on the expression of various 





The marked rise in total cholesterol, LDL cholesterol, VLDL cholesterol, 
triglycerides, free fatty acids, ALT, AST in serum, as well as hepatic cholesterol, 
triglycerides of HFD-fed rats were significantly reduced by low and moderate 
alcohol treatment. Furthermore, the major proteins such as AMPK-α1, p-AMPK-
α1, LKB1, p-LKB1, SIRT1, ACC, p-ACC and SREBP1 were quantified. Low and 
moderate alcohol groups with HFD-diet have shown an increased expression of 
AMPK-α1, p-AMPK, LKB1, p-LKB1 proteins. Besides, the results of the in vitro 
experiments resembles the results observed in in vivo studies. Furthermore, the 




activation of AMPK-α1 and SIRT1. In contrast, the SIRT1 and AMPK-α1 
inhibitory studies indicate that low-to-moderate alcohol regulate the expression 





Overall, this study demonstrated that (i) chronic feeding of HFD to rats 
caused hepatic steatosis by accumulation the lipid in the liver which mimics the 
initial stage of NAFLD, (ii) Long-term feeding of low and moderate alcohol 
improved serum and hepatic lipid profile by inhibiting the progression to NASH, 
 
(iii) Low and moderate alcohol feeding over a long-term increases lipid 
metabolism by increasing AMPK-α1, SIRT1 and LKB1 proteins, (iv) alcohol 
groups with FFA treated HepG2 cells produced a similar result to that in vivo 
 
studies, (v) HeLa cells failed to reduce lipid synthesis proteins involved, due to 
the lack of LKB1 an upstream kinase for activating AMPK, (vi) Low and 
moderate alcohol increase SIRT1 in HepG2 cells( AMPK inhibited), likewise 
increase AMPK-α1 and LKB1 in FFA-treated HepG2 cells (SIRT1 inhibited). 






Future studies are required to find out the role of low to moderate alcohol on 
individual downstream proteins involved in regulating the lipid metabolism 
pathways. Furthermore, a more detailed studies are required on how low to 
moderate alcohol regulates the inflammatory pathways and oxidative stress, 
which play a major role in the pathogenesis of NAFLD. In addition, the role of 




studies. Apart from HepG2 cells, all the in vitro studies need to be done in VA-13 
cell lines for in-depth understanding of alcohol dehydrogenase-mediated alcohol 
































































































































1.1 Non-alcoholic fatty liver disease(NAFLD) 
 
Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized 
disease in which lipid accumulates in the liver in the absence of alcohol [1]. It is a 
clinico-pathological entity that comprehends liver disease spectrum which 
progresses from fatty liver to non-alcoholic steatohepatitis (NASH), fibrosis, and 
then to cirrhosis. 
 
1.1.1 Progressive stages involved in fatty liver disease 
 
 
NAFLD describes a range of conditions caused by a build-up of fat within 
liver cells. It is helpful to divide NAFLD into four stages for easy identification as 
below[1]: 
 
1.1.1.1 Fatty liver disease (FLD or hepatic steatosis) 
 
Fatty liver is defined by the presence of triglycerides (TG) 
accumulation in hepatocytes conventionally defined as the presence of 
lipid droplets within the cytoplasm in more than 5% of hepatocytes. 
 
1.1.1.2 Non-alcoholic steatohepatitis (NASH) 
 
NASH is a subcategory of NAFLD and is defined as the presence of 
hepatic steatosis and inflammation with hepatocyte injury. 
 
1.1.1.3 Liver fibrosis 
 
Any form of persistent hepatitis, including steatohepatitis, may 
eventually cause scar tissue (fibrosis) to form within the liver. When 
fibrosis first develops, often there are many liver cells that continue to 





1.1.1.4 Liver cirrhosis 
 
 
This is a serious condition where normal liver tissue is replaced by a lot of 
fibrosis. The structure and functions of the liver are badly disrupted. It is, in effect, 
like a severe form of liver fibrosis. Many liver conditions can lead to cirrhosis, 
including NAFLD. Severe cirrhosis can lead to liver failure. 
 
1.2 Etiology and pathogenesis of NAFLD: The nature and mechanisms 
 
 
NAFLD etiology and its progression is clearly multifunctional, complex and 
incompletely understood. NAFLD is associated with many different agents and 
conditions. These may be due to acquired insulin resistance, metabolism errors, 
medical conditions or surgeries associated with weight loss, various drugs and 
toxins [2]. Most cases of NAFLD are related to “Western lifestyle” i.e., nutrient 
abundance coupled with a sedentary lifestyle; however, genetic predisposition 
plays an important role, if not decisive, role in determining which individuals are at 
increased risk for development of NAFLD and for its progression. 
 
 
1.2.1 Genetic factors in NAFLD 
 
Over the years, a number of studies have implicated the role of genetic 
predisposition in NAFLD. It is clear that how ethnic differences play a role in 
affecting NAFLD, especially explained on the basis of diet or socioeconomic 
differences in NAFLD progression. A recent study shows a higher incidence of 
NASH in Hispanic origin in the US population relative to whites and low rate of 





racial heritage population in the US would be useful in future to identify them using 
racial origin genetic markers. This kind of accumulating data may ultimately be 
used for screening population and/or public health intervention strategies. The 
South Asian population is the next high risk for development of NAFLD [5, 6]. 
 
In recent studies, sample population obtained with well-defined NAFLD have 
been used for genome scans to discover gene variants that are more common in 
NAFLD patients than in normal population. Some groups examined single 
nucleotide polymorphism (SNP) variants in candidate genes and implicated in the 
regulation of lipid metabolism or relation with risk factors for NAFLD [7]. 
 
 
1.2.2 Environmental factors in NAFLD 
 
 
Exposure to environmental factors, especially dietary factors, is likely to 
contribute to the generation and accumulation of intrahepatic lipids [8]. Some 
studies suggest that specific dietary fats, such as trans-unsaturated fats, contribute 
to hepatic steatosis [9]. Contrarily, monounsaturated lipids such as oleic acid, 
linoleic acid, 33 or n-3 fatty acids decrease intrahepatic lipid accumulation and 
improve postprandial triglyceride levels, possibly by increasing peroxisomal activity 
and reduces damage by reactive oxygen species(ROS) [10]. The monosaccharide 
fructose is another dietary factor that contributes to hepatic steatosis. In a case-
controlled study, sugar-sweetened beverage consumption was associated with 
hepatic steatosis, and this association was independent to the degree of obesity 
 
[11]. In addition, consumption of total fructose was known to be associated with 





obesity and is associated with insulin resistance which is in-part due to decreased 
adiponectin (Figure 1.1). All these factors contribute to NAFLD development 
indirectly by incresing the de novo lipogensis and directly by increasing the FFA 




































Figure 1.1 Schematic representation of mechanisms of high fat diet-induced 





1.2.3 Pathogenesis of NAFLD 
 
The pathogenesis of NAFLD is based on 2-hit hypothesis. The ‘first hit’, 
hepatic steatosis is a prerequisite for histological diagnosis of NAFLD. Several 





fat diet and excess adipose lipolysis; (2) decreased fat export in the form of very 
low density lipoprotein-triglycerides; (3) decreased -oxidation of free fatty acids; and 
(4) increased de novo lipogenesis (DNL) [14]. All these factors increases the 
vulnerability of the liver to various possible ‘second hits’ such as inflammatory 
cytokines, oxidative stress, mitochondrial dysfunction which lead to steatohepatitis 
and/or fibrosis [15]. However, the insights on the role of free fatty acids (FFA) in 
promoting liver injury lead to modification of the theory. Hepatic fat accumulation 
was observed when there is an influx of FFA to the liver in obesity and insulin 
resistance. These FFA either undergo β-oxidation or are esterified with glycerol to 
form triglycerides, leading to hepatic fat accumulation. There is now substantial 
evidence that FFA can directly cause toxicity by activation of inflammatory 
pathways or by increasing oxidative stress [16]. 
 
 
1.2.3.1 Hepatic steatosis / Lipid accumulation 
 
 
Hepatic steatosis results from an imbalance in lipid flux. Factors that 
contribute towards hepatic fat accumulation include an increase in lipid supply from 
increased adipose tissue lipolysis and/or high dietary fat intake, a decrease in lipid 
oxidation, an increase in hepatic de novo lipid synthesis and decreased hepatic 
very low density lipoprotein (VLDL) secretion [17]. Lipid utilization in the liver for 
energy occurs by FFA oxidation which is inhibited by increased levels of malonyl-
CoA, as a result of insulin mediated activation of sterol regulatory element binding 
protein-1c (SREBP-1c) (Browning [18]. A second possible fate of hepatic lipid is the 





lipid export from the liver by incorporating triglyceride before being secreted. Hence 
hepatic fat accumulation can occur as a result of increased fat synthesis, increased 
fat delivery, decreased fat export, and/or decreased fat oxidation [19]. Modern diets 
containing trans-fatty acids (found in processed oils) and fructose which is a 
common sweetener, may also contribute to the pathogenesis of NAFLD. In 
humans, a high fructose diet is associated with increased insulin resistance and 
more severe hepatic inflammation and fibrosis in subjects with NAFLD[20]. 
 
 
1.2.3.2 The role de novo lipogenesis (DNL) in NAFLD 
 
 
In liver Hepatic de novo lipogenesis (DNL) is a fundamental biosynthetic 
pathway contributing to the lipids that are stored and secreted by hepatocytes [21]. 
The increase in lipogenesis in liver could increase the steatotic nature of NAFLD. 
Several studies have shown that diets enriched in both saturated fat and simple 
sugar carry a high risk of hepatic steatosis, at least in part, through enhanced 
DNL[22, 23]. In NAFLD patients about 59% of TG in livers were from FA flux 
(possibly from lipolysis in adipocytes), 26% from DNL and 15% from the diet [24]. 
This is supported by data analysing the FA composition of TGs in subjects with and 
without NAFLD, showing increased levels of saturated FAs in subjects with NAFLD 
pointing toward DNL as the source, due to the major product of DNL being 
saturated FAs [25]. In hepatic insulin resistance, DNL regulate a transcription factor 
sterol regulatory element-binding protein-1 (SREBP1). DNL enzymes are also 
regulated by glucose through the action of a second transcription factor, 





ChREBP promote hepatic DNL in response to high carbohydrate feeding, 
hyperglycaemia, and hyperinsulinemia[19]. 
 
1.2.3.3 The role of sterol regulatory element-binding proteins (SREBPs) in NAFLD 
 
 
The sterol regulatory element-binding proteins (SREBPs) are a family of 
membrane-bound transcription factors synthesized in the endoplasmic reticulum 
(ER) as precursors with 125 kD. Proteolytic cleavage then allows the accumulation 
of active SREBP in the nucleus. SREBP-1c, the predominant isoform in the liver is 
one of three SREBP isoforms (SREBP-1a, SREBP-1c, and SREBP-2) and 
preferentially affects the transcription of genes that regulate de novo lipid synthesis, 
although SREBP2 regulates [26]. SREBP1a is expressed only at very low levels in 
the liver of adult mice, rats, and humans. SREBP1c. Enzymes that catalyze the 
synthesis of fatty acids, TG, and NADPH required for fatty acid synthesis are 
regulated by SREBP-1c. The typical genes regulated by SREBP-1c are ATP-citrate 
lyase, acetyl-coenzyme A (acetyl CoA) carboxylase, fatty acid synthase, ELOVL6 
(elongation of long chain fatty acids family member 6), stearoyl-CoA desaturase, 
glycerol-3-phosphate acyl transferase, malic enzyme, and glucose 6-phosphate 
dehydrogenase [27]. In vivo transgenic model demonstrated that overexpression of 
SREBP-1c in the liver, which leads to the development of hepatic steatosis due to 
the increase in lipogenesis [28]. Increased rates of hepatic fatty acid synthesis 
contribute to the development of hepatic steatosis in rodent models of insulin-
resistance and obesity. In ob/ob mice deletion of SREBP-1c gene results in an 







role of SREBP-1c in the hepatic steatosis exhibited in the ob/ob mouse, a model of 
insulin resistance [29]. 
 





Carbohydrate regulatory element-binding protein (ChREBP), is a 
transcription factor that is independently activated by glucose rather than insulin. In 
contrast to SREBP1c, ChREBP is activated by the postprandial rise in glucose 
delivery to hepatocytes. It activates liver pyruvate kinase, which generates 
pyruvate, a source of acetyl-CoA, from phosphoenolpyruvate, as well as genes 
involved in fatty acid synthesis [30]. When glucose is abundant, adenosine 
monophosphate kinase (AMPK) is suppressed, leading to nuclear translocation of 
ChREBP and induction of glucose-responsive genes. ChREBP activity is activated 
by dephosphorylation [31]. ChREBP target genes include not only enzymes of 
glycolysis and lipogenesis that predispose to hepatic steatosis, but also glucose 6-
phosphatase (G6PC), which catalyses the final reaction in glucose production, and 
glucokinase regulatory protein (GCKR), which inhibits hepatic glucose uptake [32]. 
Transcriptional induction of G6PC and GCKR manifests as hepatic glucose 
intolerance or insulin resistance (IR) [33]. Inhibition of ChREBP in liver of ob/ob 
mice, lipogenesis and triglyceride (TG) synthesis are decreased. As a result, the 
improvement of blood glucose levels was done by the restored inhibition of genes 
from the gluconeogenic pathway (G6Pase and PEPCK) by insulin. Correction of 
hepatic steatosis also leads to decreased levels of plasma TG and non-esterified 




glycogen synthesis is enhanced, therefore contributing to the decrease in blood 
glucose concentrations was observed [34]. 
 
1.2.3.5 The role of AMPK in NAFLD 
 
The liver plays a dominant role in the maintenance of energy storage and 
glucose homeostasis, knowledge on physiology as well as physiopathology of 
hepatic energy metabolism is required for our understanding of whole-body 
metabolism. The synthesis and utilization of hepatic carbohydrate, lipid and protein 
are tightly regulated according to our daily needs. AMPK is considered as a cellular 
energy sensor and is important to acquire knowledge on the mechanism by which 
hepatic AMPK coordinates hepatic energy metabolism. AMPK has been implicated 
as a key regulator of physiological energy dynamics by limiting anabolic pathways 
and by facilitating catabolic pathways. Activation of hepatic AMPK leads to 
increased fatty acid oxidation and simultaneously inhibition of hepatic lipogenesis, 
cholesterol synthesis and glucose production. The identification of AMPK targets in 
hepatic metabolism should be useful in developing treatments to reverse metabolic 
abnormalities of type 2 diabetes and the metabolic syndrome. The positive effects 
of AMPK are indicated by arrows and the inhibitory effects of AMPK action was 



















































Figure 1.2 Physiological targets of AMPK (Adapted and modified from[35]) 
AMPK protein plays a critical role in sensing energy availability at the cellular 
level. Upon exposure to low glucose or decreased energy stores, AMPK inhibits 
mRNA translation and protein synthesis of pathways that are nonessential in the 
short term. In turn, during times when food is plentiful, AMPK activity is inhibited, 
mRNA translation is up-regulated, and the cells and organism can grow in size [36, 
37]. With caloric excess, there is fatty acid excess and insulin resistance fuelling 
hepatic triacylglycerol synthesis and steatosis. Excess calorie intake and lower 
adiponectin reduces AMPK activation, promoting hepatic stellate cell proliferation 
and generation of reactive oxygen species in the liver, leading to conversion from 






pathways, lower adiponectin levels reduce AMPK in podocytes to promote 
podocyte foot process effacement and albuminuria [38]. 
 
Various studies on humans and animal models have suggested that efforts 
to enhance insulin sensitivity might improve fatty liver disease. It has been 
demonstrated that hepatic AMPK activation abolishes hyperglycaemia in diabetic 
ob/ob and STZ-induced diabetic mice by suppression of gluconeogenesis [39]. 
Similarly, adiponectin restores insulin sensitivity and decreases hepatic steatosis by 
lowering TG content in liver of obese mice [40]. The adiponectin activation is linked 
to activation of hepatic AMPK, ultimately leading to decreased fatty acid 
biosynthesis and increased mitochondrial fatty acid oxidation [41]. The role of 
AMPK has been confirmed by the decrease in liver TG content in lean and obese 
rodents during AICAR infusion and treating with direct AMPK activator[42]. Recent 
studies demonstrated that resveratrol improves insulin sensitivity and protects 
against lipid accumulation in diabetic and high fat feed animals with activation of 
hepatic AMPK [43]. Activation of AMPK and adiponectin may inhibit HSCs 
proliferation and hepatic fibrosis via multiple molecular mechanisms and drugs 
activating hepatic AMPK may have an additional rationale in their antifibrogenic 
properties. In addition, evidence suggest that SIRT1 and AMPK regulate each 
other, share similar signalling pathways, and modulate many common targets [44]. 
SIRT1 is a nicotinamide adenine dinucleotide(NAD+) dependent class III histone 
deacetylase and acts as part of the de-acetylation reaction producing nicotinamide 
 
[45]. The de-acetylation of proteins and histones results in an up or down 




1.2.3.6 The role of SIRT1 in NAFLD 
 
Liver is one of the key organs where SIRT1 plays a pivotal role in the 
regulation of lipid metabolism and inflammation. The regulatory action of 
deacetylation activity of SIRT1 has been shown to have a positive impact on the 
pathophysiological mechanisms of NAFLD. The effects of SIRT1 are: healing 
activity on insulin sensitivity, there by ameliorating regulation, its antihyperlipidemic 
activities on lipid homeostasis via the adipose tissue of liver and skeletal muscles, 
and anti-inflammatory activities. 
 
Accumulating evidence suggest that SIRT1 and AMPK regulate each other, 
share similar signalling pathways and modulate many common targets [44]. Studies 
in cultured hepatic cells and in animal liver have provided evidence that SIRT1 is 
able to stimulate AMPK activity via modulation of liver kinase B1 (LKB1), an 
upstream AMPK kinase [46]. On the other hand, activation of AMPK via LKB-1 
leads to increased cellular NAD+ levels, which subsequently activates SIRT1 
signalling [47, 48]. Thus, this unique SIRT1-AMPK axis participates in regulating 
various lipid metabolism and inflammation pathways [48]. 
 
1.2.3.7 The role of LKB1 in NAFLD 
 
Liver kinase B1 (LKB1), known as a serine/threonine kinase, has been 
identified as a critical cancer suppressor in many cancer cells. It was first 
discovered in 1998 in Peutz-Jeghers Syndrome [49]. Initial studies, on LKB1 
identified a little similarity to other protein kinases. LKB1 can regulate the activity of 






is a master upstream kinase of AMP-activated protein kinase (AMPK)-related 
protein kinases, and possesses versatile biological functions [50]. 
 
AMPK plays a central role in the regulation of whole-body energy 
metabolism, and its activation is beneficial for protecting the body from metabolic 
diseases, such as type 2 diabetes and obesity. Mutations of AMPK can lead to 
cardiac hypertrophy and arrhythmia. Recent findings have identified that LKB1 is an 
important upstream kinase of AMPK cascade in mammalian cells [51]. LKB1 can 
phosphorylate Thr172 on the activation loop of AMPK catalytic subunit and 
subsequently activates AMPK. In addition, inhibition of LKB1 activity in cells 
simultaneously abolishes the activation of AMPK by different stimuli [52]. LKB1-
deficient murine embryonic fibroblasts show nearly complete loss of Thr172 




1.2.3.8 The role of peroxisome proliferator-activated receptor (PPAR)α in NAFLD 
 
 
Peroxisome proliferator-activated receptor (PPAR) α is a ligand-activated 
transcription factor that is abundantly expressed in liver, which regulates lipid, 
glucose and energy homeostasis and controls body weight and vascular 
inflammation. PPARα is expressed at high levels in tissues that catabolize fatty 
acids, notably liver, skeletal muscle, and heart and at lower levels in other tissues, 
including pancreas [54]. In a clinical study with 125 subjects with suspected 
NAFLD, liver PPARα mRNA expression was found to be lower in subjects with 
NASH compared to subjects without NASH. Furthermore, a progressive decrease 




fibrosis stage. A rodent study with PPARα -null mice fed with HFD an increased 
steatosis, oxidative stress, and inflammation when compared to normal wild type 
mice, demonstrate that inhibition of PPARα functions may increase susceptibility to 
high fat–induced NASH. Administering PPARα agonists to rats not only prevents of 
MCD diet induced steatosis by preventing intrahepatic lipid and lipoperoxide 
accumulation, but also reverses hepatic fibrosis by decreasing the expression of 
fibrotic markers and reducing the number of stellate cells [55, 56]. An increased 
PPARα plays a role in modulation of hepatic steatosis by upregulating FA oxidation, 
reduction in the toxicity of FAs, and its anti-inflammatory effect. 
 
1.3 Current therapeutic strategies for NAFLD 
 
 
To date, no single therapy has been approved for treating NAFLD, but a 
growing consensus suggests that only patients with NASH require treatment and 
only they should be the targets of future clinical trials. Even so, patients with other 
forms of liver disease may be at risk for other complications of metabolic 
syndrome, and treatment for the underlying components of metabolic syndrome 
should be addressed. Several pharmaceutical agents have been used for the 
treatment of NASH; however, initial management must be focused on lifestyle 
modification and the reversal of conditions associated with NAFLD [57]. 
 
 
1.3.1 Lifestyle modification and weight loss 
 
Life style modification including increased physical activity and weight loss 
management could be achieved by dietary control. The pathophysiological basis 




tissue, which decreases Insulin resistance. Exercise can also improve muscular 
insulin sensitivity, which may improve the impact of IR on NAFLD. A few trials 
have also shown a significant reduction in ALT values in patients with biopsy 
proven NAFLD where they are put on calorie-restricted diets with or without 
exercise [57-59]. 
 
In addition to exercise and diet, few studies have investigated the use of 
medication for weight loss. A clinical trial using orlistat, an enteric lipase inhibitor, 
showed a mean decrease in body weight and significant reductions in serum 
transaminase levels in obese patients with NASH [60]. A recent study from the 
Swedish Obese Study Group suggests that bariatric surgery can be associated 
with improved long-term outcomes in terms of cardiovascular risk factors such as 
diabetes mellitus, hypertriglyceridemia and hypertension compared to a 
conventional weight loss group[61]. In fact, another study by Dixon et al. showed 
that NASH resolved in 82% of patients undergoing laparoscopic adjustable 
gastric banding (LAGB) [62]. 
 
1.3.2 Bariatric surgery 
 
NAFLD per se is not an indication for bariatric surgery [63]. But now a days, 
among morbidly obese patients an increasing bariatric surgery was an option 
for controlling NAFLD. Bariatric surgery-induced weight loss appears to have 
beneficial effects on lipid profile, hepatic steatosis, steatohepatitis, as well as 
reducing long-term mortality[64]. From a meta-analysis of clinical trials have 
confirmed that NAFLD patients undergoing bariatric surgery reported that 
steatosis resolved in 91.6 %, steatohepatitis improved in 81.3 %, and fibrosis in 




patients with NASH, and before any further recommendations are made, a 
more robust data from random clinical trials are needed. 
 
 
1.3.3 Treating insulin resistance 
 
Drugs that enhance insulin action are a logical approach to treat NAFLD 
because insulin resistance is present in most patients [66, 67]. Metformin, 
thiazolinediones, rosiglitazone and pioglitazone, have been tested in several pilot 
studies. Metformin is now positioned as the first-line therapy, because of its low 
cost, weight-reducing effect, preventive effect on cardiovascular event, and 
safety profiles. Unfortunately, metformin has no data regarding improvement in 
liver enzymes and histology in NASH/ NAFLD, although it is associated with a 
reduced incidence of HCC and extrahepatic malignancies. An improvement in 
serum aminotransferase levels and hepatic steatosis was observed in 
rosiglitazone patients, but it failed to control the inflammation or fibrosis [68]. 
Pioglitazone significantly improved aminotransferase levels, steatosis, 
ballooning, and inflammation in patients with NASH who had impaired glucose 
tolerance or T2DM. The NASH improved with pioglitazone in 73% compared with 
24% of placebo-treated patients (p<0.001) and there was a trend toward 
improvement in fibrosis [69]. 
 
 
1.3.4 Anti-oxidant drugs 
 
Increased oxidative stress has been reported in both patients with NAFLD 
and patient with cardiovascular risk factors. Thus, oxidative stress represents a 




therapeutic efforts have been made using several pharmacological agents proven 
to be anti-oxidants such as vitamin E, vitamin C and betaine [70]. Oxidative stress 
is considered to be one of the key mechanisms leading to hepatocellular injury and 
disease progression. Vitamin E is currently the most widely assessed antioxidant 
and has been investigated as a potential treatment for NASH. Based on the 
available evidence, vitamin E (RRR-α-tocopherol) is currently only recommended in 
NASH adults without diabetes or cirrhosis and with aggressive histology [71]. 
 
 
1.3.5 Hepatoprotective agents 
 
Historically speaking, several compounds have been claimed to have a 
theoretical protective effect on the liver cells, which in some patients could be 
clinically relevant and had been applied in practice either on empiric, local 
experience, or traditional management basis. Some of these products are available 
as nutritional supplements and may have a convincing rationale, whereas some 
others such as “essential phospholipids (EPL) may have evidence furnished on 
research basis. These medicines included N-acetyl cysteine, choline bitartrate, 
artichoke extract, dandelion root, taraxacin and inulin, turmeric (curcumin), milk 
thistle extract (silymarin), essential phospholipids, UCDA, vitamin E, S-adenosyl 
methionine, Ganoderma spores, traditional Chinese medicine, including Gansu and 
some herbal compounds [72]. The myriad of hepatoprotective effects exerted by 
the hydrophilic natural bile acid ursodeoxycholic acid (UDCA) led investigators to 
test this agent in both experimental models and patients with NAFLD [73]. Some 
conceptual support for the potential usefulness of UDCA therapy in NAFLD comes 




[73, 74]. Promising effects were seen in rodents and in pilot human trials [75-77], 
but two randomized controlled trial (RCTs) involving 27 and 166 patients, 
respectively, did not show positive effects either in liver chemistry or in histology 
[78, 79]. Phosphatidylcholine (PC), a main component of EPL, is one of the most 
important support nutrients for the liver and is considered as a universal building 
block for cell membranes, which regulate most of the activities that make up life. 
PC helps recovery and maintenance of the consistency of the hepatocytes; it 
activates the phospholipid-depending enzymes and improves lipid metabolism by 
accelerating synthesis of lipoproteins in the liver [80]. EPL treating 324 patients of 
NAFLD or NAFLD associated with comorbid clinical conditions such as T2DM and 
hyperlipidaemia. It was concluded from the study that there was a significant 
improvement for all symptoms, general and gastrointestinal, and a significant 






The term alcohol is conventionally used to refer ethyl alcohol (alcohol) which 
has a molecular formula of C2H6O and molecular weight of 46.07 g/mol. Alcohol will 
be present in any yeast habitat and also commonly be found in overripe fruit 
 
[82]. Alcohol is also produced during the germination of many plants as a result of 
natural necrobiosis [83]. It is a colour less, volatile, flammable liquid with a specific 
gravity of 0.785. It is the principal type of alcohol found in alcoholic beverages and 








uses, alcohol is a psychoactive drug and one of the oldest recreational drugs used 
by humans. 
 
1.4.1 Pharmacokinetics of alcohol 
 
Alcohol is a commonly used recreational drug that has many important 
health consequences. Therefore, it is imperative to understand the pharmacokinetic 





Oral administration of alcohol determines the rate and proportion at which 
alcohol reaches the blood and body tissues. Alcohol is a small water soluble 
molecule that can cross cell membranes, it is absorbed from both the stomach (20 
%) and the upper small intestine (80 %) [84, 85]. The rate of absorption vary 
significantly in both intra individual and inter individual even at standardised 
conditions [86]. The speed of absorption is also influenced by variation in portal 
blood flow; because alcohol crosses the biological membrane by passive diffusion 
thus good blood flow will maintain the concentration gradient and promote 
absorption [87]. The rate of alcohol absorption depends on whether food is 
consumed at the same time and the macronutrients within that food. Foods 
containing fat and protein slow gastric emptying and therefore consumption of 
alcohol with these foods can slow alcohol absorption [88]. The rate of alcohol 
absorption is also determined by the type of drink consumed. Drinks with alcohol 
content between 20-30% are absorbed quickest. Whereas, drinks with a higher 





irritates the gastric mucosa increasing mucus secretion and decreasing gastric 
emptying. Thus, drinks with alcohol content above 30% can cause a faster rise in 
BAC if served diluted with a mixer; especially carbonated drink can also increase 
the rate of absorption than if they are served without dilution [84]. 
 
 
1.4.1.2  Distribution 
 
 
Alcohol enters the portal vein and the liver before entering the general 
circulation. Thus the bioavailability of alcohol is reduced by first pass metabolism. 
Majority of alcohol oxidation occurs via oxidation by alcohol dehydrogenase (ADH) 
in the liver hepatocytes. But a small portion of alcohol oxidation occurs in gastric 
mucosa by gastric ADH [87]. The absorbed alcohol which escapes first pass 
metabolism enters the systemic circulation and is rapidly distributed throughout the 
body tissues via the blood plasma until an equilibrium between the blood alcohol 
content and tissue concentration is reached [85]. The pharmacokinetics of alcohol 
will be influenced by the total body water, because it determines the volume of 
distribution available for alcohol distribution within the body. Therefore body 
composition is an important consideration in pharmacokinetic studies because both 






Liver is the main organ responsible for metabolizing alcohol. In human’s, 
elimination of alcohol is done by various mechanisms. A small portion of absorbed 




The majority of alcohol (90%) is eliminated via ADH, the major pathway of 
oxidative. In general alcohol metabolism is achieved by both oxidative pathways, 
(ADH, cytochrome P450, and catalase enzymes) and non-oxidative pathways. 
 
1.4.3.1  Oxidative Pathways 
 
The process of alcohol oxidation involves at least three distinct enzymatic pathways  
[92]. They are 
 
• Alcohol dehydrogenase ADH 
 




Each of these pathways produces a specific metabolic and toxic disturbances and 
all these results in the production of acetaldehyde, a highly toxic metabolite. 
 
ADH, cytochrome P450 2E1 (CYP2E1), and catalase all contribute to oxidative 




































Alcohol Dehydrogenase (ADH) 
 
 
Alcohol metabolism by the oxidative pathway is majorly involved by ADH 
(present in cytosol), an enzyme with different variants (isozymes). ADH converts 
alcohol to acetaldehyde. This reaction involves an intermediate carrier of electrons, 
nicotinamide adenine dinucleotide is an (NAD+) which is reduced by two electrons 
to form NADH [94]. In humans five classes of ADH has been categorized based on 
the kinetic and structural properties (Table 1.1). At higher concentrations, alcohol is 
eliminated at the higher rate because of the presence of enzyme systems with 
higher activity levels (Km) 2 , such as class II ADH, β3-ADH( encoded by ADH4 and 
ADH1B genes respectively) and CYP2E1 [95]. Alcohol oxidation causes damage 






The Oxidation of alcohol in liver is also contributed by cytochrome P450 
isozymes, including CYP2E1, CYP1A2, and CYP3A4 which are predominantly 
present in the liver microsomes. During chronic alcohol consumption, CYP2E1 is 
induced and plays an important role in metabolizing alcohol to acetaldehyde at 
elevated alcohol concentrations. In addition, alcohol oxidation that occurs in other 
tissues such as brain is CYP2E1-dependent, where ADH activity is low. CYP2E1 
also produces reactive oxygen spices (ROS), including hydroxyethyl, superoxide 







It is another enzyme which is located in peroxisomes, is capable of oxidizing 
alcohol in vitro in the presence of hydrogen peroxide(H2O2) generating the enzyme 
complex NADPH oxidase or the enzyme xanthine oxidase. It is considered as a 
minor pathway of alcohol oxidation ,except in the fasted state [96]. 
 
Table 1.1 Nomenclature for ADH genes and enzyme subunits [adapted and 
modified from [94]] 
 
Class Gene Nomenclature Protein Km Vmax Tissue Alcohol 
    mM   catalytic 
       efficiency 
 New Former      
I ADH1A ADH1 α 4.0 30 Liver Low 
 ADH1B*1 ADH2*1 β1 0.05 4 Liver, High 
      Lung  
 ADH1B*2 ADH2*2 β 2 0.9 350  High 
 ADH1B*3 ADH2*3 β 3 40.0 300  Low 
 ADH1C*1 ADH3*1 γ 1 1.0 90 Liver, High 
      stomach  
 ADH1C*2 ADH3*2 γ 2 0.6 40  High 
II ADH2 ADH4 Π 30.0 20 Liver, Low 
      Cornea  
III ADH3 ADH5 χ >1,000 100 Most Very low 
      Tissues  
IV ADH4 ADH7 Σ(μ) 30.0 1,800 Stomach High 
V ADH5 ADH6 Not ? ? Liver, Nit 
   identified   Stomach identified 
 
The ADH1B and ADH1C genes have several variants with differing levels of 
enzymatic activity. Km is a measurement used to describe the activity of an 
enzyme. It describes the concentration of the substance upon which an enzyme 
acts that permits half of the maximal rate of reaction. Vmax is a measure of how fast 




1.4.3.2 Non-oxidative Pathways 
 
 
Alcohol metabolism through non-oxidative pathways occurs to a minimal 
 





oxidative metabolism of alcohol is done by at least two pathways. When alcohol 
reacts with fatty acids it leads to formation of molecules called fatty acid ethyl 
esters (FAEEs) which are weak organic acids that play a functional role in human 
cells. The other non-oxidative pathway results in formation of a type of fat molecule 
containing phosphorus (phospholipid) known as phosphatidyl alcohol (Figure 1.4). 
After alcohol ingestion, FAEEs are detectable in serum and other tissues and 
persist a longer time after alcohol is eliminated. The metabolic pathways of alcohol 
metabolism are correlated. Alcohol oxidation inhibition by compounds that inhibit 
ADH, CYP2E1, and catalase result in an increase in the non-oxidative metabolism 



































Figure 1.4 Non-oxidative pathways of alcohol metabolism 








About 95% of ingested alcohol in the body will be eliminated through 
metabolism done by liver. The remaining alcohol in the body is eliminated through 
breath, urine, sweat, faeces and saliva. The body uses several different metabolic 
pathways in oxidation of alcohol to acetaldehyde to acetic acid to carbon dioxide 
and water [98]. Fair consistent rate of alcohol metabolism takes place in healthy 
people. A person will eliminate one average drink or 5oz (15ml) of alcohol per hour 
which is influenced by several factors. The rate of elimination tends to be higher 
when the blood alcohol concentration in the body is very high. Also, chronic 
alcoholics may (depending on liver health) metabolize alcohol at a significantly 
higher rate than the average. Finally, the body's ability to metabolize alcohol quickly 
tend to diminish with age [98]. 
 
1.4.2 Pharmacodynamics of alcohol 
 
 
Alcohol affects a number of physiological systems. The pharmacological 
effects of alcohol depend upon the concentration of alcohol that is being consumed 
by the people. The clinical response ranges from mild anxiolytic effect, disinhibition 




1.4.2.1 Standard drink and drinking patterns 
 
 
A clear understanding of what constitutes a ‘standard drink’ is essential for 
the accurate interpretation and application of alcohol guidelines. The present 




drink as containing 10 g of alcohol (equivalent to 12.5 mL of alcohol). The notion of 
a standard drink issued widely, but the definition varies from country to country [99] 
 
. Accordingly, the alcohol drinking pattern as defined below is divided into (i) light 
alcohol drinking; (ii) moderate alcohol drinking; (iii) heavy alcohol drinking; and (iv) 
binge alcohol drinking 
 
Light alcohol drinking: Alcohol consumption up to ONE standard drink per day 
(ONE Standard drink = 10 g of alcohol) by an average 60 kg adult. 
 
Moderate alcohol drinking: Alcohol consumption up to TWO standard drinks per 
day by an average 60 kg adult. 
 
Heavy alcohol drinking: Alcohol consumption more than TWO standard drinks per 
day by an average 60 kg adult. 
 
Binge alcohol drinking/single occasion of drinking: Drinking up to FIVE or more 
standard alcohol drinks in a single occasion [100] 
 




The levels of alcohol in your bloodstream is referred to as blood alcohol 
concentration (BAC). It is also called blood alcohol content, or blood alcohol level 
and is most commonly used as a metric of alcohol intoxication for legal or medical 
purposes. BAC is determined by how quickly alcohol is absorbed, distributed, 
metabolized, and excreted. 
 
BAC is usually expressed as a percentage of alcohol in the blood in units of 
mass of alcohol per volume of blood. For humans in most of the countries the legal 




on its concentration in the blood (blood alcohol concentration [BAC]) over time. The 
effects of alcohol with different BAC’s is mentioned below Table 1.2. The factors 
effecting the BAC levels are empty stomach, body fat, sex, inexperience 
 
Table 1.2 BAC Vs effects of alcohol [102] 
 
BAC Effect of Alcohol 
Level  
BAC = 0.02 to No loss of coordination, slight euphoria and loss of shyness. 
0.03% Depressant effects are not apparent. 
BAC = Feeling of wellbeing, relaxation, lower inhibitions, and sensation 
0.04 to of warmth. Euphoria. Some minor impairment of reasoning and 
0.06% memory, lowering of caution. 
BAC = Slight impairment of balance, speech, vision, reaction time, and 
0.07 to hearing. Euphoria. Reduced judgment and self-control. Impaired 
0.09% reasoning, memory, and sense of cautiousness. 
BAC = Significant impairment of motor coordination and loss of good 
0.100.125% judgment. Speech may be slurred; balance, vision, reaction time, 
 and hearing will be impaired. 
BAC = Gross motor impairment and lack of physical control. Blurred 
0.130.15% vision and major loss of balance. Euphoria is reducing, and 
 dysphoria is beginning to appear. 
BAC = Dysphoria predominates, nausea may appear. The drinker has 
0.160.20% the appearance of a “sloppy drunk.” May vomit. 
BAC = 0.25% Needs assistance in walking; total mental confusion. Dysphoria 
 with nausea and some vomiting. Death has occurred at this level, 
 and it is considered a medical emergency. 
BAC = Loss of consciousness. 
0.30%  






The Blood alcohol concentrations similar to our alcohol doses from 
previously published papers are as follows. The BAC concentration of doses similar 
to the doses used in our studies (1.2 g/kg and 1.6 g/kg) showed a maximum 
concentration of 0.15 mg/dL at 20 minutes after alcohol administration and reached 




different doses (1.16 g/kg/BW, 2.44 g/kg/BW, 3.38 g/kg/BW) via intra gastric 
infusion, the low alcohol rats (1.16 g/kg/BW) showed a peak BAC 1.1 mg/ml at 60 
minutes and reached base line by 240 minutes. Whereas, the moderate alcohol 
group showed a peak of 1.5 mg/ml at 150 minutes of BAC and remained elevated 
 
through 240 minutes [104]. Based on the above alcohol doses and BAC 
concentrations in rodents via different routes of alcohol administration was similar 
to the standard drink that was recommended for humans. 
 
1.4.2.3 Benefits of alcohol consumption 
 
Two decades ago, the first quantitative estimate of long-term safe 
consumption of alcohol based on public health perspective was presented. The 
proposed acceptable daily intake (ADI) for a healthy and nondependent male was 
set at 0.1 g/kg bodyweight. Lemmens et al (1995) [105] demonstrated the found 
empirical evidence for four types of dose-response curves for the effects of alcohol 
consumption on health : (a) a linear curve, (b) a convex or exponential curve, (c) a 
curve with a threshold, and (d) a U-shaped risk curve. Particular attention is often 
focused on the U- or J-shaped curve that suggests that light-to-moderate drinking 
produces a protective effect. Such an inverse relationship indicates a reduction of 
risk for both light and moderate consumers and an excess risk not only for 
excessive users. 
 
The psychological benefits of drinking include the reduction of tension, self-
consciousness, stress, fear, pain, and depression, and the increase in affective 














A numerous studies has demonstrated a U-shape and J-shape relation 
between alcohol intake, cardiovascular disease and all cause of mortality [107, 
108]. Friesema et al (2007) has demonstrated that non alcoholics and former 
drinkers were less healthy than the moderate drinkers [109]. The levels of alcohol 
consumption that have been associated with protective effects range as widely as 
from one drink every other day to about five drinks per day [110]. There are 
indications that low-level consumption may be particularly protective if alcohol is 
taken with meals [111]. 
 
The protective effect has been demonstrated across all age ranges [112, 113] 
although it appears stronger for older people,[114, 115] and it is present for both 
men and women [107, 116, 117]. The cardioprotective effects of moderate alcohol 
might be due to increase in HDL-cholesterol levels [118] . 
 
 
Type 2 diabetes 
 
Low to moderate alcohol consumption was associated with reduced risk of 
T2DM among normal weight and overweight individuals. However, there was no 
significant association between alcohol consumption and risk of T2DM in obese 
individuals. Analyses categorised alcohol into various groups, there appeared to be 
an approximate U-shaped relationship between alcohol consumption group and risk 




obese group. A study of 84,941 female nurses reported a U-shaped association 
between alcohol consumption and risk of T2DM over 16 years of follow up in those 
with a body mass index (BMI) < 25 kg/m2 but an inverse association in the 
overweight and the obese [119]. However, in the same study carried out 6 years 
earlier in 109,690 nurses aged 25 to 42 years, they reported an inverse relationship 
between alcohol intake and incidence of T2DM in both the obese (BMI ≤ 30 kg/m2) 
and non-obese[120]. 
 
A randomized controlled clinical trial concludes that in post-menopausal 
women drinking at 30g/d (2 drinks per day) of alcohol has beneficial effects on 
insulin and inulin sensitivity in normal women [121]. Schrieks etal (2015) from his 
meta-analysis and systemic review concludes that moderate alcohol consumption 
may decrease fasting insulin concentration among non-diabetic subjects, which 
was more among women [122]. It has also been hypothesized that regular 
moderate alcohol consumption promotes insulin sensitivity of skeletal muscle, 
resulting in a protective effect for risk of T2DM [123]. 
 
 
Protection against cognitive loss 
 
Low to moderate alcohol consumption in older women is associated with better 
cognitive performance than not drinking. Differences were seen across all the cognitive 
domains that were tested, including global cognition, speed of information processing, 
and verbal memory. Approximately 11,000 women were followed up with serial 
cognitive testing over 2 years. Those with low alcohol intake (up to 7 U per week) 
performed better than non-drinkers on tests of general cognitive function and verbal 




alcohol intakes did not differ significantly in cognitive performance from non-
drinkers [124]. Another study followed up a community sample of more than 1,200 
older people (61% women) for 7 years and found low to moderate alcohol intake to 
be associated with attenuated decline in MMSE score and trail making but no 
effects on memory (delayed recall)[125]. If low to moderate alcohol protects against 
cognitive decline, it might be hoped that this would lead to a reduced risk of 
dementia. One study (833 subjects) has claimed benefit in terms of reduced risk of 
Alzheimer’s disease with wine (up to 3 U per day) but a trend toward greater risk 
with spirits or beer [126]. There are a number of potential mechanisms by which low 
to moderate alcohol intake might protect against cognitive decline in older people. 
The alterations in lipids [127], lower fibrinogen levels [128] and inhibition of platelet 
aggregation [129] that occur with low to moderate alcohol intake might be expected 
to reduce the risk of ischemic cerebrovascular events. The hypothesized 
mechanism by which low to moderate alcohol intake might protect against cognitive 
decline in older people is many alcoholic beverages contain antioxidants that could 
theoretically protect against vascular and Alzheimer’s pathology by reducing 
oxidative stress [130]. 
 
1.5 Experimental models of NAFLD 
 
 
1.5.1 In vivo models of NAFLD 
 
 
The clinical spectrum of NAFLD develops over years and results from an 
inter play of several risk factors including over nutrition and /or inappropriate dietary 





sedentary life styles and genetic susceptibility , all leading to multiple molecular 
alterations in the humans [131]. Researchers have attempted to introduce a 
suitable rodent model (mice and rat) of NAFLD imitating at least the most important 
pathogenic and histological features of NAFLD. Apart from NAFLD model, animal 
models are designed for different stages of disease progression like NASH or even 
fibrosis and cirrhosis. Furthermore these models should also display metabolic 
abnormalities like overweight, insulin resistance, impaired glucose tolerance, 
dyslipidemia and altered adipocytokines profiles as well as the increased bacterial 
endotoxin levels frequently found in patients with NAFLD [131]. 
 
1.5.1.1 Dietary rodent models of NAFLD 
 
High fat diet-induced NAFLD: Animals’ feeding with HFD 30-60% fat is commonly used 
rodent model for human relevant NAFLD. However, the amount of fat, the composition 
of the HFD and the duration of the diet regime may cause different responses with 
respect to obesity, impaired glucose tolerance, dyslipidemia, increased lipogenesis 
(SREBP1c, LXR, and PPARγ), production of proinflammatory cytokines depending on 
the species, strain and gender [132, 133]. In HFD feeding rat model (71% energy from 
fat, 11% from carbohydrates and 18% from protein), the histopathology of these rats 
resembles to human NASH, increased insulin levels, insulin resistance, hepatic 
intracellular lipid accumulation, oxidative stress, collagen type I and α1 (I) procollagen 
mRNA upregulation, an increase in TNF levels and abnormal mitochondria was seen in 
these rats [134]. There are inter strain differences in susceptibility of rats to HFD. Male 
rats of three different strains (Wister, Lewis, and Sprague-Dawley) were fed with HFD 





weeks showed that all three stains develop steatosis affecting >66% of liver cells, 
but the histological patterns were different [135]. In all the strains microvesicular, 
mixied, and macrovesicular were found, but Sprague-Dawley rats exhibited highest 
degree of fibrosis, hepatocytes damage, and reduced blood flow velocity in central 
veins than rest. The effect of HFD seems to be more pronounced in rats than mice 
as the pathology better resembles that seen in human NASH [136]. Unlike various 
other animal models, animals fed an HFD mimic both the histopathology and 
pathogenesis of human NAFLD, as they have the hallmark features observed in 
human NAFLD patients, including obesity and IR. The degree of hepatic steatosis, 
however, seems to depend on various factors, including rodent strain. 
 
Fructose rich diet-induced NAFLD: A shift in increased consumption of mono and 
disaccharides, primarily sucrose (50% fructose) and fructose (i.e., candy, soft 
drinks), is reported to be a risk factor for the development of NAFLD in humans. 
Ingestion of fructose promotes de novo lipogenesis, ATP depletion, the formation of 
reactive oxygen species and insulin resistance [20, 23]. In mice, the addition of 
30% fructose to drinking water caused a fourfold increase in the levels of hepatic 
triglycerides and a marked increase in steatosis and weight over 8 weeks [137]. 
The C57BL/6 mice accessed to different, mono and disaccharides in drinking water 
revealed that fructose had the most damaging effect on the liver despite having the 
least impact on body weight gain [46]. With regards to NAFLD, no published data 
have shown that fructose alone can alter metabolic parameters, but biochemically it 
has been argued that fructose has potent metabolic attributes and can promote 





mice fed with high fat and high carbohydrate diet with fructose 55% in drinking 
water for 16 weeks develop NASH like phenotype with significant fibrosis as well as 
obesity [139]. In summary, HFD closely resembling not only the pathological and 
molecular alterations but also the dietary patterns found in humans with NAFLD. 
 
Methionine and choline deficient (MCD) diet-induced NAFLD: The MCD diet, one of 
the most commonly used dietary models of NAFLD and NASH, this model produces 
more significant cell injury and cell death compared to other NAFLD models. The 
MCD diet contains high sucrose and fat (40% sucrose and 10% fat), this diet is lack 
of choline and methionine, which are essential for hepatic β-oxidation and very low 
density lipoprotein (VLDL) [140]. Choline is an essential substance that is involved 
in many metabolic reactions in rats (e.g., methylation or transport of lipids). 
Methionine can be used for the synthesis of choline, when the diet is lacking 
choline. Moreover, lack of methionine may be partially responsible for the decrease 
of glutathione synthesis. The absence of both choline and methionine substantially 
disturbs the formation of phosphatidylcholine, which is essential for the normal 
formation of VLDL and its secretion from the liver [141]. Rodents fed a MCD diet 
rapidly develop hepatic steatosis within 1 to 2 weeks due to enhanced uptake of 
fatty acids and decreased secretion of VLDL [142]. Despite the fact that with MCD 
diet rodents develop significantly faster and more pronounced liver damage, this 
dietary feeding regiment does not reflect several causative features of human 
NASH [143]. The metabolic profile of this model is opposite to that of typical human 








which is opposite of that seen in NASH patients. These changes do not reflect the 
pathophysiology of NASH in humans. 
 
1.5.1.2 Genetic rodent models of NAFLD 
 
SREBP transgenic mice: Sterol regulatory element binding proteins (SREBPs) 
are important transcription factor that regulate hepatic cholesterol homeostasis. 
SREBPs activate the expression of more than 30 genes regulating the synthesis 
and uptake of cholesterol, fatty acids, triglycerides and phospholipids, as well as 
the NADPH cofactors required to synthesize these molecules [144, 145]. In liver 
three SREBPs (SREBP-1a, SREBP-1c and SREBP-2) regulate the production of 
lipids for export as lipoproteins and as bile. The mammalian genome encodes 
three SREBP isoforms, designated. Over expression of SREBP-1c model 
creates a model of congenital lipodystrophy in which severe insulin resistance 
and diabetes develop secondary to impaired adipose differentiation [146]. On 8th 
day of age marked hepatic steatosis occurs in these mice , when fed with 
standard diet, results in dysregulation of the bio synthetic pathways which 
generate cholesterol and fatty acids resulting in hepatic steatosis, lobular 
inflammation and perivenular and pericellular fibrosis develop at 20 week [147]. 
However, due to decrease in white adipose tissue mass questionable whether 
this model can be used as a model for typical NAFLD/NASH because visceral fat 
characteristically increases in human NAFLD/NASH and exhibits low levels of 









ob/ob mice: This model has been extensively studies and is used as a model for 
various metabolic diseases, among them NAFLD [149-151]. ob/ob mice carries a 
mutation in the leptin gene, which leads to leptin deficiency, subsequently leading 
to a hyperphagic, obese, inactive and show hyperglycaemia, insulin resistance, 
hyperinsulinemia and diabetic phenotype accompanied by the development of 
NAFLD [152, 153]. In ob/ob mice, fat is redistributed from adipose tissue to the liver 
and other non-adipose tissue. Fat accumulation in the liver induces hepatocyte 
lipotoxicity and lipoapoptosis. Early studies of ob/ob mice demonstrated that the 
hepatic steatosis enhances the vulnerability towards pro-injurious stimuli including 
endotoxin (lipopolysaccharide) or TNF[154, 155]. ob/ob mice develop spontaneous 
hepatic steatosis [156], however development of steatosis to steatohepatitis do not 
occur spontaneously, but require some kind of second hit such as dietary 
intervention such as methionine and choline diet (MCD) or HFD or challenge with 
small dose of endotoxin [157, 158]. Interestingly, ob/ob mice are protected against 
MCD diet induced fibrosis despite developing similar necro-inflammatory lesions as 
their genetic controls [159]. 
 
db/db mice: Contrary to what is seen in ob/ob mice, db/db mice carry a 
spontaneous mutation in the leptin receptor (ob-Rb) gene [160]. Although these 
mice have normal or elevated levels of leptin, due to the mutation confers 
resistance to the effects of leptin. These mice are hyperphagic and develop obesity, 
hyperglycemia, hyperinsulinemia, insulin resistance and develop macrovasicular 
hepatic steatosis [161, 162]. These mice develop to NASH when a “second hit" 





receptor in db/db or fa/fa mice resembles the human condition more closely. when 
these mice are feed with MCD diet , significant liver fibrosis was observed 
compared to ob/ob mice, due to an important role of the short-form leptin receptor 
in hepatic fibrogenesis in NAFLD [163]. 
 
1.5.2 In vitro models of NAFLD 
 
1.5.2.1 Monolayer cultures of primary hepatocytes 
 
Primary hepatocyte cell lines are the most relevant in vivo like liver based in 
vitro model used extensively in basic research of liver functions, pathophysiology, 
pharmacological, disease and other related subjects [164]. Isolation of primary 
hepatocytes from a freshly removed liver tissue is done by two step collagenase 
perfusion technique which was introduced by Berry and Friend in 1969 [165] which 
was later modified by many and the most common method was described by [166]. 
Oleic and palmitic acid causes liver steatosis, combined action of oleic and palmitic 
acid causes more steatosis when compared individually [167, 168]. Interleukin-17, a 
pro inflammatory cytokine , exacerbated the accumulation of lipid droplets in 
 
hepatocytes [169]. Interestingly, an increased presence of triglycerides based 
 
lipid drop lets and VLDL secretion without change in apolipoprotein B has been 
 
absorbed in human hepatocytes treated with oleic or eicosapentaenic acid which 
 
makes these cell lines a suitable in vitro model for the study of liver steatosis 
 
[170]. The cons with primary hepatocytes are , they lose their liver specific 
functionality and morphology in culture, moreover their availability is limited, 
phenotypic instability and limited life spam [171]. CYP activity especially CYP1A2 





the metabolism of administered drugs [172]. Disturbances in gene expression 
mainly in those involved an antioxidant process, heat shock proteins, NO synthase, 




1.5.2.2 Monolayer culture of liver-based cells lines / Immortalized cell lines 
 
 
Cell lines derived from hepatocarcinoma has some advantages and 
disadvantages over primary hepatocytes. The cell lines are being attractive due to 
their highly availability, easy handling and unlimited life span, whereas the draw 
backs are genetic instability and a phenotype that strongly differs from primary 
hepatocytes [175]. The mostly used human hepatocyte cell lines are HepG2, 
HUH7, H4IIE, PAV-1, and LX2 which are used to explore the molecular events in 
NAFLD. HepG2, which are originated from Human HCC, can retain several 
biochemical functions including the potential to secrete lipoproteins [176, 177] . 
Accordingly, using HepG2 cell lines is an appropriate model for studying the human 
lipid metabolism. Triglycerides and intra cellular accumulation of lipid droplets are 
exhibited when HepG2 cell lines are exposed to different concentration of oleic acid 
and palmitic acid [167, 178, 179]. However, these cell lines lack CYP activity, which 
is important for xenobiotic metabolism. Therefore characterized for drug 
metabolizing is potential for Hepg2 cell is essential before used in in vitro studies 
 
[180]. Thus a number sub-clones, such as HepG2/C3A, which express functional 
CYP activity and that display accumulation of TGs after exposure to oleic acid 
either alone or combined with plamatic acid [181]. The HepaRG cell lines which 




quickly recover the bipotent progenitors and actively divide until they reach 
confluence, when seeded in low density. These cells express major liver specific 
functions, including CYP activity, are functionally stable at confluency and have an 
indefinite growth potential [171]. These cell lines have great potential in invite liver 
steatosis research, as they accumulate lipid droplets following exposure to stearic 
acid, palmitic acid, oleic acid linoleic acid, eicosapentaenoic acid, docosahexaenoic 
acid and amiodarone [182]. 
 
1.6 Rational and objectives 
 
 
From literature, it has been confirmed that NAFLD is a spectrum, ranging from 
NAFL to NASH, advance fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). It 
is also associated with the traditional metabolic conditions: obesity, diabetes 
mellitus, and dyslipidaemia. Given the role of dyslipidaemia in the progression of 
NAFLD and the associated metabolic disorders therapeutics interventions to 
improve lipid metabolism are important in the management of NAFLD. As limited 
drug are available for protecting the liver from dyslipidaemia such as anti-oxidants, 
hepatoprotective agents and targeting insulin resistance and changes in lifestyle 
modifications and weight loss. 
 
On the other hand, alcohol use on limited basis have beneficial effects on 
health. From the previous studies it was confirmed that light and moderate alcohol 
activates the molecules that control the lipid synthesis pathways in rodents and 
clinical studies [183, 184]. The chronic therapeutic intervention with low and 
moderate alcohol to alleviate dyslipidaemia by increasing the AMPK-α a “master 




SIRT1 proteins which decreases the lipogenesis and increase the lipolysis 
pathways. A very few studies were reported on rodents feeding HFD with low and 
moderate alcohol regulating insulin resistance, there are no specific studies on 
HFD induced NAFLD treated with low and moderate alcohol doses. Hence, the 
specific objectives of the project were to: 
 
• Investigate the in vivo effects of low and moderate alcohol on protecting the 
liver from HFD-induced NAFLD in animal model. 
 
• Elucidate the possible mechanism(s) of action of low and moderate alcohol 
on HFD-induced NAFLD 
 
• Investigate the in vitro effects of low and moderate alcohol on protecting the 
HepG2 cells from FFA-induced NAFLD in animal model. 
 
• Elucidate the possible mechanism(s) of action of low and moderate alcohol 
on HFD-induced NAFLD 
 
• Elucidate the role of AMPK, SIRT1 and LKB1 in protecting the HepG2 cells 





Thus, in this study, low and moderate alcohol was examined in high fat diet induced 
NAFLD in Sprague Dawley rats. The proposed research project was based on the 
hypothesis that low and moderate alcohol feeding may improve lipid metabolism 























EFFECT OF LOW AND MODERATE 
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Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation 
of the metabolic syndrome and is defined as the accumulation of fat in the liver of 
patients who do not consume excessive alcohol [185]. It is estimated that about 
24% of world population are affected with NAFLD [186]. The prevalence of NAFLD 
across geographical locals was assessed by utilizing ultrasonography and proton 
NMR spectroscopy [187], whereas studies based on elevated liver enzymes 
systematically underestimated the true prevalence [186]. Even though NAFLD is 
highly prevalent in all countries, but the highest rates are reported from South 
America (31%) and the Middle East (32%), followed by Asia (27%), the USA (24%) 
and Europe (23%), whereas NAFLD is less common in Africa (14%) [186]. The 
prevalence of NAFLD is constantly increasing (15% in 2005 to 25% in 2010) and 
similarly the rate of NASH in the same timeframe has almost doubled (59.1% 
versus 33%) [186]. NASH is now considered the second most common indication 
for liver transplantation in the USA after chronic hepatitis C, and is still growing 
[188]. 
 
The pathogenesis of NAFLD is described as a two-hit model. The first-hit 
consisting of hepatic lipid accumulation, due to sedentary lifestyle, high fat diet 
consumption, obesity, and insulin resistance [185]. The second-hit activates 
inflammatory cytokines, oxidative stress, mitochondrial dysfunction with associated 
fibrogenesis [189]. However, the insights on the role of free fatty acids (FFA) in 
promoting liver injury lead to modification of the theory. Hepatic fat accumulation 




resistance. These FFA either undergo β-oxidation or esterified with glycerol to form 
triglycerides, leading to hepatic fat accumulation. There is now substantial evidence 
that FFA can directly cause toxicity by activation of inflammatory pathways or by 
increasing oxidative stress [16]. This two-hit model has lost some favour as it was 
believed to be too simplistic to fully describe the intricacy of human NAFLD where a 
multitude of factors are acting in concert with one another in a genetically 
predisposed individual [189]. Evidence based on the results of various studies 
performed in recent years suggest apart from genetic predisposition, alterations of 
the intestinal barrier function, and over-nutrition, but also certain dietary patterns 
(e.g. a diet rich in fat and sugar or iron/animal-derived protein) may be responsible 
in the development of NAFLD [190]. 
 
For better understanding and investigation in the progression of NAFLD, 
three types of NAFLD animal models were developed such as genetic, nutritional, 
or a combination of genetic and nutritional factors. Nutritional factor-induced NAFLD 
models include methionine- and choline-deficient diet, high-fat diet (HFD), high-
cholesterol and high-cholate diet, cafeteria diet, and high-fructose diet [191]. Apart 
from the nutritional factors, several lifestyle activities such as alcohol consumption, 
smoking and physical inactivity were implicated in the pathogenesis of metabolic 
disorders. Notably, heavy alcohol consumption (>50 g/day) was implicated in the 
pathogenesis of metabolic disorders leading to late stage complications, including 
atherosclerosis and fatty liver disease [192, 193]. Thus, alcoholic liver disease is 








threshold of alcoholic consumption causing an adverse effect on the liver and 
metabolic dysfunction is still controversial [194, 195]. 
 
In contrast, population-based studies suggest that moderate alcohol 
consumption (<20 g on 1–3 days/week) may even decrease the odds to develop 
NAFLD [196, 197]. These data are in line with the findings of others who reported 
that moderate drinkers (<20 g/day) had a lower risk of being diagnosed with non-
alcoholic steatohepatitis (NASH) and also fibrosis than lifetime non-drinkers [198]. 
Results of human studies suggest that the beneficial effect of moderate alcohol 
intake may be associated with increased levels of adiponectin [199]. 
 
Several epidemiological studies have reported an association between 
regular low-to-moderate alcohol consumption and lower risk of mortality and 
morbidity from life-threatening diseases [200]. It was shown that low-to-moderate 
alcohol consumption is associated with lower risk of development of insulin 
resistance [201, 202] and type 2 diabetes [184, 203] and protection against the risk 
of major cardiovascular disease events such as myocardial infarction and coronary 
artery disease in healthy population [204, 205] and in patients with type 2 diabetes 
[206, 207], and hypertension [208, 209]. Other health benefits of regular light-to-
moderate alcohol consumption include lower risk of dementia and cognitive 
impairment [124, 210] osteoporosis [211] and cancer [212]. 
 
However, the molecular mechanisms involved in the beneficial effects of 
moderate intake of alcoholic drinks have not yet been fully understood as the 
results obtained in animal experiments are inconsistent. Indeed, chronic alcohol 





effect on NAFLD in ob/ob mice [213]. In contrast, results of other studies suggest 
that moderate to high consumption of plain alcohol may actually add to the 
progression of NAFLD [214, 215] and that this could even be dose dependent [216, 
217]. Furthermore, it was argued that the protective effect found in human studies 
might not be resulted from the intake of alcohol itself but rather from other factors 
associated with the intake of alcohol (e.g. intake of resveratrol in red wine or hops 
ingredients in beer or even changes in lifestyle [218-221]. 
 
Starting from this background, the primary aim of the present study was to 
determine the effects of low, moderate and high alcohol (1 g/kg/day, 2 g/kg/day, 6 
g/kg/day) on the development of HFD-induced NAFLD in Sprague-Dawley rats. It 
was hypothesized that low and moderate alcohol intake may protect the liver from 




2.2 Materials and Methods 
 
 
2.2.1 Chemicals used 
 
 
Alcohol (100%) was purchased from Chem-Supply (Gilman, SA, Australia) 
while the high fat diet (60% fat with 2% cholesterol) was supplied by Speciality 
Feeds (Glen Forrest WA, Australia). The diagnostic kits for triglycerides, total 
cholesterol, HDL cholesterol, glucose, aspartate aminotransferase (AST), and 
alanine aminotransferase (ALT) used in this study were obtained from Pointe 
Scientific (Canton, MI, USA) whereas non-esterified free fatty acids kit was 
obtained from Wako Diagnostics (Osaka, Japan). Rat insulin EIA kit was purchased 





2.2.1.1 10% neutral buffered formalin 
 
Sodium dihydrogen phosphate, monohydrate (NaH2PO4.H2O) (4 g) and 
disodium hydrogen phosphate, anhydrous (Na2HPO4) (6.5 g) were added to 100 
mL of water, pH was adjusted to 7.0 and made up the final volume to 1 litre. 
 
 
2.2.2 Animals and diets 
 
 
Adult male Sprague-Dawley rats (198 g-235 g) obtained from the Animal 
Resource Centre (Canning Vale, WA, Australia) were used in the studies. The rats 
were housed in a well ventilated animal facility maintained at an ambient 
temperature of 24 2 C having 50-60% relative humidity with 12-h light/dark cycle 
and provided with standard pellet diet and water ad libitum. Both the standard diet 
(AIN93G) and high-fat diet (HFD) (SF12-017) were supplied from Speciality Feeds 
(Glen Forrest, WA, Australia). The standard diet contained (in weight percentage) 
approximately: 60% carbohydrate, 17.5% protein, 5% fat, 7% crude fibre, with a 
digestible energy of 16.1 MJ/kg and the 60% HFD contained (in weight percentage) 
approximately: 8.6 g sucrose, 20.0 g casein (acid), 10 g canola oil, 40 g cocoa 
butter, 10 g clarified butter, 5 g cellulose, plus 2% cholesterol with a digestible 
energy of 24.1 MJ/kg. All procedures involving animals are conducted by the terms 
of the Institutional Animal Ethics Committee of the Western Sydney University 
(Project code: A9387) following the NHMRC guidelines on the “Australian Code of 







2.2.3 Experimental design and treatments 
 
 
The rats were weight-matched and divided into six groups, each consisting 
of five to six rats. The normal and the high-fat diet (HFD) control groups received 
the standard diet and the high-fat diet respectively and treated with vehicle (water) 
by oral gavage twice daily for 15 weeks. The low, moderate, and high alcohol 
groups received HFD along with respective alcohol doses (1 g/kg/day, 2 g/kg/day, 6 
g/kg/day) twice daily around 9 am and 5 pm by oral gavage for a period of 15 
weeks. The daily food intake from each cage was determined daily at around 9 am 
while the body weight of each animal was recorded daily at around 4 pm. At the 
end of the 15-week treatment schedule, animals were kept on overnight fasting for 
12 hours, animals were euthanized with an intraperitoneal injection of ketamine (75 
mg/kg), and xylazine (10 mg/kg). Blood was collected from the cardiac puncture, 
serum was extracted from the blood and kept at -20 ºC until analysis for various 
biochemical parameters. The livers were dissected out, weighed and snap frozen in 
liquid nitrogen and stored at -80 C for molecular analysis. 
 
2.2.4 Biochemical estimations 
 
2.2.4.1 Body weight and food intake 
 
 
The daily food intake from each cage was determined daily at around 9 am while the 
body weight of each animal was recorded daily at around 4 pm up to 15 weeks. 
 
2.2.4.2 Determination of serum triglycerides 
 
Serum triglycerides were estimated using an enzymatic colorimetric assay based 








2.2.4.3 Determination of serum total cholesterol 
 
Total cholesterol in serum was estimated using an enzymatic colorimetric assay 
based on cholesterol esterase and oxidase, in a single reagent to determine total 
cholesterol [223] following the manufacturer’s instructions (Point Scientific, USA) 




2.2.4.4 Determination of serum HDL cholesterol 
 
 
Serum HDL cholesterol was estimated using an enzymatic colorimetric assay 
based on the cholesterol oxidase method after removal of other lipoproteins with 
phosphor tungstate-magnesium [224], following the manufacturer’s instructions 
(Point Scientific, USA) with absorbance measured at 550 nm using Ultrospec 2100 
Pro UV/VIS spectrophotometer. 
 
 
2.2.4.5 Determination of serum LDL and VLDL cholesterols 
 
Serum LDL and VLDL cholesterols were calculated using Friedwald’s equation 
[225]. 
 
LDL = Total cholesterol- [HDL + (Triglycerides/5)] 







2.2.4.6 Determination of serum non-esterified free fatty acids (NEFA) 
 
Serum NEFA were estimated using an enzymatic colorimetric assay based on acyl-
CoA synthetase, acyl-CoA oxidase (ACS-ACOD) [226] method following the 
manufacturer’s instructions (Wako Diagnostics, Japan) with absorbance measured 
at 550 nm using Ultrospec 2100 Pro UV/VIS spectrophotometer. 
 
 
2.2.4.7 Determination of serum glucose 
 
Serum glucose was measured using an enzymatic colorimetric assay based on 
glucose oxidase-peroxidase (GOD-POD) [227] method following manufacturer’s 




2.2.4. 8 Determination of serum insulin 
 
Serum insulin was measured using an enzyme-immuno assay (EIA) [228] method 
following the manufacturer’s instructions with absorbance measured at an 
excitation of 414 nm Thermo Multiskan microplate reader. 
 
 
2.2.4.9 Homeostatic model assessment of insulin resistance (HOMA-IR) 
 
HOMA-IR, a measure of insulin resistance index [229] was calculated from the real-
time fasting serum glucose and fasting insulin concentrations of different groups of 
rats using the mathematical HOMA-IR formula: HOMA-IR = (fasting serum insulin in 








2.2.4.10 Determination of aspartate amino transferase (AST) 
 
Serum AST was measured using an enzymatic colorimetric assay based on 
oxidation of L- aspartate to L-malate and NADH to NAD+ in presence of (AST-
MDH) [230, 231] method following manufacturer’s instructions with absorbance 




2.2.4.11 Determination of alanine amino transferase (ALT) 
 
Serum ALT was measured using an enzymatic colorimetric assay based on oxidation 
of L- aspartate to L-malate and NADH to NAD
+
 in presence of (AST-MDH) 
[232] method following manufacturer’s instructions with absorbance measured at 
 





2.2.4.12 Determination of hepatic lipids 
 
Total lipids were extracted from the liver by the modified method of Hara and 
Radin et al (1978) [233]. Briefly, 75-100 mg aliquots of liver tissue was 
homogenized in 20 volumes of isopropanol, shaken in an orbital shaker for 45 
minutes and centrifuged at 3000 g for 15 minutes and the supernatant was 

















2.2.5 Histological analysis of liver 
 
2.2.5.1 Haematoxylin and eosin staining 
 
 
The liver was fixed in 10% neutral-buffered formalin, dehydrated in 
increasing concentrations of alcohol, cleared with xylene and embedded in paraffin. 
Liver sections (3-5 µM) were prepared using the paraffin blocks in fully automated 
rotary microtome (Leica RM2255, Leica Biosystems, Germany) and stained with 
haematoxylin and eosin (H & E). Briefly, deparaffinised and re-hydrated sections by 
2 changes of xylene for 10 minutes and 5 changes of absolute alcohol for 5 minutes 
respectively. Thereafter, sections were dipped in 95% alcohol for 2 minutes and 
70% alcohol for 2 minutes and wash briefly in distilled water. After that, sections 
were stained with Harris Hematoxylin solution for 8 minutes and Wash in running 
tap water for 5 minutes. Afterwards, sections were dipped in 0.2% ammonia water 
followed by washed in running tap water for 5 minutes and rinsed in 95% alcohol 
(10 dips). Thereafter, sections were counterstained in eosin-phloxine solution for 1 
minute. The sections were cleared in 2 changes of xylene and mounted in xylene 
based mounting medium[234]. The sections were examined for assessment of 
histopathological features such as inflammation cells, macro vesicular steatosis 
hepatic ballooning, using a binocular Olympus CX31 microscope 
 
 
2.2.5.2 Oil Red O staining 
 
Oil Red O staining was done by using frozen sections. Samples were 
sectioned at 5μm thickness and mount on the slides for air drying, slides were 





slides were washed with running tap water for 3 minutes, mounted with glycerine 
[235, 236] were examined for assessment of lipid droplets using a binocular 
Olympus CX31 microscope. 
 
 
2.2.6 Data and statistical analysis 
 
All the results are expressed as means ± SEM. To examine the quantitative 
differences among the experimental groups, the respective data were subjected to 
analysis of variance (ANOVA) using GraphPad Prism-7.03 (GraphPad Software 
Inc., California, CA) statistical programme. Post hoc comparisons were made using 
Dunnett’s multiple comparisons test. In all tests, p<0.05 value was used as the 








































2.3.1 Body weight & Food intake 
 
The changes in the mean body weight of the different experimental groups of 
rats over the 15-weeks treatment period are shown in Figure 2.1. There was no 
significant difference in the initial body weight (from 198.1 ± 3.0 g to 236.1 ± 8.2 g; n=4-
6) among the groups and continued up to week 5 (402.8 ± 2.5, 391.3 ±8.1, 399.5 
±11.3, 399.9 ± 6.5, 425 ± 22.3). During the 15-week feeding with HFD, the growth rate 
of the HFD-fed control group (582.4 ± 13.1 g) was not significantly different (p=0.57) to 
that of standard chow-fed rats (543.4 ± 9.5 g), as shown in Figure 2.1. From week 6, 
the low alcohol-treated group (n=5) exhibited a decrease (p=0.36) in body weight when 
compared to rest of the alcohol treated groups and this has continued up to end of 
week 15 (532.0 ± 26.5 g). At the end of 15 weeks there was no significant difference 
(p=0.99 to 0.32) in body weights were observed in moderate alcohol-treated group 
(n=6) (590.2 ± 19.8 g) and high alcohol-treated group (n=4) (635.125 ± 40.5 g) when 
compared to the HFD-fed control group. The average amount of food consumption in 
HFD-fed control group (34.1 ± 2.8 mg/24h/g BW) was significantly lower (p<0.001) than 
that in standard chow-fed normal group (62.6 ± 4.6 mg/24h/g BW) (Table 2.1). 
However, their calculated energy intakes were similar in terms of digestive energy units 
(Kcal). The feeding efficiency [body-weight gain (g)/ energy intake (kcal)] in these 
groups was compared to that of HFD control. The effects of low, moderate and high 
alcohol with HFD on liver weight and liver index are shown in Table 2.1. The HFD 
group (n=6) showed a significant difference (p<0.01) in liver weights and (p<0.001) with 







treated (p=0.05), moderate alcohol-treated (p=0.99), and heavy alcohol-treated 
(p=0.96) groups did not exhibit any significant difference in liver weights when 
compared to HFD control group. No significant difference in liver index was 
observed in low alcohol-treated (p=0.08), moderate alcohol-treated (p=0.52), and 



























































































Figure 2.1 Effect of low, moderate and high alcohol on body weight change in 
HFD-fed rats for 15 weeks. 
 
(A) Daily recordings of the mean body weight changes of the experimental 
groups of rats and (B) comparison of the mean bodyweights of rats prior to (open 
columns) and after treatment (closed columns) either with the HFD alone or with 























Table 2.1 Effect of low, moderate and high alcohol on food intake and feeding efficiency in rats fed with HFD for 15 
weeks 
 
Parameters Normal HFD  Low alcohol + Moderate alcohol + High alcohol + 
 control control HFD  HFD  HFD  
       
Initial body weight 198.1 ± 3.0 214.4 ± 5.3 ns 236.1 ± 8.2 ns 211.0 ± 3.0 ns 231.375 ± 13.1 ns 
Final body weight 543.4 ± 9.5 582.4± 13.1 
ns 
532.0 ± 26.5 
ns 590.2 ± 18.0 ns 635.1 ± 40.5 ns 
Weight gain(g) 344.8 ± 5.5 370.5 ± 9.2 
ns 
282.5 ± 24.0 
ns 363.1± 3.2 ns 388.5 ± 39.2 ns 
         
Food consumption 62.6 ± 4.6 34.1 ± 2.8
### 32.6 ± 2.0 ns 28.2 ± 1.9 
ns 
38.2 ± 1.9 
ns 
(mg/24h/g bw)           
Total energy intake 194.33 ± 14.42 219.96 ± 18.22 
ns 210.14 ± 12.86 ns 199.60 ± 13.43 ns 196.57 ± 11.26 ns 
(Kcal/g/day)           
Feeding efficiency 2.52 ± 0.31 2.62 ± 0.34 
ns 2.62 ± 0.34 ns 2.46 ± 0.28 
ns 
2.46 ± 0.24 
ns 
(g/Kcal)           
Liver weight 19.5 ± 0.34 26.7 ± 1.2
## 
21.90 ± 1.70(0.05) 26.3 ± 1.7 ns 26.3 ± 2.9 ns 
Liver Index 3.41 ± 0.08 4.76 ± 0.14
### 4.14 ± 0.27(0.08) 4.45 ± 0.20 
ns 
4.07 ± 0.17 
ns 
 
Values represent the mean ± SEM of 4-6 rats  
Significant difference from normal control: ##p<0.01, ###p<0.0001 



















2.3.2 Serum triglycerides 
 
 
The levels of serum triglycerides in different groups are shown in Table 2.2. 
The HFD-fed control group (n=6) showed a significant (p<0.05) 1.6-fold increase in 
serum triglycerides when compared to the normal control group (n=5) at the end of 
the treatment. The moderate alcohol-treated group (n=6) showed a non-significant 
(p=0.82) decrease in serum triglycerides when compared to the HFD control group. 
In contrast, the low alcohol-treated group HFD (n=5) and high alcohol-treated group 
(n=4) showed non-significant increase in triglycerides levels by 1.1-fold (p=0.70) 
and 1.2-fold (p=0.35) respectively when compared to the HFD-treated control 
group. 
 
2.3.3 Serum total cholesterol 
 
 
Table 2.2 shows the total serum cholesterol levels among the experimental 
groups. The rats fed with HFD (n=6) showed significant (p<0.001) 2.3-fold increase 
in total cholesterol level when compared to the normal control group (n=5) at the 
end 15-week treatment. A 1.2-fold decrease in total cholesterol was noticed in 
moderate alcohol-treated group (n=6) but failed to achieve significance (p=0.10) 
when compared to the HFD-fed control group. On the other hand, the low alcohol-
treated (n=5) and high alcohol-treated (n=4) groups did not show significant change 
in serum cholesterol (p=0.96 to 0.97) when compared to the HFD-fed control group. 
 
2.3.4 Serum HDL cholesterol 
 
 
The levels of HDL cholesterol observed in different groups are shown in 




significantly (p<0.001) decreased by 3.3-fold when compared to the normal control 
group (n=5). The low alcohol (n=5) and moderate alcohol (n=6) treated groups 
showed a mild but significant (p<0.001) increase in serum HDL levels by 1.4 and 
1.5-fold respectively when compared to the HFD-treated control group. On the 
other hand, no significant difference (p=0.99) in serum HDL levels was observed 
between high alcohol-treated group and the HFD-treated control groups. 
 
2.3.5 Serum LDL cholesterol 
 
 
The LDL cholesterol levels were calculated by using Friedewald’s equation. 
The LDL levels of various groups are shown in Table 2.2. Rats fed with HFD (n=6) 
showed a significant (p<0.001) 4.6-fold increase of serum LDL levels when 
compared to the normal control rats. Moderate alcohol-treated rats (n=6) showed a 
non-significant (p=0.28) 1.3-fold decrease in serum LDL when compared to the 
HFD-fed rats. In contrast, no significant change in serum LDL was observed with 
low alcohol-treated (n=5; p=0.65) and high alcohol-treated (n=4; p=0.99) rats 
compared to the HFD-fed control rats. 
 
2.3.6 Serum VLDL cholesterol 
 
 
The VLDL cholesterol levels are shown in Table 2.2. The HFD-fed control 
group (n=6) showed a significant (p<0.05) 1.7-fold increase in serum VLDL when 
compared to the normal control group (n=5) at the end of the treatment. Moderate 
alcohol-treated group (n=6) showed a non-significant (p=0.82) decrease in serum 
VLDL when compared to the HFD control group. On the other hand, low alcohol-





fold (p=0.70) and 1.2-fold (p=0.35) increase in VLDL respectively when compared 
to the HFD-fed control at the end of the treatment. 
 
2.3.7 Serum non-esterified fatty acids (NEFA) 
 
 
Serum NEFA levels are shown in Table 2.2. The HFD-fed control group 
(n=6) showed a significant (p<0.001) 1.4-fold increase in serum NEFA levels when 
compared to the normal control rats (n=5). While the moderate alcohol-treated 
group (n=6) showed a significant (p<0.01) 1.2-fold decrease in serum NAFA, the 
low alcohol-treated group did not show any significant change (p=0.99) in serum 
NEFA when compared to the HFD-fed control group. In contrast, the high alcohol-
treated rats (n=4) showed a significant (p<0.01) 1.2-fold increase in serum NEFA, 




































Table 2.2 Effects of low, moderate, high alcohol on serum lipid parameters in rats fed with HFD for 15 weeks 
 
 
Parameter Normal HFD  Low alcohol + Moderate alcohol High alcohol + 
 control control HFD  + HFD  HFD 




71.53 ± 4.55 
ns 98.36 ± 7.40 ns 
Total cholesterol (mg/dL) 147.56 ± 5.89 338.62 ± 24.63
### 352.92 ± 14.84 ns 276.02 ± 19.73 
ns 325.30 ± 33.74 ns 
HDL (mg/dL) 73.13 ± 2.03 22.11 ± 1.75
### 
30.61 ± 0.34*** 35.05 ± 0.53*** 21.89 ± 0.60 
ns 
LDL (mg/dL) 64.77 ± 6.29 300.47± 23.82
### 304.07 ± 14.05 ns 226.66 ± 20.55 
ns 
283.74 ± 33.65 
VLDL (mg/dL) 9.66 ± 1.08 16.03 ± 1.19
# 
18.25 ± 2.78 
ns 
14.31 ± 0.91
ns 19.67 ± 1.48 ns 
NEFA (µEq/L) 824.7 ± 12.1 1154.54 ± 16.75
### 1151.27 ± 57.79 ns 986.71 ± 12.61** 1385.28 ± 82.21**   
Values represent the mean ± SEM of 4-6 rats.  
Significant difference from normal control: #p<0.05, ###p<0.001 
Significant difference from HFD control group: **p<0.01, ***p<0.001, 
 
No significant difference from HFD control: ns (p>0.05) 
 
HFD: High-fat diet, HDL: High density lipoprotein, LDL: Low density lipoprotein, 
 






















2.3.8 Serum glucose 
 
 
The serum glucose levels among the experimental groups are shown in 
Table 2.3. The HFD-fed control group (n=6) showed a significant (p<0.001) 3.2-fold 
increase in fasting blood glucose compared with the normal control group (n=5). 
The moderate alcohol-treated group (n=6) showed a mild but significant (p<0.001) 
decrease in serum glucose by 1.8-fold when compared to the HFD-fed control 
group. On the other hand, the low alcohol-treated rats (n=5) did not show any 
significant (p=0.93) change in serum glucose when compared to the HDF-fed 
control group. Furthermore, the high alcohol-treated group (n=4) showed a mild 
non-significant (p=0.86) increase in serum glucose when compared to the HFD-fed 
control group. 
 
2.3.9 Serum insulin 
 
 
Serum insulin levels of HFD-fed group (n=6) were found to be significantly 
(p<0.001) increased by 2.9-fold when compared to the normal control group (n=5). 
On the other hand, the low alcohol-treated (n=5) and moderate alcohol-treated 
(n=6) groups showed a mild non-significant (p=0.14 to 0.49) decrease in serum 
insulin levels when compared to the HFD-fed control group. Furthermore, high 
alcohol-treated group (n=4) exhibited a mild non-significant (p=0.94) decrease in 
serum insulin levels when compared to HFD-fed control group. 
 
2.3.10 Homeostatic model assessment of insulin resistance (HOMA-IR) 
 
 
The development of insulin resistance as assessed by the mathematical 
 





group (n=6) developed a significant (p<0.001) 9.4-fold increase in insulin resistance 
when compared to the normal control rats (n=5). The moderate alcohol-treated 
group (n=6) showed a significant (p<0.001) 1.9-fold increase in serum insulin 
resistance compared to the HFD-fed control group. On the other hand, low alcohol-
treated group (n=5) showed a non-significant (p=0.11) decrease in insulin 
resistance when compared to the HFD-fed control group. Whereas, high alcohol-
treated with HFD (n=4) showed a mild non-significant (p=0.99) increase insulin 
resistance compared to the HFD-fed control group. 
 
2.3.11 Serum aspartate aminotransferase (AST) 
 
 
The serum AST levels among the experimental groups are shown in Table 
2.3. The HFD-fed control group (n=6) showed a significant (p<0.001) 1.9-fold 
increase in serum AST levels when compared to the normal control rats (n=5). The 
moderate alcohol-treated group showed a mild but significant (p<0.05) 1.3-fold 
decrease in serum AST levels when compared to the HFD-fed control group. 
Similarly, the low alcohol-treated group (n=5) show a non-significant (p=0.98) 
decrease in serum AST when compared with HFD-fed control group. In contrast, 
the high alcohol-treated group (n=4) showed a significant (p<0.001) 1.5-fold-
increase in serum AST levels when compared to the HFD-fed control group. 
 
2.3.12 Serum alanine aminotransferase (ALT) 
 
 
The serum ALT levels among the experimental groups are shown in Table 
2.3. A significant (p<0.001) 2.7-fold increase of serum ALT was observed in HFD-





the moderate alcohol-treated rats (n=6) showed a significant (p<0.05) 1.5-fold 
decrease in serum ALT levels when compared to the HFD-fed control group. 
Similarly, low alcohol-treated group (n=5) showed a non-significant (p=0.07) 1.3-
fold decrease in serum ALT levels when compared to the HFD-fed control group. 
On the other hand, the high alcohol-treated group (n=4) showed a non-significant 



















































Table 2.3 Effects of low, moderate, and high alcohol on serum glucose, serum insulin, insulin index, and serum 
alanine transaminase (ALT) and aspartate transaminase (AST) in rats fed with HFD for 15 weeks 
 
Parameter Normal HFD Low alcohol + Moderate alcohol + High alcohol + 
 control control HFD HFD   HFD  
Serum glucose (mg/dL) 115.18 ± 3.52 372.90 ± 11.70
### 359.64 ± 18.15 ns 211.22 ± 10.90*** 390.43 ±1 2.64 
ns 
Serum insulin (ng/mL) 1.49 ± 0.13 4.29 ± 0.13
### 3.63 ± 0.21 ns 3.93 ± 0.24 
ns 4.11 ± 0.37 ns 
Insulin index 0.42 ± 0.03 3.96 ± 0.20
### 3.20 ± 0.28 ns 2.05 ± 0.17*** 3.98 ± 0.44 
ns 
AST (IU/L) 33.95 ± 2.05 63.21 ± 2.26
### 61.26 ± 6.69 ns 49.06 ± 3.18* 91.94 ± 2.07*** 
ALT (IU/L) 24.40 ± 3.33 73.37 ± 5.30
### 55.16 ± 3.58 ns 47.96 ± 2.76** 77.35 ± 11.24 
ns 
 
Values represent the mean ± SEM of 4 to 6 rats  
Significant difference from Normal control: ###p<0.001, 
Significant difference from HFD control group: *p<0.05, **p<0.01 ***p<0.001,  
No significant difference from HFD control: ns (p>0.05) 
 


























2.3.13 Hepatic lipid levels 
 
 
The levels of hepatic triglycerides in different groups are shown in Table 2.4. 
The HFD-fed control group (n=6) showed a significant (p<0.001) 4.8-fold increase 
in hepatic triglycerides at the end of 15 weeks treatment when compared with the 
normal control (n=5) fed with standard diet alone. On the other hand, low alcohol-
treated (n=5) and moderate alcohol-treated (n=6) groups showed a non-significant 
(p=0.30 to 0.22) decrease in hepatic triglycerides by 1.2 to 1.2-fold when compared 
to the HFD-fed control group. In contrast, the high alcohol-treated group (n=4) 
showed a non-significant (p=0.71) 1.1-fold increase in hepatic triglycerides when 
compared to the HFD-fed control. 
 
Table 2.4 shows the hepatic total cholesterol levels among the experimental 
groups The hepatic total cholesterol levels of HFD-fed group (n=6) were 
significantly (p<0.001) increased by 9.3-fold when compared with the normal control 
group (n=5). The moderate alcohol-treated group (n=6) showed a significant 
(p<0.05) 1.3-fold decrease in hepatic total cholesterol when compared to the HFD-
fed control group. However, the low alcohol-treated (n=5) and high alcohol-treated 
(n=4) groups showed a non-significant (p=0.61 to 0.85) increase in hepatic total 




















Table 2.4 Effect of low, moderate, and high alcohol on hepatic triglycerides and total cholesterol in rats fed with HFD 
for 15 weeks 
 
Parameter Normal control HFD Low alcohol + Moderate alcohol High alcohol + 
  control HFD + HFD HFD 
Hepatic triglycerides (mg/g 30.54 ± 2.29 148.07 ± 14.69
### 119.83 ± 16.00 ns 118.25 ± 12.54 ns 166.13± 7.71 ns 
liver)      
Hepatic total cholesterol (mg/g 10.73 ± 0.90 100 ± 7.14
### 112.78 ± 12.62 ns 71.95 ± 5.35* 109.39  ±  8.83 
liver)     ns 
       
Values represent the mean ± SEM of 4 to 6 rats  
Significant difference from Normal control:  ###p<0.001 
Significant difference from HFD control group: *p<0.05 
 
No significant difference from HFD control: ns (p>0.05) 
 



























2.3.14 Histological analysis of liver 
 
 
The H&E staining of HFD-fed rat liver showed increased fat deposits as 
evidenced by distended intracellular fat in comparison to the liver of rats fed with 
standard diet was shown in Figure 2.2 A & B. The images of H&E stained HFD-fed 
liver also displayed macro-vesicular steatosis, as many single large droplets 
displaced the nucleus and ballooning degeneration causing conspicuous swelling of 
the cell and cytoplasmic vacuolation as shown in Figure 2.2 B. The low and 
moderate alcohol-treatment groups showed marked reduction of liver fat deposits 
(Figure 2.2 C & D) whereas the high alcohol-treated group (Figure 2.2 E ) showed a 
more pronounced steatosis and ballooning degeneration compared to HFD-fed 
control rat liver. 
 
The Oil red O staining of HFD-fed rat liver showed increased accumulation 
lipid droplets in liver sections, comparison to the liver of rats fed with standard diet 
was shown in Figure 2.2 F & G. The histology of low alcohol-treated and moderate 
alcohol- treated group’s showed a marked reduction of lipid droplet accumulation 
when compared to the HFD control group (Figure 2.2 H & I). In contrast, the high 
alcohol-treated liver (Figure 2.2 j) showed a more pronounced lipid droplets 
































































Figure 2.2 Effect of low, moderate, and high alcohol on histological changes 
produced by HFD-induced NAFLD in rats Representative photomicrographs of 
H& E staining of the liver of experimental groups at 20x. A: Normal control, B: HFD 
conrol, C: Low alcohol with HFD, D: Moderate alcohol with HFD, E: High alcohol 
with HFD. The colour arrows represent histological changes in the liver. Red arrow: 
Macrovesicular steatosis, Black arrow: Microvesicular steatosis, Open arrow: 
cytoplasmic vacuolation. The Oil red O staining of the experimental groups at 20x 
were shown in F: Normal control, G: HFD control, H: Low alcohol with HFD, I: 
Moderate alcohol with HFD, J: High alcohol with HFD. The black arrows in Oil red 







In the present study, we examined the protective effects of low and 
moderate alcohol in HFD-fed rat model of NAFLD which is commonly associated 
with metabolic co-morbidities like obesity, metabolic syndrome and type 2 diabetes 
 
[237]. Since rats possess a similar metabolic pattern as that of human beings, it is 
rational to use this disease model to examine the prophylactic effects of chronic 
treatment of low and moderate alcohol. Metabolic syndrome is a complex polygenic 
disorder including obesity, impaired fasting glucose and /or impaired glucose 
tolerance, reduced insulin sensitivity, hyperinsulinemia, dyslipidaemia, and 
hypertension has gained importance because of its association with the 
subsequent development of type 2 diabetes and its complications [238]. Fats 
become the major source of energy, during a low supply of carbohydrates or when 
their breakdown is incomplete [239]. As a result, fatty acids are mobilized into the 
general circulation leading to secondary triglyceridemia in which the total serum 
lipids, including triglycerides, and cholesterol increase, leading to life-threatening 
lipid disorder [240]. The development of metabolic syndrome is influenced by a 
combination of genetic and environmental factors. Among the environmental 
factors, long-term intake of high-fat is most intensively studied because of its 
contribution to the development of metabolic syndrome [241]. Apparently, high fat 
diet/western diet characterised by high-calorie and low-fibre content is believed to 
be associated with the current day lifestyle in most societies of the world. Long-
term intake of HFD leads to abnormal blood lipid profiles which is highly prevalence 
in metabolic disorders [242]. In addition to hepatic steatosis, HFD-feeding in rats 




syndrome components with pathophysiology that is more similar to that observed in 
human NAFLD than that generated by other animal models of NAFLD [140, 243]. 
 
The main mechanisms involved in diet-induced models in the pathogenesis 
of NAFLD, include increased de novo lipogenesis, increased dietary FFA levels, 
increased adipose tissue, impaired β-oxidation and impaired VLDL synthesis. 
These all lead to hepatic triglycerides accumulation and ultimately NAFLD [244]. 
Feeding rats with HFD, a rodent model of NAFLD, which show the characteristics 
of metabolic disorders such as insulin resistance, hyperlipidaemia and obesity were 
widely used due to its similar pathogenesis in humans [133]. 
 
Several epidemiological studies suggest that moderate alcohol may possess 
beneficial effects on the development and the progression of liver damage in 
patients with NAFLD. Daily consumption of less than 20 g of alcohol lowers the 
odds of NASH as well as fibrosis in a large biopsy-proven NAFLD population [196]. 
However, from the results of these epidemiological studies, it cannot be ruled out 
that compounds are taken in along with alcoholic’s beverage (e.g. compounds 
derived from hops or grapes or lifestyle modification associated with moderate 
alcohol consumption rather than the alcohol itself. Indeed, it was shown that chronic 
intake of high amounts of beer and wine in comparison with spirits may have less 
harmful effects on the liver [218, 245]. Results of animal studies assessing the 
effect of plain alcohol on the liver in settings of NAFLD are inconsistent as doses 
and models used varied considerably between studies [213, 214, 217]. We studied 
that HFD (60% fat with 2% cholesterol) fed rats did not show a significant increase 




increased liver weights, liver index and metabolic changes were observed. This 
could be explained by the fact that the caloric ingestion was equivalent in the two 
groups. Similar results were previously reported by other groups [246-250]. Even 
though the HFD-fed model used in our study did not show any effect on increase in 
body weight, but it managed to alter the metabolic changes in rats. 
 
Dyslipidaemia is the most important modifiable risk factor contributing to the 
development of atherosclerosis in type 2 diabetes [251]. Thus, the importance of 
blood levels of triglycerides, free fatty acids, cholesterol in the pathogenesis of lipid 
disorders were extensively reviewed [252]. Hypertriglyceridemia is one of the most 
common quantitative lipid abnormalities in NAFLD patients [253]. The excess 
supply of FFAs, directly via intake and via increased lipolysis, brings about 
triglycerides accumulation in the liver [244]. In present study, HFD-fed control rats 
exhibited increased concentrations of triglyceride (TG) and TG rich lipoprotein 
VLDL (very low-density lipoprotein). The de novo lipogenesis plays a substantial 
role in the pathogenesis of NAFLD accounting for 26% hepatic triglycerides in 
human subjects [24]. Nammi et al [183] demonstrated that light and moderate 
alcohol on normal rats did not show any significant changes in serum and liver 
triglycerides. However, in our present study low alcohol-treated group did not show 
any trend in controlling the serum and liver triglycerides, but the moderate alcohol-
treated group managed to reduce the serum and liver triglycerides levels when 
compared to HFD-fed control group. Furthermore, similar results to our data were 
reported by others stating that low and moderate alcohol did not show any effect on 





VLDL receptor belongs to the low-density lipoprotein (LDL) receptor family and is 
widely expressed in the brain, heart, skeletal muscle, and adipose tissue, whereas 
its expression is very low in the liver under normal conditions [256, 257]. In normal 
conditions, insulin downregulates VLDL secretion. Over production of large TG-rich 
VLDL in hypertriglyceridemia condition is observed in NAFLD [252, 258]. NAFLD 
was found to be associated with the overproduction of large VLDL in humans [259-
261]. In addition, Adiels et al (2006) [259] had demonstrated that HFD-fed rats 
appear to show the hepatic steatosis and increased secretion of VLDL associated 
with NAFLD and insulin resistance. HDF fed group showed an increase in serum 
VLDL levels similar to that of previous results [258, 262], whereas low and 
moderate alcohol-treated groups did not show any significant trend in regulating 
VLDL levels in treatment groups. 
 
Accumulation of neutral lipids is one of the hallmarks of NAFLD, which 
results from an imbalance between lipid availability and lipid removal. Recent data 
suggest that disturbed hepatic cholesterol homeostasis and liver free cholesterol 
accumulation are relevant to the pathogenesis of NAFLD/NASH [263]. Cholesterol 
homeostasis is extensively dysregulated at different levels in NAFLD and thus 
promotes free cholesterol accumulation. Multi-level changes occur in the liver, 
including the activation of cholesterol biosynthetic pathways, increased cholesterol 
de-esterification, and attenuated pathways in cholesterol export and bile acids 
synthesis. These changes may contribute to free cholesterol accumulation in the 
setting of NAFLD [263]. Excess free cholesterol in the liver leads to ER stress 





binding protein-1c (SREBP-1c) and SREBP-2 in insulin-resistance, playing a 
relevant role in the synthesis of fatty acids and cholesterol [264, 265]. Several 
animal studies showed an increased total cholesterol levels in rats fed with HFD 
[188, 266]. Our observations from light to moderate alcohol with HFD did not show 
any significant change in the serum cholesterol, whereas moderate alcohol with 
HFD managed a significant reduction of total cholesterol in liver tissue. 
 
In our study, a marked increase in LDL cholesterol of serum was found in 
HFD-fed rats. The increase in LDL-cholesterol may be due to reduced expression 
or activity of LDL- receptor sites in response to HFD feeding [267]. Therefore, 
lowering the LDL-cholesterol level may be important in lowering the serum total 
cholesterol level in rats fed with HFD. Fan et al (2014) demonstrated that low and 
moderate alcohol increased LDL cholesterol levels in wild-type and as well in as 
ALDH2 Knock out mice [268]. Likewise, low and moderate alcohol with HFD did not 
show any significant trend in reducing the serum LDL levels when compared to the 
HFD group. 
 
Decreased serum HDL-cholesterol is one of the typical characteristics in 
NAFLD [269]. In the present study, HFD-fed control rats demonstrated decreased 
concentrations of HDL-cholesterol compared to the normal control rats. However, 
chronic low and moderate alcohol with HFD feeding markedly elevated the serum 
HDL levels. Apo-I and Apo-II are the primary protein constituents of HDL-
cholesterol. Serum concentration of Apo-I apolipoprotein is significantly reduced in 
animals with metabolic syndrome [217, 270]. Impaired Lecithin–cholesterol 




homeostasis of acute-phase HDL compared with native HDL. The suggested 
alcohol protective mechanism takes into consideration its influence on lipoprotein 
synthesis, mainly through the increase of the HDL-cholesterol levels and a rise in 
the hepatic Apo A1 production [127]. One additional mechanism that may explain 
some of the beneficial effects of lower doses of alcohol could be its effects on the 
liver. The liver is the organ primarily responsible for detoxifying a wide variety of 
metabolic and environmental toxins so consumption of low doses of alcohol could 
enhance its ability to remove toxic compounds from the body by potentiation of key 
liver enzyme systems such as cytochrome P450 [271]. 
 
The first event in the development of NAFLD is the accumulation of 
circulating FFA in the liver. Fatty acids enter into liver cells by simple diffusion and 
accumulate in high amounts (macro-vesicular steatosis) [272]. Whenever large 
amount of fatty acids is present in the liver environment, liver cells increase lipid 
degradation pathways (lipolysis) but also suppress other pathways including insulin 
receptor activation [273]. Insulin resistance caused by hepatic de novo lipogenesis 
leads to fat accumulation in the liver from different sources including excessive 
intake of dietary free fatty acids, increased influx of FFA [274, 275]. In NAFLD 
patients, about 26% of FFAs are accumulated from de novo lipogenesis [24]. An 
earlier study demonstrated that HFD increases the serum FFA in rodents [185, 242, 
276]. Likewise, the HFD-fed control rats showed an increase in serum FFA when 
compared to the normal control group. The hypothetical mechanism behind the 
salutary effect of moderate alcohol on controlling the serum FFA is alcohol converts 





into the plasma [277], from where it associates with adipocyte-GPCR43 [278], 
which initiates a series of signal transduction steps that inhibit lipolysis [279]. With a 
decrease in lipolysis, there is a subsequent reduction in fatty acid release into the 
plasma. Thus, the decrease in serum FFA in moderate alcohol-treated group could 
be due to the acetate, the end product of alcohol metabolism. 
 
Insulin resistance is one of the key components of metabolic syndrome 
which leads to the overt onset of type 2 diabetes. High content of lipid in the diet is 
believed to contribute greatly to the occurrence of insulin resistance [280]. 
Aberration in de novo lipogenesis may lead to NAFLD and this is also marked by 
increased rate of gluconeogenesis, impaired insulin response to suppress 
gluconeogenesis. Chronic hyperinsulinemia promotes hepatic de novo lipogenesis 
through up-regulation of lipogenic transcription factors [281, 282]. In the present 
study, HFD-fed rats showed a significant increase in serum glucose and insulin 
concentrations when compared to the normal control group. Whereas moderate 
alcohol with HFD treated group showed a significant decrease in serum glucose 
and HOMA-IR. Contrary to serum glucose levels, low and moderate alcohol with 
HFD showed a non-significant trend in decreasing but managed to decrease the 
serum concentration. Insulin resistance is most commonly evaluated by the 
homeostatic model assessment of insulin resistance (HOMA-IR) which takes 
consideration of both fasting glucose and insulin concentration. In the present 
study, the calculated HOMA-IR values of HFD group (3.96 ± 0.20) is significantly 
higher than the propose cut-off point (=2.29), indicating severe insulin resistance 





serum glucose and insulin levels in ob/ob mice over a period of six months. 
Moreover, a large body of compelling evidence from various experimental animal 
and epidemiological studies had shown significant decrease in blood glucose and 
insulin resistance [284-286]. The suggested biological mechanisms underlying the 
association between alcohol consumption and alteration in insulin resistance and 
hepatic glucose metabolism is by increasing the plasma adiponectin levels, which 
is an attractive hypothesis because this adipokine is known to improve insulin 
sensitivity and fatty acid oxidation in different tissues muscle and liver), at least in 
part through an AMPK-dependent pathway [287, 288]. 
 
HFD-induced obesity and abnormal lipid metabolism are associated with 
NAFLD, causing an hepatocellular injury, increasing the serum concentrations of 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) which are 
the major markers for hepatocellular injury [289]. The increased liver enzyme levels 
and the formation of hepatic steatosis in the HDF-fed group are associated with a 
significant increase in liver weight [290]. The HFD-fed rats exhibited increased total 
liver weight. Liver injury was also confirmed by significant increases of serum AST 
and ALT in the HFD-fed group. An elevated serum activity of ALT was suggested 
as the fatty liver disease in the general human population [291]. Furthermore, 
patients with high ALT among those with the metabolic syndrome may leads to 
systemic inflammation that may, in turn increase the risk of atherosclerosis, leading 
to coronary artery or cerebrovascular disease [292]. Whereas serum AST levels are 
characteristically higher than ALT levels which contrasts with the pattern usually 





groups, moderate alcohol with HFD effectively reduce the serum AST and ALT 
levels in concordance with earlier report [255]. Furthermore, Duly et al.(2015) 
demonstrated in his study that moderate alcohol reduces serum AST and ALT 
levels when compared to HFD diet and chow diet groups [296]. 
 
 
Liver tissue for histopathology was removed from each rat, and the same 
part of each liver was dissected, fixed in 10 % formalin, and then embedded in 
paraffin wax for staining with haematoxylin and eosin (H&E). In the present study, 
H&E and Oil red O staining on the liver samples revealed distended hepatocytes 
with increased lipid droplets, macro- and micro-vesicular steatosis, indicating 
simple steatohepatitis [297]. The histological abnormalities in the HFD-fed rats of 
this study were consistent with the findings of previous studies [298, 299]. Previous 
studies demonstrated that chronic alcohol administration substantially aggravated 
the development of fatty liver in in ob/ob mice with standard diet and ob/ob mice 
with HFD [213, 300]. Similar to these results, a developed fatty liver was observed 
in high alcohol-treated with HFD. 
 
In conclusion, NAFLD induced by chronic feeding of HFD to rats leads to 
augmented metabolic dyslipidaemia. This is associated with altered serum lipid 
profile with increased serum insulin and glucose and elevated liver enzymes ALT 
and AST. Thus, long-term feeding with moderate alcohol reduced the serum 
glucose, HDL cholesterol and liver ALT and AST enzymes in animals with HFD-
induced NAFLD. Whereas as low alcohol with HFD showed its effects on 
increasing serum HDL levels. Further studies are being undertaken to explain the 
















Evaluating the mechanistic action of low and 
moderate alcohol on protecting the liver 















































Non-alcoholic fatty liver (NAFLD), a condition caused by the pathological 
accumulation of fat in the liver affecting billions of people in the world. It is a 
spectrum of disorders, beginning as simple steatosis, which can evolve into non - 
alcoholic steatohepatitis (NASH) and fibrosis, often resulting in cirrhosis and even 
hepatocellular carcinoma [301]. NAFLD pathogenesis is mainly characterized by 
the multiple-hit hypothesis, manifestation of both genetic and environmental factors, 
dysfunction of various organs, and organelles, as well as the complex interaction 
between hepatocytes and other cells (e.g., Kupffer and stellate cells) in the liver 
[185]. Moreover, as liver is a hub for many metabolic pathways making NAFLD a 
multistage, progressive disease with systemic consequences. It is commonly 
associated with obesity, insulin resistance, and enhanced risk of cardiovascular 
disease and mortality. All the above-mentioned cluster of physiological 
abnormalities are also common in NAFLD which is a component of metabolic 
syndrome [302]. 
 
The diagnosis of NAFLD is confirmed by hepatic steatosis, which is a 
prerequisite to making a histological diagnosis of NAFLD [14]. Several mechanisms 
may lead to steatosis, including increased fat supply such as high-fat diet and 
excess adipose lipolysis; decreased fat export in the form of very low density 
lipoprotein-triglyceride decreased free fatty -oxidation; and an increased DNL [14, 
303-305]. The enhancement of hepatic DNL is deemed to be a unique feature in 
steatosis, increased DNL synthesis of fatty acids in hepatocytes, the retention of 
lipids due to impaired hepatocyte apolipoprotein secretion or β-oxidation [306]. 
More importantly, insulin resistance appears to be at center stage for the massive 
 
80 
metabolic dysregulations of NAFLD that initiate and aggravate hepatic steatosis 
 
[262]. Several prior studies have reported that diets with saturated fat and simple 
sugars enhances the DNL, increased DNL leads to development of hepatic 
steatosis with metabolic syndrome and high content of liver fat [23, 307, 308]. Apart 
from increasing the DNL in liver, decrease in fatty acid oxidation caused by HFD 
substantially decreased the activities of both isoforms of AMPK in white adipose 
tissue, heart, and liver [309]. The HFD increase inflammation, obesity, and 
diabetes, all these physiological changes also leads decrease in AMPK activity 
 
[310]. The increase in systemic inflammation, hyperglycaemia or elevated levels of 
free fatty acids leads to decreases AMPK levels in liver [309]. 
 
AMP-activated protein kinase (AMPK) is a master regulator of energy 
balance, it regulates a large array of intracellular processes including the cellular 
uptake of glucose and free fatty acids, cell cycling, mRNA stability, and apoptosis 
[311, 312]. Furthermore, AMPK plays a more global role, regulating multiple 
aspects of whole-body energy balance including appetite, insulin sensitivity, and 
the actions of adipokines/cytokines [39, 69, 313]. Apart from AMPK, HFD 
decreases LKB1 (liver kinase B1) expression which is an up regulator of AMPK 
which directly phosphorylates AMPK at Thr-172 [53]. Besides AMPK, SIRT1 also 
plays an important role in regulating metabolic activities related to NAFLD 
pathophysiology [314]. On the other hand, AMPK activation by LKB1 leads to 
 
increase cellular NAD+ levels which subsequently activates SIRT1 signalling [104]. 
Moreover, HFD reduces the SIRT1 expression in liver, which is also a novel up- 
 
stream regulator for LKB1/AMPK signalling and plays an important role in 




controversial. Excessive alcoholic consumption may leads to obesity, accumulation 
of hepatic fat, altering the physiological and pathological changes in the liver [214, 
315]. In contrast to the excessive high alcohol, consumption, the low and moderate 
alcohol consumption increases AMPK protein expression in animal models [192, 
213]. Interestingly, however, an epidemiological review of health status data for a 
general population has demonstrated that the prevalence of metabolic syndrome is 
lower in individuals with low to moderate alcohol consumption than in those who do 
not consume alcohol [316]. Thus, in the present study we investigate the role of 
low, moderate and high alcohol on the hepatic AMPK-α1, LKB1 and SIRT1 proteins 
and their downstream targets such as ACC and SREBP1, which play a key role in 






































3.2 Materials and methods 
 
 
3.2.1 Chemicals used 
 
 
Electrophoresis and electro-blotting consumables were purchased from Bio-
Rad (Hercules, CA, USA). Primary antibodies of AMPK-α1, p-AMPK-α1, p-ACC, 
LKB1, p-LKB1, SIRT1 and SREBP1 were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) while ACC was obtained from (Abcam, Cambridge, United 
Kingdom). Enhanced chemiluminescence kit was obtained from Bio-Rad (Hercules, 
CA, USA). All other chemicals used were of analytical or molecular biology grade. 
 
3.2.2 Reagents used 
 
(1) Radio immunoprecipitation assay (RIPA) buffer (pH 8.0) 
 
 
Sodium chloride (150 mM), sodium deoxycholate (0.5%), sodium dodecyl 
sulfate (0.1%), Tris base (50 mM) and 1 mL of triton X-100 (1%) were added into a 
volumetric flask and made up to 100 mL with distilled water. The solution was 
transferred into a beaker and the pH was adjusted to 8.0 and filtered before use 
through a 0.2 μM membrane. 
 
(2) Running buffer 
 
 
Glycine (14.42 g), tris base (3.03 g), sodium dodecyl sulfate (1 g) were 
added into a volumetric flask and made up to 1000 mL with distilled water. The 
solution was transferred into a beaker and the pH was adjusted to 8.3 and filtered 







(3) Transfer buffer 
 
 
Tris base (3.03 g), glycine (14.41 g) and methanol (200 mL) were added into 
a volumetric flask and made up to 1000 mL with distilled water. The solution was 
filtered before use through a 0.2 μM membrane. 
 
(4) Tris-buffered saline (TBS) 
 
 
Tris-base (2.4 g) and NaCl (8 g) were added into a volumetric flask and 
made up to 1000 mL with distilled water. The solution was transferred into a beaker 
and the pH was adjusted to 7.6 and filtered before use through a 0.2 μM 
membrane. 
 
(5) Phosphate buffered saline (PBS) 
 
 
Sodium chloride (8 g), potassium chloride (0.2 g), disodium hydrogen 
phosphate (1.44 g), and potassium dihydrogen phosphate (0.24 g) were added into 
a volumetric flask and made up to 1000 mL with distilled water. The solution was 
transferred into a beaker and the pH was adjusted to 7.6 and filtered before use 
through a 0.2 μM membrane. 
 
3.2.3 Liver protein extraction 
 
 
Frozen liver samples were homogenized on ice for 30 seconds using a 
Tissue Master homogenizer (Omni International, GA, USA) with five volumes of 
radio immunoprecipitation assay (RIPA) buffer (pH 8.0) containing 50 mM Tris, 150 
mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 




homogenates were centrifuged at 4 °C at 10,000 g for 15 minutes, and the 
supernatants were collected. Protein concentrations were measured by the 
Bradford assay using bovine serum albumin as standard. 
 
3.2.4 Western blot analysis 
 
 
The samples were mixed with loading buffer, proteins were denatured by 
heating at 95 oC for 5 minutes, and 25 g of total protein was electrophoretically 
resolved on 10% Mini-PROTEAN® TGX™ Poured gels (Bio-Rad, Australia) at 135 
V for 90 minutes and then transferred onto a nitrocellulose membrane (Bio-Rad, 
Australia) using a wet transfer (100 V for 135 minutes). After blotting, the 
membranes were blocked with 5% non-fat dry milk for 1 hour at room temperature. 
The membranes were then washed three times for 5 minutes each with tris-buffered 
saline-0.1% Tween-20 (TBST, pH 7.6) and incubated for overnight at 4 C with 
mouse anti-p-ACC reductase (1:1000) or mouse anti-AMPK (1:1000) or mouse anti- 
LKB1 (1:1000) or mouse anti- p-LKB1(1:1000) or mouse anti- SIRT1 (1:1000) or 
mouse anti- SREBP1(1:1000) antibody (Santa Cruz, Biotechnology, CA, USA) 
,rabbit anti-p-AMPK(1:500) or rabbit anti-ACC(1:1000) (Abcam, Cambridge, UK) 
diluted with TBST. Blots were then again washed three times for 5 minutes each 
with TBST and incubated for 1 hour at room temperature with an appropriate 
horseradish peroxidase-conjugated secondary antibody (Santa Cruz, 
Biotechnology, CA, USA) diluted at 1:10,000 with phosphate-buffered saline (PBS, 
pH 7.4). The membranes were again washed three times for 5 minutes each with 
TBST and incubated with enhanced chemiluminescence reagent (Clarity™ Western 




were detected after exposing the blots to ChemiDoc™ XRS system (Bio-Rad, 
Australia) for various time point. Quantitative image analysis was performed using 
NIH Image software (Image J) to determine the intensity of the protein signal, which 
was expressed relative to the amount of -actin used as an internal control. 
 
3.2.5 Data and statistical analysis 
 
 
The results are expressed as mean ± SEM. To analyse the quantitative 
differences among the experimental groups before or after treatments, the data 
were subjected to analysis of variance (ANOVA) using the GraphPad 7.03 
(GraphPad Software Inc., California, CA, USA) statistical software. Post-hoc 









































3.3.1 Effect of low, moderate, and high alcohol on AMPK-α1 and its 
phosphorylation in the liver of HFD-fed rats 
 
The effect of low, moderate and high alcohol on the protein expression of 
AMPK-α1 in rat liver was shown in Figure 3.1A. The HFD-fed control group (n=6) 
showed a significant (p<0.001) 1.7-fold decrease in AMPK-α1 protein expression 
when compared to the normal control rats (n=5). On the other hand, both the low 
alcohol-treated (n=5) and moderate alcohol-treated (n=6) groups showed a 
significant increase in AMPK-α1 protein expression by 1.2-fold (p<0.05) and 1.3-
fold (p<0.01) respectively when compared to the HFD-fed control group. In contrast, 
the high alcohol-treated group (n=4) showed a significant 1.5-fold (p<0.01) 
decrease in AMPK-α1 protein expression when compared to the HFD-fed control 
group. 
 
Figure 3.1B illustrates the effect of low, moderate and high alcohol on 
phosphorylation of AMPK-α1 in rat liver. The HFD-fed control group (n=6) showed a 
significant (p<0.01) 1.8-fold decrease in phosphorylation-AMPK-α1 protein when 
compared to the normal control rats (n=5). On the other hand, both the low alcohol-
treated (n=5) and moderate alcohol-treated (n=6) groups showed a significant 
increase in phosphorylation of AMPK-α1 protein by 1.5-fold (p<0.05) and 1.5-fold 
(p<0.05) respectively when compared to the HFD-fed control group. In contrast, the 
high alcohol-treated group (n=4) showed a non-significant (p=0.30) decrease in 

















































Figure 3.1 Protein expression of AMPK-α1 and p-AMPK-α1 in the liver of HFD-
fed rats treated with chronic low, moderate and high alcohol for 15 weeks. (A) 
AMPK-α1 (B) p-AMPK-α1 protein expression as determined by western blot 
analysis in the liver of HFD-fed rats for 15 weeks either with low or moderate or 
high alcohol. 
 
Each bar represents the mean ± SEM of n=4-6 rats calculated relative β-actin 
used as internal control. 
Significant difference from normal control: ###p<0.001, ##p<0.01 
Significant difference from FFA control: **p<0.01, *p<0.05  










3.3.2 Effect of low, moderate, and high alcohol on LKB1 and its 
phosphorylation in the liver of HFD-fed rats 
 
The effect of low, moderate, and high alcohol on the protein expression of 
LKB1in rat liver was shown in Figure 3.2A. The HFD-fed control group (n=6) 
showed significant (p<0.05) 1.2-fold decrease in LKB1 protein expression when 
compared to the normal control rats (n=5). On the other hand, the low alcohol-
treated group (n=5) showed a non-significant 1.2-fold (p=0.09) increase in LKB1 
protein expression when compared to the HFD-fed control group. However, the 
moderate alcohol-treated group (n=6) showed a mild non-significant 1.1-fold 
(p=0.96) increase in LKB1 expression when compared to the HFD-fed control 
group. In contrast, the high alcohol-treated group (n=4) showed a non-significant 
(p=0.63) decrease in LKB1 protein expression when compared to the HFD-fed 
control group. 
 
Figure 3.2B illustrates the effect of low, moderate and high alcohol on 
phosphorylation of LKB1 in rat liver. The HFD-fed control group (n=6) showed a 
significant (p<0.01) 1.8-fold decrease in phosphorylation of LKB1 protein when 
compared to the normal control rats (n=5). On the other hand, the moderate 
alcohol-treated rats (n=6) showed a significant 1.2-fold (p<0.05) increase in 
phosphorylation of LKB1 protein expression when compared to the HFD-fed control 
group. However, the low alcohol-treated group (n=5) showed a non-significant 1.2-
fold (p=0.12) increase in phosphorylation of LKB1 expression when compared to 








a non-significant 1.5-fold (p=0.30) decrease in phosphorylation of LKB1 protein 
















































































































Figure 3.2 Protein expression of LKB1 and p-LKB1 in the liver of HFD-fed rats 
treated with chronic low, moderate and high alcohol for 15 weeks. (A) LKB1 
 
(B) p-LKB1 protein expression as determined by western blot analysis in the liver of 
HFD-fed rats for 15 weeks either with low or moderate or high alcohol. 
 
Each bar represents the mean ± SEM of n=4-6 rats calculated relative β-actin 
used as internal control. 
Significant difference from normal control: ##p<0.01, #p<0.05 
Significant difference from FFA control:  *p<0.05  





3.3.3 Effect of low, moderate, and high alcohol on SIRT1 protein expression in 
 
the liver of HFD-fed rats 
 
 
The effect of low, moderate, and high alcohol on the protein expression of 
SIRT1 in rat liver was shown in Figure 3.3. The HFD-fed control group (n=6) 
showed a significant (p<0.01) 1.4-fold decrease in SIRT1 protein expression when 
compared to the normal control rats (n=5). On the other hand, the moderate 
alcohol-treated rats (n=6) showed a non-significant 1.2-fold (p=0.08) increased 
trend in SIRT1 protein expression when compared to the HFD-fed control group. 
Furthermore, the low alcohol-treated group (n=5) showed a non-significant 1.2-fold 
(p=0.15) increase in SIRT1 expression when compared to the HFD-fed control 
group. In contrast, the high alcohol-treated group (n=4) showed a non-significant 
1.2-fold (p=0.47) decrease in SIRT1 protein expression when compared to the 

























































Figure 3.3 Protein expression of SIRT1 in the liver of HFD-fed rats treated 
with chronic low, moderate and high alcohol for 15 weeks. SIRT1 protein 
expression as determined by western blot analysis in the liver of HFD-fed rats 
treated for 15 weeks either with normal diet (normal control) or HFD (disease 
control) alone or with low, moderate and high alcohol with HFD 
 
Each bar represents the mean ± SEM of 4-6 rats calculated relative β-actin used 
as internal control. 
Significant difference from normal control: ##p<0.01 




























3.3.4 Effect of low, moderate, and high alcohol on ACC and its 
 
phosphorylation in the liver of HFD-fed rats 
 
 
The expression of ACC protein in rat liver was shown in Figure 3.4A. The 
HFD-fed control group (n=6) showed a significant (p<0.05) 1.5-fold increase in ACC 
protein expression when compared to the normal control rats (n=5). On the other 
hand, the moderate alcohol-treated group (n=6) showed a non-significant 1.4-fold 
(p=0.07) decrease in ACC protein expression when compared to the HFD-fed 
control group. Furthermore, the low alcohol-treated group (n=5) showed a non-
significant 1.2-fold (p=0.44) decrease in ACC expression when compared to the 
HFD-fed control group. In contrast, the high alcohol-treated group (n=4) showed a 
non-significant 1.3-fold (p=0.38) increase in ACC protein expression when 
compared to the HFD-fed control group. 
 
The effect of low, moderate and high alcohol on phosphorylation of ACC in 
rat liver was shown in Figure 3.4B. The HFD-fed control group (n=6) showed a 
significant (p<0.05) 2.6-fold decrease in phosphorylation of ACC protein when 
compared to the normal control rats (n=5). On the other hand, both the low alcohol-
treated (n=5) and moderate alcohol-treated (n=6) groups showed a significant 
increase in phosphorylation of ACC protein by 2.8-fold (p<0.01) and 2.4-fold 
(p<0.05) respectively when compared to the HFD-fed control group. In contrast, the 
high alcohol-treated group (n=4) showed a non-significant 1.9-fold (p=0.77) 



















































Figure 3.4 Protein expression of ACC and p-ACC in the liver of HFD-fed rats 
treated with chronic low, moderate and high alcohol for 15 weeks. (A) ACC (B) 
p-ACC protein expression as determined by western blot analysis in the liver of 
HFD-fed rats for 15 weeks either with low or moderate or high alcohol. 
 
Each bar represents the mean ± SEM of n=4-6 rats calculated relative β-actin 
used as internal control. 
Significant difference from normal control: #p<0.05 
Significant difference from FFA control:  **p<0.01, *p<0.05  









3.3.5 Effect of low, moderate, and high alcohol on SREBP1 protein expression 
 
in the liver of HFD-fed rats 
 
The effect of low, moderate, and high alcohol on the protein expression of 
SREBP1 in rat liver was shown in Figure 3.5. The HFD-fed control group (n=6) 
showed significant (p<0.01) 1.7-fold increase in SREBP1 protein expression when 
compared to the normal control rats (n=5). On the other hand, the low alcohol-
treated rats (n=5) showed a significant 1.3-fold (p<0.05) decrease in SREBP1 
protein expression when compared to the HFD-fed control group. In contrast, both 
the moderate alcohol-treated (n=6) and high alcohol-treated (n=4) groups showed a 
mild non-significant increase in SREBP1 protein expression by 1.0-fold (p=0.81) 

































































Figure 3.5 Protein expression of SREBP1 in the liver of HFD-fed rats treated 
with chronic low, moderate and high alcohol for 15 weeks. SREBP1 protein 
expression as determined by western blot analysis in the liver of HFD-fed rats 
treated for 15 weeks either with normal diet (normal control) or HFD (disease 
control) alone or with low, moderate and high alcohol with HFD 
 
Each bar represents the mean ± SEM of 4-6 rats calculated relative β-actin used 
as internal control. 
Significant difference from normal control: ##p<0.05 
Significant difference from FFA control:  *p<0.05  


























NAFLD, which is a multi-factorial disorder associated with a variety of 
genetic and environmental factors, is the most common cause of liver disease 
 
[317]. It is proven that HFD initiates a serious of molecular events in humans as 
well as in experimental animal models, leading to elements of metabolic syndrome, 
including insulin resistance and obesity [249, 312, 318]. In the present chapter, we 
examined the molecular mechanism(s) behind low, moderate and high doses of 
alcohol on liver proteins such as AMPK-α1, LKB1 and SIRT1 which play a major 
 
role in regulating hepatic lipid metabolism in rats fed with HFD. The results from 
chapter-2 confirmed that our HFD model showed an increased serum lipids along 
with serum insulin, glucose, ALT, and AST levels, which are common indicators of 
liver injury in the majority of liver diseases [319-321]. Thus, long-term feeding with 
moderate alcohol with HFD fed rats reduced the serum glucose, HDL cholesterol 
and liver ALT and AST enzymes in animals with HFD induced NAFLD. Whereas, 
low alcohol group with HFD showed its effects on increasing serum HDL levels. The 
HFD-induced increased inflammation, obesity, and diabetes, all these physiological 
changes lead to decrease in AMPK activity [310]. AMPK is a multi-subunit protein 
kinase found in all eukaryotes. It acts as a metabolic “master switch” regulating 
cellular processes which are controlled by the body’s energy state [322, 323]. The 
activity of AMPK is stimulated by stresses which increase the AMP/ATP ratio, and 
once activated AMPK acts to inhibit pathways that consume ATP and to stimulate 
multiple events that enhance ATP generation. Thus, AMPK plays a central role in 
the regulation of lipid metabolism by inhibiting regulatory enzymes involved in 




methoxyglutaryl-CoA reductase (HMG-CoA) [324]. ACC is a key regulatory enzyme 
of fatty acid synthesis, and phosphorylation of hepatic ACC in vivo is mostly 
achieved by AMPK, rendering the enzyme inactive [325]. The malonyl-CoA, is a 
precursor for the biosynthesis of fatty acids and a potent inhibitor of mitochondrial 
fatty acid oxidation at the carnitine palmitoyl transferase-I (CPT-I) step [326]. Thus, 
when ACC is inhibited, cellular concentration of malonyl-CoA decreases, and the 
inhibition of CPT-I is relieved, resulting in increased fatty acid oxidation [327]. 
Malonyl-CoA is also degraded by malonyl-CoA decarboxylase (MCD), which is 
activated by AMPK. Several studies have demonstrated that AMPK is the major 
protein kinase responsible for the inactivation of ACC and the activation of MCD, 
resulting in reduced malonyl-CoA levels and increased fatty acid oxidation [328]. 
Our results with HFD and high alcohol group with HFD diet are similar with previous 
results showing a decrease in AMPK and phosphorylation of AMPK expression in 
rat liver [214, 329]. The mechanisms behind the decrease in AMPK, are increasing 
circulating metabolites such as glucose and FFA are decreasing AMPK activity 
 
[330]. Moreover, in the model we studied, circulating glucose and the FFA levels 
were elevated. Thus, elevated circulating levels of metabolic substrates seem likely 
to be the cause of the HFD-induced reduction in AMPK activity. The mechanism 
behind the decrease of AMPK and p-AMPK are due to increase in ROS caused by 
alcohol or increase in fatty acid synthesis, dephosphorylation of AMPK by protein 
phosphate 2A (PP2A) causing AMPK inactivation, increase in alcohol 
administration leads to increased ceramide levels, which activates the PP2A, which 
in turn inhibits the AMPK pathway activity and increases the fatty acid synthesis 




we have observed an increased phosphorylation of AMPK-α1 in the low and 
moderate alcohol with HFD groups. Our results are similar with the published data 
demonstrating that moderate alcohol consumption increases AMPK action in rats 
[183, 192, 213]. The possible mechanism behind the paradoxical dual effects of 
alcohol could be due to appropriate alcohol metabolic pathway at the threshold of 
alcohol consumption. It is well known that acetate is produced when alcohol 
metabolism takes place in the liver [334]. Most of the evolved acetate is oxidized in 
peripheral tissues. The conversion of acetate to acetyl-CoA, a reaction which 
generates AMP that triggers AMPK activation and thus support our results. 
Moreover, binding of AMP to AMPKγ is thought to promote phosphorylation of the 
critical activation loop threonine (Thr172) in AMPKα, which is required for AMPK 
activity, largely through suppression of phosphatase activity towards Thr172 [333, 
335]. Apart from AMP, LKB1, CaMKKβ (Ca2+/calmodulin-dependent protein kinase 
kinase β) have identified as physiological kinases upstream of AMPK [53, 336, 
337]. LKB1 was first identified in hereditary Peutz-Jeghers syndrome [338]. LKB1 is 
a serine/threonine protein kinase that can directly activate AMPK and 12 kinds of 
related kinases [312, 338]. Under normal physiological conditions, LKB1 is located 
in nucleus and constitutively active [339-341], which makes it necessary to have a 
counter-mechanism available to prevent persistent or exaggerated activation of 
AMPK signalling. LKB1 forms a heterotrimeric complex like AMPK with regulating 
proteins termed STRAD and MO25, which are required for its activation and 
cytosolic localization [342]. Our results were consistent with the previous results 
showing that HFD diminishes the expression of LKB1 protein and its 




alcohol administration on p-LKB1 has been limitedly reported. Moderate alcohol 
with HFD group showed a significant increase in p-LKB1 expression. The possible 
mechanisms phosphorylation of LKB1 at Ser-428/431, by activating protein kinase 
C (PKC)-zeta(ζ) which exports the LKB1 from nucleus to cytosolic for activation and 
subsequent AMPKα phosphorylation at Thr172 [344]. According to recent studies, 
deacetylation of SIRT1 regulates LKB1 and induces translocation of LKB1 to the 
cytosol from the nucleus [46, 192]. Translocated LKB1 associates with STRAD and 
MO25 and exhibits kinase activity leading to the phosphorylation of AMPK [345]. In 
this study, low alcohol with HFD groups showed an increased trend in p-LKB1 
expression. Whereas, high alcohol with HFD group showed a decrease in p-LKB1 
levels which are consistent with the previous results [216]. Apart from AMPK and 
LKB1, SIRT1 also plays a major role in regulating lipid metabolism in the liver. A 
decrease in SIRT1 is associated with a diminished LKB1 and AMPK activity [46, 
192, 346]. SIRT1 is widely expressed in mammalian cells and has been studied in 
many tissues including brain, skeletal muscle, adipose tissue, pancreas (β-cells), 
and liver [347-349]. SIRT1 is an NAD1-dependent deacetylase and its enzymatic 
activity may be regulated by cellular energy and enhanced by an increase in the 
NAD + /NADH ratio 
 
[350]. SIRT1 plays a key role in many cellular processes of mammalian cells in vivo 
[351-353]. Apart from LKB1 deacetylation by SIRT1 protein, it deacetylates P53, Tata 
box-binding protein-associated factor I (TAFI68), p300 (CREB-binding protein 
homologue), p300/CREB-binding protein-associated factor (PCAF), myoblast 
determination protein (MyoD), Forkhead transcription factors (FOXO), p65 subunit of 




peroxisome proliferators activated receptor γ co-activator 1α (PGC-1α) [167]. 
SIRT1 and its activators play a key role in lipid and glucose homeostasis and 
insulin sensitivity via regulating mitochondrial biogenesis and β-oxidation and 
improving anti-inflammatory activities [354]. A lot of published evidence indicates 
that HFD and high alcohol reduces SIRT1 expression in the liver [214, 355-357]. In 
experimental condition, alcohol is firstly metabolized by either alcohol 
dehydrogenase (ADH) in the cytosol or cytochrome P450 2E1 (CYP2E1) in the 
endoplasmic reticulum to produce acetaldehyde, which is further rapidly 
metabolized by mitochondrial aldehyde dehydrogenase (ALDH2) to form acetate 
and convert NAD+ to NADH [93, 94]. Moreover, reduced NAD+ level and SIRT1 
activity were concomitant with dietary energy/nutrition overload status such as high-
fat diet and/or high-calorie diet feeding conditions [358, 359]. The effects of 
moderate alcohol on SIRT1 protein are not consistent. Kanuri et al (2016) [255] 
demonstrated that moderate alcohol has increased SIRT1 mRNA expression in 
visceral adipose tissue in mice. In our study, low and moderate alcohol with HFD 
groups showed an increased trend in SIRT1 protein expression in the liver. The 
possible mechanism behind the increase in trend in SIRT1 expression is due to 
AMPK which enhances SIRT1 activity by increasing cellular NAD+ levels, resulting 
in the deacetylation and modulation of the activity of downstream SIRT1 targets 
[48]. 
 
SREBP-1 and -2 are important transcription factors in the liver, SREBP-1 
controls the expression of genes involved in fatty acid and triglyceride synthesis, 
and SREBP-2 controls the expression of genes involved in cholesterol synthesis 




regulation in the liver by nutrients and hormones is different. SREBP-1 and 
SREBP-2 regulate the fatty acid and cholesterol synthesis, respectively, by 
activating the enzymes involved in the fatty acid and cholesterol biosynthetic 
pathways including ATP citrate lyase (ACL), fatty acid synthase (FAS), stearoyl-
CoA desaturase (SCD) and HMG-CoA reductase [360]. SREBPs are expressed as 
precursor proteins that span the endoplasmic reticulum membrane, are 
proteolytically cleaved and translocated to the nucleus under the influence of 
SREBP cleavage-activating protein (SCAP) to activate transcription. Nammi et al 
(2013) [183] demonstrated that low and moderate alcohol reduced the SREBP1 
protein levels in normal rats. Our results were consistent showing that low alcohol 
with HFD group showed a decreased SREBP1 expression. AMPK activation 
resulted in a dramatic reduction of SREBP-1 in the liver, suggesting a direct link 
between AMPK action and SREBP transcriptional activity [362, 363] which support 
our present observations that low alcohol treatment tended to increase the liver 
AMPK-α1 phosphorylation and decrease SREBP-1 protein expression leading to 
increased fatty acid oxidation. Even though moderate alcohol with HFD group 
showed an increase in p-AMPK levels, but increased p-AMPK protein didn’t show 
any effect in controlling SREBP1 expression. Nevertheless, it is not clear from our 
studies why increased p-AMPK levels did not regulate the SREBP1. Whereas, high 
alcohol with HFD group did not show any effect in controlling the SREBP1 
expression. Acetyl CoA carboxylase (ACC), a key enzyme in de novo lipogenesis, 
exists around the mitochondria and controls β-oxidation of fatty acids in the 
mitochondria. ACC is a physiologic inhibitor of CPT, which synthesizes malonyl 




metabolism and β-oxidation of fatty acids in the liver. Fatty acids are converted into 
acetyl-CoA through mitochondrial oxidation. Fatty acid oxidation is repressed by 
dephosphorylated AMPK which conserves serine/threonine protein kinase that acts 
as a metabolic master switch [365]. Phosphorylated AMPK inactivates ACC by 
phosphorylation and lessen the intracellular malonyl-CoA level, which is the 
substrate for synthesis of fatty acid and, at the same time, the inhibitor of CPT-1, 
the rate-limiting enzyme of mitochondrial fatty acid oxidation. Repression of ACC 
causes the inhibition of endogenous free fatty acids [366]. In this study, the eminent 
expressions of ACC were found in HFD fed rats. The increase in p-ACC levels has 
been observed in low and moderate alcohol groups, possibly due to the increase in 
p-AMPK which regulated the phosphorylation of ACC. 
 
In the present study we found that HFD increased the expression of 
SREBP1 and ACC proteins which play a major role in regulating fatty acids 
synthesis and β-oxidation of fatty acids which leads to increase the lipid deposition 
in the liver leads to steatosis the first stage of NAFLD. The low and moderate 
alcohol-treated groups increased AMPK-α1, p-AMPK-α1, LKB, p-LKB1, and SIRT1 
proteins which regulate each other and regulates the lipid metabolism pathways. 
Further studies have been undertaken for understand the role of each protein in 




































Evaluating the mechanistic action of low and 
moderate alcohol on protecting the HepG2 










































Non-alcoholic fatty liver (NAFLD) has become a significant public 
health burden effecting millions of people worldwide [186]. NAFLD encompasses a 
spectrum of liver diseases ranging from a benign fatty liver disorder to the 
nonalcoholic steatohepatitis (NASH) that may progress to cirrhosis in up to 25% of 
patients. It is closely associated with metabolic syndrome which is a cluster of 
complex conditions including central obesity, hypertriglyceridemia, hyperglycemia, 
hypertension, and low HDL (high density lipoprotein) that are predictive risk factors 
of cardiovascular disease, stroke, and diabetes [367-369]. 
 
From the evidence from Berson et al (1998) Day and James first 
proposed a two-hit process for the pathogenesis of NAFLD [15, 370]. Accumulation 
of triglycerides in hepatocytes leads to the development of hepatic steatosis which 
is the first hit, which increases the vulnerability of the liver to various possible 
“second hits” that in turn lead to the inflammation, fibrosis, and cellular death 
characteristics of NASH. The second hit can be a variety of factors, such as 
oxidative stress, endoplasmic reticulum stress, pro-inflammatory cytokines, and 
gut-derived bacterial endotoxin [190]. However, increased FFA can lead to 
excessive hepatic lipid accumulation correlating with disease severity [371]. 
Numerous studies have suggested that FFA influx and de novo lipogenesis are the 
major pathogenic processes in the development of non-alcoholic fatty liver [372]. 
This has been supported by animal models of genetic, dietary and combined 
models characterized by increased hepatic lipid accumulation, where a second 




limitations in regards to tissue collection, required long period to study, animal models 
which depending on the model used may more or less mimic the situation found in 
humans. More recently, in vitro models of steatosis have been used to study the 
hepatocellular consequences of lipid accumulation in hepatic cells of a human origin 
[375, 376]. Primary human hepatocytes are the gold standard for in vito cellular 
studies. However, they present issues with availability, inter-donor variability and the 
short time frame during which they remain differentiated [377, 378]. As a result, 
proliferating human hepatoma cell models are the most widely used option. A first 
alternative is the widely used human hepatocellular carcinoma cell line HepG2. These 
cells are human hepatoblastoma cell line that displays many of the genotypic features, 
including some liver-specific metabolic functions, have been widely used as a human-
derived in vitro model for investigating basic hepatic metabolism and drug 
hepatotoxicity as well as liver steatosis [379-382]. The main fatty acids in the human 
body consist of palmitic acid (PA) and oleic acid (OA) 
 
[383]. A combination (OA+PA) or individual usage of FFA are widely used in vitro to 
induce steatosis in cultured human liver cell lines [384-387]. These FFAs are 
absorbed by liver cells through facilitated transport mechanisms and converted to 
triacylglycerides [388]. Understanding the intracellular absorption of free fatty acids 
and their role in cellular cytotoxicity is critical towards elucidating the causes of 
NASH [389]. 
 
Excessive alcoholic consumption leads to induce the oxidative stress and activate 
the inflammatory pathways, that produce cytokines, tumour necrosis factor-alpha, 





believed to play a major role in pathogenesis and progression of alcoholic liver 
diseases [164, 390, 391]. HepG2 cells cannot produce alcohol dehydrogenase 
activity, however, incubation with alcohol resulted in the appearance of such 
activity which could explain the alcohol toxicity [392]. 
 
In contrast to heavy alcohol that precipitates alcoholic fatty liver 
disease, low and moderate alcohol showed beneficial effects on rodent model 
[192]. The results from (chapter 3) prove that low and moderate alcohol protects the 
liver from NAFLD by increasing the phosphorylation of AMPK-α1 in rats fed with 
HFD. A numerous in vito and in vivo studies have demonstrated that AMPK-α1 
activation protects the liver from NAFLD by increasing the fatty acid oxidation, 
inhibition of cholesterol synthesis, glucose production and hepatic lipogenesis [393, 
394]. 
 
The aim of this chapter was to investigate the role of low to moderate 
alcohol on protecting the HepG2 cells from FFA-induced hepatic steatosis by 
increasing the proteins AMPK, and SIRT1 proteins which further suppress the ACC 























4.2 Materials and methods 
 
4.2.1 Chemicals used 
 
Electrophoresis and electro-blotting consumables were purchased from Bio-
Rad (Hercules, CA, USA). Primary antibodies of AMPK-α1, p-AMPK-α1, p-ACC, LKB1, 
p-LKB1, SIRT1 and SREBP1 were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) while ACC was obtained from (Abcam, Cambridge, United Kingdom). 
Enhanced chemiluminescence kit was obtained from Bio-Rad (Hercules, CA, USA). 
DMEM ( modified basal medium eagle), low glucose, alcohol, Fetal bovine serum 
(FBS), sodium oleate, sodium palmitate from Sima (Sigma St. Louis, MO, USA). All 
other chemicals used were of analytical or molecular biology grade. 
 
 
4.2.2 Reagents used 
 
(1) Radio immunoprecipitation assay (RIPA) buffer (pH 8.0) 
 
 
Sodium chloride (150 mM), sodium deoxycholate (0.5%), sodium dodecyl 
sulfate (0.1%), Tris base (50 mM) and 1 mL of triton X-100 (1%) were added into a 
volumetric flask and made up to 100 mL with distilled water. The solution was 
transferred into a beaker and the pH was adjusted to 8.0 and filtered before use 
through a 0.2 μM membrane. 
 
(2) Running buffer 
 
 
Glycine (14.42 g), tris base (3.03 g), sodium dodecyl sulfate (1 g) were 
added into a volumetric flask and made up to 1000 mL with distilled water. The 
solution was transferred into a beaker and the pH was adjusted to 8.3 and filtered 





(3) Transfer buffer 
 
 
Tris base (3.03 g), glycine (14.41 g) and methanol (200 mL) were added into 
a volumetric flask and made up to 1000 mL with distilled water. The solution was 
filtered before use through a 0.2 μM membrane. 
 
(4) Tris-buffered saline (TBS) 
 
 
Tris-base (2.4 g) and NaCl (8 g) were added into a volumetric flask and 
made up to 1000 mL with distilled water. The solution was transferred into a beaker 
and the pH was adjusted to 7.6 and filtered before use through a 0.2 μM 
membrane. 
 
(5) Phosphate buffered saline (PBS) 
 
 
Sodium chloride (8 g), potassium chloride (0.2 g), disodium hydrogen 
phosphate (1.44 g), and potassium dihydrogen phosphate (0.24 g) were added into 
a volumetric flask and made up to 1000 mL with distilled water. The solution was 
transferred into a beaker and the pH was adjusted to 7.6 and filtered before use 
through a 0.2 μM membrane. 
 
(6)  Stacking gel buffer 
 
Tris base (15.14 g), SDS (1.0 g) were added into volumetric water and made up 
to 250ml with distilled water. The solution was transferred into a beaker and the pH 










(7) Sodium oleate 
 
Sodium oleate (40.58 mg) in 10 mL (13.33 mM) stock of plain DMEM at 
37ºC with fatty acid-free BSA and filtered with a 0.2 μM membrane and stored in - 
20° 
 
(8) Sodium palmitate 
 
 
Sodium palmitate (18.54 mg) in 10 mL of plain DMEM at 50 ºC with constant 
shaking with Fatty acid-free BSA and filtered with a 0.2 μM membrane and stored in 
-20°C. 
 
(9) 400 mM alcohol 
 
Alcohol 184.28 mg or 235 μL of alcohol in 10 mL of plain DMEM for 400 mM 
stock and filtered with a 0.2 μM membrane and stored in 4 ºC. 
 
4.2.3 Cell culture 
 
HepG2 cells (passage-7) are obtained from the University of Sydney, which 
were previously maintained in DMEM with low glucose, 10% FBS, 1% antibiotics 
(10,000 I.U./mL Penicillin, 10,000 (μg/mL) Streptomycin) as per mentioned in ATCC 
guidelines for HepG2 cells. They were maintained in same incubator conditions, at 
37º C with 5% CO2 changing the growth medium for every two days. After 70-80% 
confluence of cells they were washed thrice with PBS and then added 3-5ml of 
trypsin with EDTA. After the cells completely detach, they were added into DMEM 
to neutralise the trypsin and the cells were centrifuged at 300 g for 3 minutes. The 
subculture was done with a ratio of 1:3 or 1:6. The remaining cell were stored with 





4.2.4 Experimental design and treatments 
 
 
HepG2 cells were grown up to 70% confluence and then transferred into 6 
well plates at 2.5*105 cells per well and divided into six groups. Control cells were 
incubated with plain medium and free fatty acid group received 1 mM fatty acids 
mixture (containing 0.66 mM sodium oleate and 0.33 mM sodium palmitate) 
whereas the treatment groups received low (10 mM) and moderate (20 mM) 
concentrations of alcohol with 1 mM fatty acids mixture (0.66 mM sodium oleate 
and 0.33 mM of sodium palmitate)[395]. The rest of the groups received 10 mM 
and 20 mM of alcohol without any FFA treatment. Alcohol is a volatile substance in 
order to maintain a stable alcohol concentration inside the 6 well plate, for the cells, 
double the concentration of alcohol was placed in a Petri dish during the 24-hour 
experiment. After 24 hours of treatment, the cells were removed from the incubator 
and proceeded for lipid extraction and cellular protein extraction. 
 
4.2.5 Extraction of lipids from HepG2 cells 
 
 
The total lipids from HepG2 cells were extracted by the modified method of 
Bligh and Dyer [396] as described by Li and Lin [397]. The treated cells were 
homogenized with chloroform-methanol solution (chloroform-methanol-water,8:4:3). 
Further the resulting mixture was shaken at 37ºC for 1hour and then centrifuged at 
1,100 g for 10 minutes. The bottom layer was collected and again centrifuged, the 










4.2.6 Cell protein extraction 
 
 
After 24 hours of treatment, 6 well plates with cells were removed from 
incubator, washed with PBS, and then added Radioimmunoprecipitation assay 
(RIPA) buffer (pH 8.0) containing 50 mM Tris, 150 mM NaCl, 1% Triton X-100, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate and 10 l/ml protease and 
phosphatase inhibitors cocktail to each well and cells were scraped on ice over an 
orbital shaker for 1hr. The homogenates were collected and then sonicated at 
60AMP of total time for 30seconds with on time 5 sec and off time 15 seconds. The 
homogenates were centrifuged at 4 °C at 10,000 g for 15 minutes, and the 
supernatants were collected. Protein concentrations were measured by the 
Bradford assay using bovine serum albumin as standard. 
 
4.2.7 Western blot analysis 
 
The samples were mixed with loading buffer, proteins were denatured by 
heating at 95 oC for 5 minutes, and 25 or 50 g of total protein was 
 
electrophoretically resolved on 10% Mini-PROTEAN® TGX™ Poured gels (Bio-
Rad, Australia) at 135 V for 90 minutes and then transferred onto a nitrocellulose 
membrane (Bio-Rad, Australia) using a wet transfer (100 V for 135 minutes). After 
blotting, the membranes were blocked with 5% non-fat dry milk 1hour at room 
temperature. The membranes were then washed three times for 5 minutes each 
with tris-buffered saline-0.1% Tween-20 (TBST, pH 7.6) and incubated for 
overnight at 4 C with mouse anti-p-ACC reductase (1:1000) or mouse anti-AMPK-
α1 (1:1000) or mouse anti- LKB1 (1:1000) or mouse anti- p-LKB1(1:1000) or mouse 




Biotechnology, CA, USA) ,rabbit anti-p-AMPK-α1 (1:500) or rabbit anti-
ACC(1:1000) (Abcam, Cambridge, UK) diluted with TBST. Blots were then again 
washed three times for 5 minutes each with TBST and incubated for 1 hour at room 
temperature with an appropriate horseradish peroxidase-conjugated secondary 
antibody (Santa Cruz, Biotechnology, CA, USA) diluted at 1:10,000 with phosphate-
buffered saline (PBS, pH 7.4). The membranes were again washed three times for 
5 minutes each with TBST and incubated with enhanced chemiluminescence 
reagent (Clarity™ Western ECL, Bio-Rad, Australia) for 1 min at room temperature. 
Immune complexes were detected after exposing the blots to ChemiDoc™ XRS 
system (Bio-Rad, Australia) for various time point. Quantitative image analysis was 
performed using NIH Image software (Image J) to determine the intensity of the 
protein signal, which was expressed relative to the amount of -actin used as an 
internal control. 
 
4.2.8 Data and statistical analysis 
 
The results are expressed as means ± SEM. To analyse the quantitative 
differences among the experimental groups before or after treatments, the data 
were subjected to analysis of variance (ANOVA) using the GraphPad 7.03 
(GraphPad Software Inc., California, CA, USA) statistical software. Post-hoc 


















4.3.1 Effect of low and moderate alcohol on triglycerides and total cholesterol 
levels in FFA-treated HepG2 cells 
 
The levels of triglycerides in different experimental groups are shown in 
Figure 4.1A. The FFA-treated cells (n=6) showed a significant (p<0.001) 1.6-fold 
increase in triglycerides levels when compared to the normal control cells (n=6). On 
the other hand, both the low alcohol-treated (n=6) and moderate alcohol-treated 
(n=6) groups showed a mild non-significant decrease in triglycerides levels by 1.5-
fold (p=0.19) and 1.5-fold (p=0.18) respectively when compared to the FFA-treated 
control cells. In contrast, low alcohol treatment in normal cells (n=6) showed a 
significant 1.1-fold (p<0.05) increase in triglycerides levels when compared to the 
normal control cells, while normal cells treated with moderate alcohol (n=6) showed 
a non-significant (p=0.43) increase in triglycerides when compared to the normal 
control cells. 
 
The total cholesterol levels in different experimental cellular groups are 
shown in Figure 4.2B. HepG2 cells (n=6) treated with FFA showed a significant 
(p<0.001) 1.4-fold increase in total cholesterol levels when compared to the normal 
control cells (n=6). On the other hand, both the low alcohol-treated (n=6) and 
moderate alcohol-treated (n=6) cellular groups tended to show a non-significant 
decrease in total cholesterol levels by 1.4-fold (p=0.44) and 1.3-fold (p=0.16) 
respectively when compared to the FFA-treated control cells. In contrast, both the 





significant increase (p<0.05) in total cholesterol levels respectively when compared 
 




































































































Figure 4.1 Effect of low and moderate alcohol on triglycerides and total 
cholesterol levels in FFA-treated HepG2 cells. (A) triglycerides (B) total 
cholesterol accumulation in HepG2 cells incubated with FFA 1mM mixture final 
concentration for 24 hours either with normal control cells or FFA (disease control) 
alone or with low, moderate alcohol with FFA and low and moderate alcohol only 
 
Values represent the mean ± SEM of n=6 
 
Significant difference from normal control cells: ###p<0.001, 
 
Significant difference from normal control group vs normal cells treated with 
alcohol groups: §p<0.05, 
 
NS: No significant difference between the groups in comparison  













4.3.2 Effect of low and moderate alcohol on AMPK-α1 and its phosphorylation 
 
expression in FFA-treated HepG2 cells 
 
 
The effect of low and moderate alcohol on the protein expression of AMPK-
α1 in HepG2 cells is shown in Figure 4.2A. The FFA-treated HepG2 cells (n=6) 
showed a significant (p<0.01) 1.6-fold decrease in AMPK-α1 protein expression 
when compared to the normal control cells (n=6). On the other hand, cells treated 
with moderate alcohol (n=6) showed a significant 1.2-fold (p<0.001) increase in 
AMPK-α1 protein expression when compared to the FFA-treated HepG2cells. 
However, the low alcohol-treated cells (n=6) showed no significant change (p=0.99) 
in AMPK-α1 protein expression when compared to the FFA-treated cells. In 
contrast, both low alcohol and moderate alcohol treatment in normal cells (n=3) 
showed a significant increase in AMPK-α1 protein expression by 1.1-fold (p<0.05) 
and 1.5-fold (p<0.001) respectively when compared to the normal control cells. 
 
Figure 4.4B illustrates the effect of low and moderate alcohol on 
phosphorylation of AMPK-α1 in HepG2 cells. The FFA-treated control group (n=6) 
showed a significant (p<0.01) 1.2-fold decrease in phosphorylation of AMPK-α1 
protein when compared to the normal control cells (n=6). On the other hand, the 
moderate alcohol-treated group (n=6) showed a significant (p<0.05) increase in 
phosphorylation of AMPK-α1 protein when compared to the FFA-treated control 
group. The low alcohol-treated group (n=6) tended to show a slight increase in 
phosphorylation of AMPK-α1 protein but failed to reach significance (p=0.99) when 
compared to the FFA-treated group. In contrast, normal cells treated with moderate 




AMPK-α1 protein when compared to the normal control group while low alcohol 
treatment in normal cells (n=3) show a non-significant (p=0.88) increase in 






































































































Figure 4.2 Protein expression of AMPK and p-AMPK-α1 in FFA-treated HepG2 
cells. (A) AMPK (B) p-AMPK-α1 protein expression as determined by western blot 
analysis in HepG2 cells treated with 1 mM of FFA for 24 hours either with normal 
control cells or FFA (disease control) alone or with low, moderate alcohol with FFA 
and low and moderate alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ##p<0.01 
Significance difference from FFA control: ***p<0.001, *p<0.05  
Significant difference from normal control group vs normal cells treated with 
alcohol groups: §p<0.05, §§§p<0.001 
 
NS: No significant difference between the groups in comparison 
 







4.3.3 Effect of low and moderate alcohol on LKB1 and its phosphorylation in 
 
FFA-treated HepG2 cells 
 
 
The effect of low and moderate alcohol treatment on LKB1 protein 
expression was investigated by western blot analysis in HepG2 cells Figure 4.3A. 
The FFA-treated HepG2 cells (n=6) showed a significant (p<0.001) 1.4-fold 
decrease in LKB1 protein expression when compared to the normal control group 
(n=6). The moderate alcohol-treated group (n=6) showed a significant (p<0.05) 1.2-
fold increase in LKB1 protein expression when compared to the FFA-treated group. 
However, the low alcohol treated group (n=6) showed a 1.0-fold non-significant 
(p=0.12) increase in LKB1 protein when compared to FFA-treated cells. 
Furthermore, normal cells treated with moderate alcohol (n=3) showed a significant 
(p<0.01) 1.3-fold increase in LKB1 protein expression when compared to the 
normal control group whereas, low alcohol treatment in normal cells (n=3) showed 
a mild non-significant (p=0.25) increase in LKB1 protein expression when 
compared to the normal control group. 
 
Figure 4.3B, illustrates the effect of low and moderate alcohol on 
phosphorylation of LKB1 in FFA-treated HepG2 cells. The FFA-treated control 
group (n=6) showed a significant (p<0.01) 1.6-fold decrease in phosphorylation of 
LKB1 protein when compared to the normal control cells (n=6). On the other hand, 
the moderate alcohol-treated cells (n=6) showed a significant 1.7-fold (p<0.05) 
increase in phosphorylation of LKB1 protein when compared to the FFA-treated 





significant (p=0.43) increase in phosphorylation of LKB1 when compared to the 
FFA-treated control group. In contrast, both the low alcohol-treated (n=3) and 
moderate alcohol-treated (n=3) normal cell groups showed a significant (p<0.001 
and p<0.05) decrease in phosphorylation of LKB1 protein respectively when 
































































































Figure 4.3 Protein expression of LKB1 and p-LKB1 in FFA-treated HepG2 
cells. (A) LKB1 (B) p-LKB1 protein expression as determined by western blot 
analysis in HepG2 cells treated with 1 mM of FFA for 24 hours either with normal 
control cells or FFA (disease control) alone or with low, moderate alcohol with FFA 
and low and moderate alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001 
Significance difference from FFA control:  *p<0.05 
 
Significant difference from normal control group vs normal cells treated with 
alcohol groups: §p<0.05, §§p<0.01, §§§p<0.001 
NS: No significant difference between the groups in comparison 
 






4.3.4 Effect of low and moderate alcohol on SIRT1 protein expression in FFA- 
 
treated HepG2 cells 
 
 
The effect of low and moderate alcohol on the protein expression of SIRT1 
in FFA-treated HepG2 cells is shown in Figure 4.4. The FFA-treated control group 
(n=6) showed a significant (p<0.001) 1.6-fold decrease in SIRT1 protein expression 
when compared to the normal control cells (n=6). On the other hand, both the low 
alcohol-treated (n=6) and moderate alcohol-treated (n=6) groups showed a 
significant increase in SIRT1 protein expression by 1.2-fold (p<0.01) and 1.4-fold 
(p<0.001) respectively when compared to the FFA-treated control group. In 
contrast, both the low alcohol (n=3) and moderate alcohol treatments (n=3) in 
normal cells showed a non-significant decrease (p=0.10 to 0.11) change in SIRT1 


























































Figure 4.4 Protein expression of SIRT1 in FFA-treated HepG2 cells. SIRT1 
protein expression as determined by western blot analysis in HepG2 cells treated 
with 1 mM of FFA for 24 hours either with normal control cells or FFA (disease 
control) alone or with low, moderate alcohol with FFA and low and moderate 
alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001 
Significance difference from FFA control:  **p<0.01, ***p<0.001  
NS: No significant difference between the groups in comparison 
 

























4.3.5 Effect of low and moderate alcohol on ACC and its phosphorylation in 
 
FFA-treated HepG2 cells 
 
 
The expression of ACC protein in HepG2 cells is shown in Figure 4.5A. The 
FFA-treated control group (n=6) showed a significant (p<0.001) 1.4-fold increase in 
ACC protein expression when compared to the normal control group (n=6). On the 
other hand, the moderate alcohol-treated group (n=6) showed a significant 1.1-fold 
(p<0.01) decrease in ACC protein expression when compared to the FFA-treated 
control group. However, the low alcohol-treated group (n=6) showed a mild non-
significant (p=0.12) decrease in ACC protein expression when compared to the 
FFA-treated group. In contrast, normal cells treated with either low alcohol (n=3) 
moderate alcohol (n=3) treated groups showed a non-significant (p=0.15 to 0.69) 
increase in ACC protein expression when compared to the normal control cells. 
 
Figure 4.5B shows the effect of low and moderate alcohol on 
phosphorylation of ACC in HepG2 cell. The FFA-treated group (n=6) showed a 
significant (p<0.001) 1.9-fold decrease in phosphorylation of ACC protein when 
compared to the normal control group (n=6). The moderate alcohol-treated group 
(n=6) showed a significant (p<0.01) 1.3-fold increase in phosphorylation of ACC 
protein when compared to the FFA-treated cells. However, the low alcohol treated 
group (n=6) showed a non-significant (p=0.17) increase in phosphorylation of ACC 
protein when compared to FFA-treated group. In contrast, both the low alcohol-
treated (n=3) and moderate alcohol-treated (n=3) normal cell groups showed a non-
significant decrease (p=0.62 to 0.77) decrease in phosphorylation of ACC protein 







































Figure 4.5 Protein expression of ACC and p-ACC in FFA-treated HepG2 cells.  
(A) ACC (B) p-ACC protein expression as determined by western blot analysis in 
HepG2 cells treated with 1 mM of FFA for 24 hours either with normal control cells 
or FFA (disease control) alone or with low, moderate alcohol with FFA and low and 
moderate alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001 
Significance difference from FFA control: **p<0.01  
NS: No significant difference between the groups in comparison 
 














4.3.6 Effect of low and moderate alcohol on SREBP1 protein expression in 
 
FFA-treated HepG2 cells 
 
 
The SREBP1 protein expression in different experimental groups is shown 
in Figure 4.6. The FFA-treated cell group (n=6) showed a significant (p<0.01) 1.3-
fold increase in SREBP1 protein expression when compared to the normal cell 
group (n=6). Interestingly, the low alcohol-treated cells (n=6) showed a mild 
increase in SREBP1 protein expression although not significant (p=0.32) when 
compared to the FFA-treated group. On the other hand, the moderate alcohol-
treated group (n=6) tended to show a decrease in SREBP1 protein expression 
although not significant (p=0.40) when compared to the FFA-treated control group. 
In contrast, normal cells treated with either low or moderate alcohol (n=3) showed 
no significant difference (p=0.87 to 0.69) in SREBP1 protein expression when 



























































Figure 4.6 Protein expression of SREBP1 in in FFA-treated HepG2 cells. 
Protein expression as determined by western blot analysis in HepG2 cells treated 
with 1 mM of FFA for 24 hours either with normal control cells or FFA (disease 
control) alone or with low, moderate alcohol with FFA and low and moderate 
alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ##p<0.01 
NS: No significant difference between the groups in comparison 
 



























NAFLD is a leading cause of hepatic dysfunction with intracellular lipid 
accumulation in hepatocytes in the absence of alcohol. It was first officially reported in 
1958, gradually become a widespread and serious disease with an average annual 
increase of 20% [398]. The combination of genetic factors with external environmental 
and metabolic stress results in the pathogenesis of NAFLD and the overwhelming 
theory for the molecular mechanism of NAFLD is the two-hit theory [399, 400]. The first 
hit is the lipid accumulation in the liver. Fatty degeneration of hepatocytes is more 
susceptible to ‘second’ hit (oxidative stress, etc.) than normal one, which further 
promotes the generation of inflammation that is the development of NAFLD. Cellular 
FFA loading is commonly utilised to develop in-vitro models of steatosis, and these 
models can reliably reproduce key features of hepatic steatosis in humans [401]. 
Insulin resistance which is commonly associated in NAFLD, along with the resulting 
hyperinsulinemia leads to increase liver FFA synthesis via de novo lipogenesis, along 
with the increased delivery of FFA from adipose tissue to liver which impairs the FFA β-
oxidation. FFA synthesis is essential for the regulation of fat metabolism in the liver. 
FFA synthesis is mediated by seven enzymes, among which acetyl coenzyme A 
carboxylase (ACC) is the rate-limiting enzyme. In the present study, HepG2 cells were 
supplemented with excess FFAs in hepatocytes that results in hepatic steatosis. This 
was a successful model for hepatic steatosis; the observations are similar with 
previously published results showing an increased level of intracellular TG and TC 
[402-404]. Similar to in vivo studies (chapter 2), low and moderate alcohol with FFA 
groups did not show significant ability to control lipid accumulation in HepG2 cells 




Jimenez et al.(2002) has demonstrated that HepG2 cells treated with high 
concentration of alcohol 100 mM for 7 days, which did not show any effect on lipids 
HepG2 cells, but in contrast our results showed that low and moderate alcohol 
increases lipid levels in HepG2 cells [405]. Accumulation of triglycerides in liver 
cells is the first step for hepatic steatosis, which may progress to non-alcoholic 
steatohepatitis (NASH), which is associated with hepatocyte damage, chronic 
inflammation, and fibrosis, and may progress to cirrhosis and liver failure. 
Henriksen et al ( 2013) has demonstrate that activation of AMPK by AICAR 
reduces the hepatic triglycerides which protects the liver from hepatic steatosis 
 
[394]. Adenosine monophosphate-activated protein kinase (AMPK) is a cellular 
nutrient sensor and a central nutrient sensor and regulator of energy homeostasis 
in most tissues and organs including adipose tissue, skeleton muscle and the liver. 
AMPK regulates hepatic energy metabolism through regulating the genes involved 
in lipid metabolism or direct phosphorylation of metabolic proteins or enzymes, such 
as sterol regulatory element binding protein 1(SREBP-1), carbohydrate-responsive 
element-binding protein (ChREBP), HMG-CoA reductase (HMGCR), acetyl-CoA 
carboxylase-1(ACC1), and fatty acid synthase (FAS) [406]. In the present study, 
FFA treated cells managed to decrease AMPK and p-AMPK levels in disease 
control groups [407]. An increase in AMPK and p-AMPK protein expression was 
observed in moderate alcohol-treated normal and moderate alcohol with FFA 










HepG2 cells, which have a very weak capability of metabolizing 
alcohol due to the lack of alcohol dehydrogenase (ADH) and cytochrome 
P450(CYP2E1) [408, 409] resulting in the lack of producing acetate, the end 
product of alcohol metabolism which enhances AMPK. A very limited studies 
demonstrated that long-term exposure (12 months) to high concentrations of 
alcohol can stimulate cultured HepG2 liver cells to significantly increase the 
expression and enzymatic activity of key alcohol-metabolizing enzymes, i.e., 
alcohol dehydrogenase and cytochrome P450 2E1 [410, 411]. The possible 
hypothesized mechanism behind the increase of phosphorylation of AMPK in 
moderate alcohol group might be either due to activation by LKB1 an upstream 
kinase for activating AMPK or CaMKK-β which play a physiological role in 
activating AMPK in mammalian cells [412]. Increase in LKB1 and p-LKB1 was 
observed in normal cells treated with moderate alcohol, and moderate alcohol with 
FFA which further confirms that the activation of AMPK is by LKB1 pathway. 
 
In our study, an incresase in SIRT1 was observed in low and moderate 
alcohol with FFA groups and no change in SIRT1 was observed in alcohol treated 
normal cells. Sirtuin-1 (SIRT1) is an NAD
+
-dependent class III histone deacetylase that 
acts as a metabolic “sensor,” and is implicated in regulating a wide range of 
intracellular processes including aging, DNA repair, apoptosis, inflammation, and 
energy production and storage[413] . SIRT1 activity is regulated by the imbalance of 
the NAD
+
-NADH ratio, and accumulation of the NAD
+
 degradation product, 
nicotinamide (NAM) [414]. Thompson et al.(2015) [415] has proved that no change in 





mM of alcohol for 24 and 48 hours. The no change in SIRT1 in HepG2 cells might 
be due to very low levels of ADH and CYP2E1. The other possible mechanism 
behind the increase in SIRT1 in low and moderate alcohol treated group might be 
due to the increase of AMPK. An AMPK activation leads to SIRT1 activation by 
increasing NAD+ levels [48]. 
The hypothesized mechanism behind the increase of LKB1 was, via 
AMPK, and SIRT1, they regulates each other and increased SIRT1 increases LKB1 
and LKB1 regulate each other. Berghein et.al (2008). has demonstrated that SIRT1 
lead to deacetylation of one (Lys-48) or more key lysine residues on LKB1. This in 
turn enhances LKB1 binding to STRAD and MO25, which increases its kinase 
activity and leads to the phosphorylation and activation of AMPK, MARK1, and 
possibly other LKB1 targets [46] . 
 
ACC is the enzyme that catalyzes the reaction forming malonyl CoA 
from acetyl CoA and constitutes the initial step in lipid synthesis [416]. An increase 
in phosphorylation of ACC was observed in moderate alcohol with FFA. The 
increased p-AMPK inhibits acetyl-CoA carboxylase (ACC) and results in reduced 
levels of malonyl-CoA product. Malonyl CoA is a substrate in the de novo synthesis 
of fatty acids and fatty acids elongation. Importantly, it is also an inhibitor of the 
carnitine palmitoyl transferase-I, required for the transfer of primed cytosolic fatty 
acids into the mitochondria where they can undergo degradative beta-oxidation 
[341]. 
 
In contrast to previously published results, an increase in p-AMPK and 




sterol regulatory element binding protein (SREBP1) [407]. SREBP1 is a key 
lipogenic transcription factor that is nutritionally regulated by glucose and insulin 
 
[417]. SREBP-1c preferentially regulates the lipogenic process by activating genes 
involved in fatty acid and triglyceride synthesis. The dysregulation of SREBP-1c 
has been implicated in the pathogenesis of hepatic steatosis, dyslipidaemia, and 
type 2 diabetes [418]. 
 
In conclusion, HepG2 cells treated with FFA showed an increase in 
triglycerides and total cholesterol leads to confirmation of hepatic steatosis, 
whereas the alcohol-treated groups did not show any effect in controlling the lipids, 
but in contract the moderate alcohol with FFA group upregulated the expression 
levels of fatty acid oxidation genes including LKB1, SIRT1 and phosphorylation of 
AMPK-α1 proteins and down regulated the ACC protein involved in lipid synthesis 
induced by FFA. LKB1, AMPK, and SIRT1 regulate each other, So a further 
examination of a possible linkage of each protein among SIRT1, AMPK, and LKB1 










































Evaluating the mechanistic action of low and 
moderate alcohol on FFA-induced NAFLD in 













































Non-alcoholic fatty liver disease (NAFLD) is a clinic-pathological 
entity, which is rapidly increasing and one of the most common liver diseases 
worldwide [419]. It is characterized by hepatic lipid accumulation (> 5%) of liver 
weight. NAFLD encompasses from steatohepatitis (NASH), cirrhosis, and hepatic 
cellular carcinoma (HCC) [420]. The pathogenies of NAFLD was proposed by a 
simplistic two-hit hypothesis [185]. Nowadays, a multiple-hit hypothesis that 
implicates a myriad of factors acting in a parallel and synergistic manner in 
individuals with a genetic predisposition is the more accepted view to explain the 
different phenotypes observed clinically [421]. The accumulation of excessive toxic 
lipids in the liver, including triglycerides, free fatty acids (FFA), ceramides, and free 
cholesterol leads to Hepatic steatosis [422]. This can occur from the excessive 
importation of FFA from adipose tissue, from diminished hepatic export of FFA 
(secondary to reduced synthesis or secretion of very low-density lipoprotein 
[VLDL]), or impaired beta-oxidation of FFA. The major sources of triglycerides are 
from fatty acids stored in adipose tissue and fatty acids newly made within the liver 
through de novo lipogenesis [423]. 
 
Previous studies have demonstrated that impairment of hepatic AMPK 
levels was observed in both in vitro and in vivo models of NAFLD [424-426]. 
Impairment of hepatic AMPK leads to the development of insulin resistance and 
metabolic disorders associated with metabolic syndrome, including hepatic 
steatosis [427]. Decreased AMPK may lead to increase lipid synthesis and 




catabolic pathways, such as fatty acid oxidation and inhibits ATP consuming 
process associated with lipogenesis, such as acetyl-CoA carboxylase (ACC) by 
phosphorylation in the liver [428]. Under fasting conditions, AMPK reduces 
lipogenesis by suppressing sterol regulatory element binding protein-1c (SREBP-
1c) activity in the liver [363]. Phosphorylation of AMPK at Thr172 reflects the 
degree of AMPK activation. AMPK responds to an increased cellular AMP: ATP 
ratio and the phosphorylation of AMPK is also regulated by the upstream kinase 
Liver kinase B1(LKB1) and calcium/calmodulin -dependent protein kinase (CaMKK) 
in mammalian cells [429, 430]. LKB1 is serine/threonine kinase which was originally 
found in tumour suppressor function [431]. Apart from phosphorylation and 
activation of AMPK, LKB1 activates the other members of the AMPK subfamily 
[432, 433]. A numerous previous studies have proven that AMPK is activated by 
LKB1 and could be a target for treatment of metabolic disorders [104, 185, 434, 
435]. 
 
Based on the literature, and our findings from previous chapters 3 and 4 we 
hypothesize that LKB1, the upstream kinase might be responsible for activating 
AMPK. This chapter aims to find the role of low and moderate alcohol in HeLa cells 


















5.2 Materials and methods 
 
 
5.2.1 Chemicals used 
 
 
Electrophoresis and electro-blotting consumables were purchased from Bio-
Rad (Hercules, CA, USA). Primary antibodies of AMPK, p-AMPK, p-ACC, SIRT1 
and SREBP1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
while ACC was obtained from (Abcam, Cambridge, United Kingdom). Enhanced 
chemiluminescence kit was obtained from Bio-Rad (Hercules, CA, USA). DMEM ( 
modified basal medium eagle), low glucose, alcohol, Fetal bovine serum (FBS), 
sodium oleate, sodium palmitate from Sima (Sigma St. Louis, MO, USA). All other 
chemicals used were of analytical or molecular biology grade. 
 
5.2.2 Reagents used 
 
 
(1) Radio immunoprecipitation assay (RIPA) buffer (pH 8.0) 
 
 
Sodium chloride (150 mM), sodium deoxycholate (0.5%), sodium dodecyl 
sulfate (0.1%), Tris base (50 mM) and 1 mL of triton X-100 (1%) were added into a 
volumetric flask and made up to 100 mL with distilled water. The solution was 
transferred into a beaker and the pH was adjusted to 8.0 and filtered before use 
through a 0.2 μM membrane. 
 
(2) Running buffer 
 
 
Glycine (14.42 g), tris base (3.03 g), sodium dodecyl sulfate (1 g) were 







solution was transferred into a beaker and the pH was adjusted to 8.3 and filtered 
before use through a 0.2 μM membrane. 
 
(3) Transfer buffer 
 
 
Tris base (3.03 g), glycine (14.41 g) and methanol (200 mL) were added into 
a volumetric flask and made up to 1000 mL with distilled water. The solution was 
filtered before use through a 0.2 μM membrane. 
 
(4) Tris-buffered saline (TBS) 
 
 
Tris-base (2.4 g) and NaCl (8 g) were added into a volumetric flask and 
made up to 1000 mL with distilled water. The solution was transferred into a beaker 
and the pH was adjusted to 7.6 and filtered before use through a 0.2 μM 
membrane. 
 
(5) Phosphate buffered saline (PBS) 
 
 
Sodium chloride (8 g), potassium chloride (0.2 g), disodium hydrogen 
phosphate (1.44 g), and potassium dihydrogen phosphate (0.24 g) were added into 
a volumetric flask and made up to 1000 mL with distilled water. The solution was 
transferred into a beaker and the pH was adjusted to 7.6 and filtered before use 
through a 0.2 μM membrane. 
 
(6) Stacking gel buffer 
 
 
Tris base (15.14 g), SDS (1.0 g) were added into volumetric water and made 
up to 250 ml with distilled water. The solution was transferred into a beaker and the 






(7) Sodium oleate 
 
 
Sodium oleate (40.58 mg) in 10 mL (13.33 mM) stock of plain DMEM at 37ºC 
with fatty acid-free BSA and filtered with a 0.2 μM membrane and stored in - 20°C 
 
 
(8) Sodium palmitate 
 
 
Sodium palmitate (18.54 mg) in 10 mL of plain DMEM at 50 ºC with constant 
shaking with Fatty acid-free BSA and filtered with a 0.2 μM membrane and stored 
in -20°C. 
 
(9) 400 mM alcohol 
 
 
Alcohol 184.28 mg or 235 μL of alcohol in 10 mL of plain DMEM for 400 mM 
stock and filtered with a 0.2 μM membrane and stored in 4ºC. 
 
5.2.3 Cell culture 
 
HeLa cells (passage-9) were obtained from the Western Sydney University, 
which was previously maintained in DMEM with low glucose, 10% FBS, 1% 
antibiotics (10,000 I.U./mL Penicillin, 10,000 (μg/mL) Streptomycin). They were 
maintained in incubator conditions, at 37º C with 5% CO2 changing the growth 
medium for every two days. After 70-80% confluence of cells, they were washed 
thrice with PBS and then added 3-5ml of Trypsin with EDTA. After the cells 
completely detach, they were added into DMEM to neutralise the Trypsin, and the 





of 1:3 or 1:6. The remaining cell were stored with 5% DMSO in growth medium and 




5.2.4 Experimental design and treatments 
 
 
HeLa cells were grown up to 70% confluence and then transferred into 6 well 
plates at 2*106 cells per well and divided into six groups. Control cells were 
incubated with plain medium, and the free fatty acid group received (sodium oleate 
0.66 mM and 0.33 mM of Sodium palmitate final fatty acids concentration 1 mM). 
The treatment groups received low (10 mM) and moderate alcohol (20 mM) with 
FFA (1 mM of sodium oleate 0.66 mM and 0.33 mM of Sodium palmitate)[395]. The 
rest of the groups received 10 and 20 mM of alcohol without any FFA treatment. 
Alcohol is a volatile substance in order to maintain a stable alcohol concentration 
inside the 6 well plate, for the cells, double the concentration of alcohol was placed 
in a Petri dish during the 24-hour experiment. After 24-hour of treatment, the cells 
were removed from the incubator and proceeded for lipid extraction and cell protein 
extraction. 
 
5.2.5 Extraction of lipids from HeLa cells 
 
 
The total lipids from Hela cells were extracted by the modified method of 
Bligh and Dyer [396] as described by Li and Lin [252]. The treated cells were 
homogenized with chloroform-methanol solution (chloroform-methanol-water,8:4:3). 








1,100 g for 10 minutes. The bottom layer was collected and again centrifuged, the 
supernatant was collected and used for analysis of hepatic lipid. 
 
5.2.6 Cell protein extraction 
 
 
After 24-hours of treatment 6 well plates with cells were removed from the 
incubator and washed with PBS. Radioimmunoprecipitation assay (RIPA) buffer 
(pH 8.0) containing 50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate and 10 l/ml protease and phosphatase 
inhibitors cocktail were added to each well and cells were scraped on ice over an 
orbital shaker for 1hour. The homogenate was then collected and sonicated at 60 
amps of total time for 30 seconds with on time of 5 seconds and off time 15 
seconds. The homogenates were centrifuged at 4°C at 10,000 g for 15 minutes, 
and the supernatants were collected. Protein concentrations were measured by the 
Bradford assay using bovine serum albumin as standard. 
 




The samples were mixed with loading buffer, proteins were denatured by 
heating at 95oC for 5 min, and 25 g of total protein was electrophoretically resolved 
on 10% lab made gels at 135 V for 90 min and then transferred onto a 
nitrocellulose membrane (Bio-Rad, Australia) using a wet transfer (100 V for 2-hour 
15 minutes). After blotting, the membranes were blocked with 5% non-fat dry milk 
1-hour at room temperature. The membranes were then washed three times for 5 
minute each with Tris-buffered saline-0.1% Tween (TBST, pH 7.6) and incubated 




AMPK reductase (1:1000) or with mouse anti-AMPK reductase (1:1000) or mouse 
anti-SIRT1 (1:1000) or mouse anti- SREBP1(1:1000) antibody (Santa Cruz, 
Biotechnology, CA, USA) , or rabbit anti-ACC (1:1000) (Abcam, Cambridge, UK) 
diluted with TBST. Blots were then washed again three times for 5 minutes each 
with TBST and incubated for 1-hour at room temperature with appropriate 
horseradish peroxidase-conjugated secondary antibody (Santa Cruz, 
Biotechnology, CA, USA) diluted at 1:10,000 with PBS, (pH 7.4). The membranes 
were again washed three times for 5 minutes each with TBST and incubated with 
enhanced chemiluminescence reagent (Clarity™ Western ECL, Bio-Rad, Australia) 
for 1 minute at room temperature. Immune complexes were detected after exposing 
the blots to ChemiDoc™ XRS system (Bio-Rad, Australia) for various time points. 
Quantitative image analysis was performed using NIH Image software (Image J) to 
determine the intensity of the protein signal, which was expressed relative to the 
amount of -actin used as an internal control. 
 
 




The results are expressed as means ± SEM. To analyse the quantitative 
differences among the experimental groups before or after treatments, the data 
were subjected to analysis of variance (ANOVA) using the GraphPad 7.03 
(GraphPad Software Inc., California, CA, USA) statistical software. Post-hoc 








5.3  Results 
 
 
5.3.1 Effect of low and moderate alcohol on triglycerides and total cholesterol 
levels in FFA-treated HeLa cells 
 
The levels of triglycerides in different experimental groups are shown in 
Figure 5.1A. The FFA-treated group (n=6) showed a significant (p<0.001) 1.5-fold 
increase in triglycerides levels when compared to the normal control cells (n=6). On 
the other hand, both the low alcohol-treated (n=6) and moderate alcohol-treated 
(n=6) groups showed a non-significant (p= 0.72 to 0.29) decrease in triglycerides 
levels when compared to the FFA-treated control group. In contrast, the low 
alcohol-treatment in normal cells (n=6) showed a non-significant (p=0.57) increase 
in triglycerides accumulation when compared to the normal control group. Whereas, 
the normal cells treated with moderate alcohol group (n=6) showed a non-
significant (p=0.36) decrease in triglyceride accumulation, when compared to the 
normal control group. 
 
The total cholesterol levels in different experimental groups are shown in 
Figure 5.2B. The FFA-treated group (n=6) showed a significant (p<0.001) 1.5-fold 
increase in total cholesterol levels when compared to the normal control cells (n=6). 
On the other hand, both the low alcohol-treated (n=6) and moderate alcohol-treated 
(n=6) groups showed a non-significant (p= 0.70 to 0.27) decrease in total 
cholesterol levels when compared to the FFA-treated control group. In contrast, the 
normal cells treated with low alcohol-treated group (n=6) showed a non-significant 
(p=0.55) increase in total cholesterol levels when compared to the normal control 
group. Whereas, the moderate alcohol-treatment in normal cells (n=6) showed a 
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Figure 5.1 Effect of low and moderate alcohol on triglycerides and total 
cholesterol levels in FFA-treated HeLa cells. (A) triglycerides (B) total 
cholesterol accumulation in HeLa cells incubated with FFA 1mM mixture final 
concentration for 24 hours either with normal control cells or FFA (disease control) 
alone or with low, moderate alcohol with FFA and low and moderate alcohol only 
 
Values represent the mean ± SEM of n=6 
 
Significant difference from normal control cells ###p<0.001, 
 
NS: No significant difference between the groups in comparison  









5.3.2 Effect of low and moderate alcohol on AMPK-α1 and its phosphorylation 
 
in the FFA-treated HeLa cells 
 
 
The effect of low and moderate alcohol on the protein expression of AMPK-
α1 in HeLa cells is shown in Figure 5.3A. The FFA-treated HeLa cells (n=6) showed 
 
a significant (p<0.001) 1.4-fold decrease in AMPK-α1 protein expression when 
compared to the normal control group (n=6). The low alcohol-treated (n=6) and 
moderate alcohol-treated (n=6) groups showed a mild non-significant increase in 
AMPK α1 protein expression by 1.0-fold (p=0.97) and 1.1-fold (p=0.22) respectively 
when compared to the normal control group. In contrast, the low alcohol-treated 
normal cells (n=3) showed a significant 1.1-fold (p<0.05) decrease in AMPK-α1 
protein expression when compared to the normal control group. Whereas, the 
normal cells treated with moderate alcohol (n=3) showed a non-significant (p=0.47) 
decrease in AMPK α1 levels when compared to the normal control group. 
 
Figure 5.4B illustrates the effect of low, and moderate alcohol on 
phosphorylation of AMPK-α1 in HeLa cells. The FFA-treated control group (n=6) 
showed a significant (p<0.001) 1.3-fold decrease in phosphorylation of AMPK-α1 
protein when compared to the normal control cells (n=6). On the other hand, the 
low alcohol-treated (n=6) and moderate alcohol-treated (n=6) groups showed a 
mild non-significant (p=0.17 to 0.16) increase in phosphorylation of AMPK-α1 
protein when compared to the FFA-treated control group. In contrast, the normal 
cells treated with low alcohol-treated group (n=3) showed a significant 1.1-fold 
(p<0.05) decrease in phosphorylation of AMPK-α1when compared to the normal 
control group. Whereas, the moderate alcohol-treated normal HeLa cells (n=3) 
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showed a non-significant (p=0.05) decrease in phosphorylation of AMPK-α1 protein 
 











































































































Figure 5.2 Protein expression of AMPK and p-AMPK-α1 in FFA-treated HeLa 
cells. (A) AMPK (B) p-AMPK-α1 protein expression as determined by western blot 
analysis in HeLa cells treated with 1 mM of FFA for 24 hours either with normal 
control cells or FFA (disease control) alone or with low, moderate alcohol with FFA 
and low and moderate alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001  
Significant difference from normal control group vs normal cells treated with alcohol 
groups: §p<0.05, 
 
NS: No significant difference between the groups in comparison 





5.3.3 Effect of low and moderate alcohol on SIRT1 protein expression in FFA- 
 
treated HeLa cells 
 
 
The effect of low and moderate alcohol on the protein expression of SIRT1 
in FFA-treated HeLa cells is shown in Figure 5.3. The FFA-treated control group 
(n=6) showed a significant (p<0.05) 1.3-fold decrease in SIRT1 protein expression 
when compared to the normal control cells (n=6). On the other hand, both the low 
alcohol-treated (n=6) and moderate alcohol-treated (n=6) groups showed a mild 
non-significant (p= 0.95 to 0.99) increase in SIRT1 protein expression when 
compared to the FFA-treated control group. In contrast, the low alcohol (n=3) and 
moderate alcohol (n=3) treated normal cells showed a non-significant decrease in 
SIRT1 protein expression by 1.2-fold (p=0.15) and 1.2-fold (p=0.10) respectively 






























































Figure 5.3 Protein expression of SIRT in FFA-treated HeLa cells. SIRT1 protein 
expression as determined by western blot analysis in HeLa cells treated with 1 mM 
of FFA for 24 hours either with normal control cells or FFA (disease control) alone 
or with low, moderate alcohol with FFA and low and moderate alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: #p<0.05 
NS: No significant difference between the groups in comparison 
 
























5.3.4 Effect of low and moderate alcohol on ACC-α1 and its phosphorylation 
 
in the FFA-treated HeLa cells 
 
 
The expression of ACC protein in HeLa cells was shown is shown in Figure 5.4A. 
The FFA-treated control group (n=6) showed a significant (p<0.01) 1.6-fold 
increase in ACC protein expression when compared to the normal control group 
(n=6). On the other hand, the low alcohol-treated (n=6) and moderate alcohol-
treated (n=6) groups showed a mild non-significant decrease in ACC protein 
expression by 1.1-fold (p=0.26) and 1.0-fold (p=0.19) respectively when compared 
to the FFA-treated control group. In contrast, the low alcohol (n=3) and moderate 
alcohol (n=3) treated normal cells showed a mild non-significant (p=0.93 to 0.99) 
increase in ACC protein expression when compared to the normal control group. 
 
The below Figure 5.4B explains the effect of low, and moderate alcohol on 
phosphorylation of ACC in HeLa cells. The FFA-treated group (n=6) showed a 
significant (p<0.001) 1.5-fold decrease in phosphorylation of ACC protein when 
compared to the normal control group (n=6). The low alcohol-treated (n=6) and 
moderate alcohol-treated (n=6) groups showed a non-significant (p=0.25 to 0.38) 
increase in phosphorylation of ACC protein when compared to the FFA-treated 
group. In contrast, the normal cells treated with low alcohol (n=3) showed a mild 
1.1-fold significant (p<0.05) decrease in phosphorylation of ACC protein when 
compared to normal control group. Whereas, the moderate alcohol-treated normal 
group (n=3) showed a non-significant (p=0.11) decrease in phosphorylation of ACC 

















































Figure 5.4 Protein expression of ACC and p-ACC in FFA-treated HeLa cells 
(A) ACC (B) p- ACC protein expression as determined by western blot analysis in 
HeLa cells treated with 1 mM of FFA for 24hours either with normal control cells or 
FFA (disease control) alone or with low, moderate alcohol with FFA and low and 
moderate alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001, ##p<0.01  
Significant difference from normal control group vs normal cells treated with alcohol 
groups: §p<0.05, 
 
NS: No significant difference between the groups in comparison 
 






5.3.5 Effect of low and moderate alcohol on SREBP1 protein expression in 
 





The SREBP1 protein expression of different experimental groups was shown 
in Figure 5.5. The FFA-treated group (n=6) showed a significant (p<0.001) 1.4-fold 
increase in SREBP1 expression when compared to the normal control group (n=6). 
On the other hand, the low alcohol-treated (n=6) and moderate alcohol-treated 
(n=6) groups showed a mild non-significant (p= 0.39 to 0.23) decrease in SREBP1 
protein expression when compared to the normal control group. In contrast, the 
normal cells treated with low alcohol (n=3) and moderate alcohol (n=3) groups 
showed a non-significant (p=0.64 to 0.72) decrease in SREBP1 protein expression 



























































Figure 5.5 Protein expression of SREBP1 in FFA-treated HeLa cells. SREBP1 
protein expression as determined by western blot analysis in HeLa cells treated 
with 1 mM of FFA for 24 hours either with normal control cells or FFA (disease 
control) alone or with low, moderate alcohol with FFA and low and moderate 
alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001 
NS: No significant difference between the groups in comparison 
 


























5.4  Discussion 
 
The present study has demonstrated the role of low and moderate 
alcohol on protecting FFA induced NAFLD in the absence of LKB1 the 
upstream kinase of AMPK, which subsequently leads to AMPK and ACC 
phosphorylation. Since HeLa cells lack the functional LKB1, these cells were 
used for this study [436]. The major findings observed from our study was Hela 
cells treated with FFA had increased the ACC and SREBP1 proteins which are 
responsible for the increase in lipid synthesis. The alcohol-treated groups (low 
and moderate with FFA) had no significant increase in AMPK-α1 and SIRT1 
proteins which play a major role in controlling ACC and SREBP1. 
 
The possible explanation for the decrease in phosphorylation of 
AMPK was may be due to the absence of LKB1. The activation of AMPK is 
mainly done with an increase in AMP/ATP ratio, LKB1 and Ca2+/calmodulin-
dependent protein kinase-β (CaMKKb), the upstream kinases of AMPK. Niu et 
al., have demonstrated that, bioactive compounds activate AMPK in an LKB1-
independent manner by increasing the AMP: ATP ratio [437]. However, alcohol 
studies showed that H4IIEC3 a (liver cells) treated with alcohol (50 mM) for 24 
hour did not show any significant change in AMP: ATP ratio from baseline 
 
[332]. Therefore, this confirms that activation of AMPK by alcohol may be due 
to independent AMP: ATP ratio. Increasing evidence has shown that the 
phosphorylation of AMPK by natural compounds is dependent on upstream 
LKB1 activation for the protection of the liver from hepatotoxicity [247]. 
Furthermore, our previous results from chapter 4 suggests that the activation 




SIRT1 is an NAD+ dependent histone/protein deacetylase whose activity is 
regulated by nutrients availability. It was proposed that, in fasting conditions an 
increase in SIRT1 activity can be seen by increasing the abundance of NAD+ 
and decrease in nicotinamide and NADH, both of which inhibit SIRT1. Apart 
from AMPK, SIRT1 is also an important regulator of hepatic metabolism[438]. 
SIRT1 also has considerable interactions with upstream enzymes that regulate 
the activity of key cellular pathways. Acetylation of LKB1 at specific lysine 
residues (K48) regulates kinase activity and the activity of its protein 
substrates. SIRT1 deacetylates LKB1, which leads to activate the LKB1 targets 
such as AMPK. SIRT1 by virtue of its interaction with the LKB1 blocks the 
synthesis of lipids via the de novo synthesis pathway [439]. Both SIRT1 and 
AMPK are known to regulate each other and share many common target 
molecules, and the interaction between SIRT1 and AMPK could be reciprocal 
 
[440]. So the hypothetical activation of SIRT1 and AMPK might be due to the 
decrease in energy state or activation of AMPK by other means that leads to 
activation of SIRT1, perhaps by increasing NAD or the NAD/NADH ratio [48]. 
SIRT1 then deacetylates and activates LKB1, which in turn activates AMPK. 
The joint activation of SIRT1 and AMPK allows for the concurrent deacetylation 
and phosphorylation of the listed target molecules and presumably others, 
resulting in a decrease in metabolic syndrome associated disorders. 
Interestingly, an increase in LKB1 and p-LKB1 was observed in the results 
from previous chapters 3 and 4. This explains that activation of AMPK was 






activation of AMPK and substantially decreases the SIRT1 activity in HeLa 
cells. 
 
Activated AMPK directly inhibits the downstream enzymatic 
target ACC, which is involved in the synthesis of malonyl-CoA. AMPK inhibits 
ACC activity by phosphorylating ACC at Ser77 and Ser79, thereby stimulating 
fatty acid oxidation and reducing fatty acid synthesis [441]. Apart from ACC, 
AMPK and SIRT1 also decrease the SREBP-1c. SREBP-1c is a key lipogenic 
transcription factor, which is abundant in the mammalian liver [442]. Mature 
SREBP-1c translocate into the nucleus and upregulates SCD-1 and FAS the 
key enzymes required for de novo fatty acid and TG synthesis in hepatocyte 
 
[443]. The alcohol treated groups failed to regulate the SREBP1 protein, the 
possible mechanism behind the regulation of SREBP1 protein was due to 
decreased AMPK and SIRT1 protein expressions. The present observations 
showed that low and moderate alcohol treatment has no effect on 
phosphorylation of AMPK and SIRT1, which increase in the SREBP-1c and 
ACC protein expression leading to increasing lipid synthesis via de novo lipid 
synthesis leading to increase in lipid profile. 
 
In conclusion, the present study demonstrated that low and 
moderate alcohol requires LKB1 for activating the AMPK and SIRT1 which 
regulate each other for inhibiting the SREBP-1C and ACC proteins responsible 


































Evaluating the mechanistic action of low and 
moderate alcohol on FFA-induced NAFLD in 









































The adenosine monophosphate-activated protein kinase (AMPK) has 
evolved as an important cellular sensor of reduced energy status that can 
subsequently phosphorylate its target proteins, slowing the rates of key 
biosynthetic processes and promoting energy producing pathways. AMPK is a 
master regulator of glucose and lipid metabolism. For the above reasons, AMPK 
has been proposed as a therapeutic target for metabolic diseases [444, 445]. It 
is a serine-threonine kinase comprising a catalytic α subunit and regulatory β 
and γ subunits. Kinase activity of α subunits is enhanced by energetic stress 
and posttranslational modification. AMP binds the AMPK γ subunit [147]. 
AMPKα1-contains complexes localised in the cytoplasm but also in the plasma 
membrane [446, 447]. 
 
AMPK is activated primarily by the increase in AMP/ATP ratio caused 
by challenges that interfere with ATP production or accelerate ATP 
consumption. Allosteric activation via the β-subunit and AMP mimetics 
increases AMPK activity independent of an energetic challenge. Once activated, 
AMPK inhibits ATP-consuming processes and activates catabolic processes. 
Apart from AMP/ATP ratio, AMPK is also activated by LKB1 and CaMKK [448]. 
In liver, AMPK decreases cholesterol and fatty acid synthesis and increases the 
fatty acid oxidation by inhibiting the enzymes acetyl-CoA carboxylase (ACC), 3-
hydroxy-3-methylglutaryl (HMG)-CoA reductase and fatty acid synthase (FAS) 
and activating the malonyl-CoA carboxylase (M-CoA). Moreover, it 




which is a transcription factor for lipogenic genes. In adipose tissue, metformin 
inhibits lipolysis through attenuation of PKA and ERK1/2 signalling [289]. 
 
As it was confirmed by previous publications that AMPK plays a major 
role in mediating the NAFLD, based on the results from chapter 3 and 4, it is 
proven that low and moderate alcohol increase AMPK. This chapter aims to 
investigate the role of low and moderate alcohol against FFA induced 
















































6.2 Materials and methods 
 
 
6.2.1 Chemicals used 
 
 
Electrophoresis and electro-blotting consumables were purchased from Bio-Rad 
(Hercules, CA, USA). Primary antibodies of Phospho-ACC, LKB1, Phospho-
LKB1, SIRT1 and SREBP1 were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) while ACC was obtained from (Abcam, Cambridge, 
United Kingdom). Enhanced chemiluminescence kit was obtained from Bio-Rad 




6.2.2 Reagents used 
 
 
(1) Radio immunoprecipitation assay (RIPA) buffer (pH 8.0) 
 
 
Sodium chloride (150 mM), sodium deoxycholate (0.5%), sodium dodecyl sulfate 
(0.1%), Tris base (50 mM) and 1 mL of triton X-100 (1%) were added into a 
volumetric flask and made up to 100 mL with distilled water. The solution was 
transferred into a beaker and the pH was adjusted to 8.0 and filtered before use 
through a 0.2 μM membrane. 
 
(2) Running buffer 
 
 
Glycine (14.42 g), tris base (3.03 g), sodium dodecyl sulfate (1 g) were added into a 








transferred into a beaker and the pH was adjusted to 8.3 and filtered before use 
through a 0.2 μM membrane. 
 
(3) Transfer buffer 
 
 
Tris base (3.03 g), glycine (14.41 g) and methanol (200 mL) were added into a 
volumetric flask and made up to 1000 mL with distilled water. The solution was 
filtered before use through a 0.2 μM membrane. 
 
(4) Tris-buffered saline (TBS) 
 
 
Tris-base (2.4 g) and NaCl (8 g) were added into a volumetric flask and made up to 
1000 mL with distilled water. The solution was transferred into a beaker and the pH 
was adjusted to 7.6 and filtered before use through a 0.2 μM membrane. 
 
(5) Phosphate buffered saline (PBS) 
 
 
Sodium chloride (8 g), potassium chloride (0.2 g), disodium hydrogen phosphate 
(1.44 g), and potassium dihydrogen phosphate (0.24 g) were added into a 
volumetric flask and made up to 1000 mL with distilled water. The solution was 
transferred into a beaker and the pH was adjusted to 7.6 and filtered before use 
through a 0.2 μM membrane. 
 
(6) Stacking gel buffer 
 
Tris base (15.14 g), SDS (1.0 g) were added into volumetric water and made up to 
250 ml with distilled water. The solution was transferred into a beaker and the pH 







(7) Sodium Oleate 
 
Sodium oleate (40.58 mg) in 10 mL (13.33 mM) stock of plain DMEM at 37ºC with 
fatty acid-free BSA and filtered with a 0.2 μM membrane and stored in -20°C. 
 
 
(8) Sodium Palmitate 
 
 
Sodium palmitate (18.54 mg) in 10 mL of plain DMEM at 50 ºC with constant 
shaking with Fatty acid-free BSA and filtered with a 0.2 μM membrane and stored 
in -20°C. 
 
(9) 400 mM Alcohol 
 
Alcohol 184.28 mg or 235 μL of alcohol in 10 mL of plain DMEM for 400 mM stock 
and filtered with a 0.2 μM membrane and stored in 4ºC. 
 
(10) Dorsomorphin (Compound C) 2HCl 
 
Compound C (10 mg) in 2 ml of plain DMEM for 10 mM stock and stored in 4ºC 
 
 
6.2.3 Cell culture 
 
HepG2 cells (passage-7) was obtained from the University of Sydney, which were 
previously maintained in DMEM with low glucose,10% FBS, 1% antibiotics (10,000 
I.U./mL Penicillin, 10,000 (μg/mL) Streptomycin) as per mentioned in ATCC 
guidelines for HepG2 cells. They were maintained in incubator conditions at 37º C 
with 5% CO2 changing the growth medium for every two days. After 70-80% 
confluence of cells they were washed thrice with PBS and then added 3-5 ml of 
Trypsin with EDTA. After cells completely detach, they were added with DMEM to 





subculture was done with a ratio of 1:3 or 1:6. The remaining cell was stored with 
5%DMSO in growth medium and stored in the liquid nitrogen vapour phase. 
 
6.2.4 Experimental designs and treatments 
 
 
HepG2 cells were grown up to 70% confluence and then transferred into 6 
well plates at 2.5*105 cells per well and divided into six groups. Cells were pre-
incubated with 40 μM compound C for 30 min, and then washed with PBS and 
proceeded for alcohol treatment [449]. Control cells were incubated with plain 
medium and Free fatty acid group received (sodium oleate 0.66 mM and 0.33 mM 
of Sodium palmitate final fatty acids concentration 1 mM) [395]. The treatment 
groups received low (10 mM) and moderate alcohol (20 mM) with FFA (1 mM of 
sodium oleate 0.66 mM and 0.33 mM of Sodium palmitate) the rest of the groups 
received 10 and 20 mM of alcohol without any FFA treatment. In-order to maintain a 
stable alcohol concentration for the cells, double the concentration of alcohol was 
placed in a Petri dish during the 24 hour-experiment. After 24 hour of treatment, the 
cells were removed from the incubator and proceeded for lipid extraction and cell 
protein extraction. 
 
6.2.5 Extraction of lipids from HepG2 cells 
 
 
The total lipids from HepG2 cells were extracted by the modified method of 
Bligh and Dyer [396] procedure as described in Li Lin [450]. The treated cells were 
homogenized with chloroform-methanol solution (chloroform-methanol-water,8:4:3). 








for 10 minutes. The bottom layer was collected and again centrifuged, the 
supernatant was collected and used for analysis of hepatic lipid. 
 
6.2.6 Cell protein extraction 
 
 
After 24 hour of treatment 6 well plates with cells were removed from the 
incubator and washed with PBS. Radioimmunoprecipitation assay (RIPA) buffer 
(pH 8.0) containing 50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate and 10 l/ml protease and phosphatase 
inhibitors cocktail were added to each well and scrape the cells kept on ice over an 
orbital shaking for 1hr. The homogenate was then collected and sonicated at 60 
amps of total time for 30 seconds with on time of 5 seconds and off time 15 
seconds. The homogenates were centrifuged at 4°C at 10,000 g for 15 minutes, 
and the supernatants were collected. Protein concentrations were measured by the 
Bradford assay using bovine serum albumin as standard. 
 
6.2.7 Western blot analysis 
 
The samples were mixed with loading buffer, proteins were denatured 
by heating at 95oC for 5 minutes, and 25 g of total protein was electrophoretically 
resolved on 10% lab made gels at 135 V for 90 minutes and then transferred onto a 
nitrocellulose membrane (Bio-Rad, Australia) using a wet transfer (100 V for 2 hour 
15 minutes). After blotting, the membranes were blocked with 5% non-fat dry milk 1 
hour at room temperature. The membranes were then washed three times for 5 
minute each with Tris-buffered saline-0.1% Tween (TBST, pH 7.6) and incubated 






LKB1 (1:1000) or mouse anti- PLKB1(1:1000) or mouse anti- SIRT1 (1:1000) or 
mouse anti- SREBP1(1:1000) antibody (Santa Cruz, Biotechnology, CA, USA) , or 
rabbit anti-ACC(1:1000) (Abcam, Cambridge, UK) diluted with TBST. Blots were 
then again washed three times for 5 minutes each with TBST and incubated for 1hr 
at room temperature with appropriate horseradish peroxidase-conjugated 
secondary antibody (Santa Cruz, Biotechnology, CA, USA) diluted at 1:10,000 with 
PBS, pH 7.4. The membranes were again washed three times for 5 minutes each 
with TBST and incubated with enhanced chemiluminescence reagent (Clarity™ 
Western ECL, Bio-Rad, Australia) for 1 minute at room temperature. Immune 
complexes were detected after exposing the blots to ChemiDoc™ XRS system 
(Bio-Rad, Australia) for various time points. Quantitative image analysis was 
performed using NIH Image software (Image J) to determine the intensity of the 
protein signal, which was expressed relative to the amount of -actin used as an 
internal control. 
 
6.2.8 Data and statistical analysis 
 
The results are expressed as means ± SEM. To analyse the quantitative 
differences among the experimental groups before or after treatments, the data 
were subjected to analysis of variance (ANOVA) using the GraphPad 7.03 
(GraphPad Software Inc., California, CA, USA) statistical software. Post-hoc 












6.3  Results 
 
 
6.3.1 Effect of low and moderate alcohol on triglycerides and total cholesterol 
levels in FFA-treated AMPK inhibited HepG2 cells 
 
The level of triglycerides in different experimental groups are shown in 
Figure 6.1A. The FFA-treated cells (n=6) showed a significant (p<0.001) 1.6-fold 
increase in triglyceride levels when compared to the normal control cells (n=6). On 
the other hand, both the low alcohol-treated (n=6) and moderate alcohol-treated 
(n=6) groups showed a mild significant increase in triglyceride levels by 1.1-fold 
(p<0.001) and 1.1-fold (p<0.001) respectively when compared to the FFA-treated 
control cells. In contrast, normal cells treated with moderate alcohol group (n=6) 
showed a significant (p<0.05) increase in triglycerides when compared to the 
normal control cells. However, the normal cells treated with low alcohol (n=6) 
showed a non-significant (p=0.07) increase in triglyceride levels when compared to 
the normal control cells. 
 
The total cholesterol levels in different experimental cellular groups in FFA 
treated HepG2 cells (AMPK inhibited) was shown in Figure 6.2B. HepG2 cells (n=6) 
treated with FFA showed a significant (p<0.01) 1.2-fold increase in total cholesterol 
levels when compared to the normal control cells (n=6). On the other hand, both 
the low alcohol-treated (n=6) and moderate alcohol-treated (n=6) groups showed a 
non-significant (p=0.63 to 0.52) increase in total cholesterol levels when compared 
to the FFA-treated control cells. In contrast, both the low alcohol and moderate 










































































































Figure 6.1 Effect of low and moderate alcohol on triglycerides and total 
cholesterol levels in FFA-treated AMPK inhibited HepG2 cells. (A) triglycerides 
 
(B) total cholesterol accumulation in HepG2 cells incubated with FFA 1mM mixture 
final concentration for 24hrs either with normal control cells or FFA (disease 
control) alone or with low, moderate alcohol with FFA and low and moderate 
alcohol only 
 
Values represent the mean ± SEM of n=6 
 
Significant difference from normal control cells: ##p<0.01, ###p<0.001 
 
Significant difference from disease control cells: ***p<0.001 
 
Significant difference from normal control group vs normal cells treated with alcohol 
group: §p<0.005 
 
NS: No significant difference between the groups in comparison 
 












6.3.2 Effect of low and moderate alcohol on LKB1 and its phosphorylation in 
FFA-treated AMPK inhibited HepG2 cells 
 
The effect of low and moderate alcohol on the LKB1 protein expression was 
investigated by western blotting in FFA treated HepG3 cells (AMPK-inhibited) 
Figure 6.2A. The FFA-treated HepG2 cells (n=6) showed a significant (p<0.001) 
1.5-fold decrease in LKB1 protein expression when compared to the normal control 
group (n=6). On the other hand, the moderate alcohol-treated group (n=6) showed 
a significant 1.2-fold (p<0.05) increase in LKB1 protein expression when compared 
to the FFA-treated cells. However, the low alcohol-treated group (n=6) showed a 
mild non-significant (p=0.15) decrease in LKB1protein expression when compared 
to the FFA-cells. In contrast, normal cells treated with moderate alcohol (n=3) 
showed a mild non-significant (p=0.94) increase in LKB1 protein expression when 
compared to the normal control group. However, low alcohol treatment in normal 
cells (n=3) showed a non-significant (p=0.23) 1.2-fold decrease in LKB1 protein 
expression when compared to the normal HepG2 cells. 
 
The below Figure 6.2 (B) illustrates the effect of low and moderate alcohol 
on phosphorylation of LKB1 in FFA induced NAFLD in AMPK inhibited HepG2 cells. 
The FFA-treated group (n=6) showed a significant (p<0.01) 1.4-fold decrease in 
Phospho-LKB1 protein when compared to the normal control cells (n=6). On the 
other hand, both the low alcohol-treated (n=6) and moderate alcohol-treated (n=6) 
groups showed a non-significant increase in phosphorylation of LKB1 protein by 
1.0-fold (p=0.98) and 1.2-fold (p=0.12) respectively when compared to the FFA-





(n=3) showed a non-significant (p=0.06 to 0.83) decrease in phosphorylation of 
 












































































































Figure 6.2 Protein expression of LKB1 and p-LKB1 in FFA-treated AMPK 
inhibited HepG2 cells. (A) LKB1 (B) p-LKB1 protein expression as determined by 
western blot analysis in AMPK inhibited by Compound C 40 µM in HepG2 cells 
treated with 1 mM of FFA for 24hrs either with normal control cells or FFA (disease 
control) alone or with low, moderate alcohol with FFA and low and moderate 
alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001, ##p<0.001 
Significant difference from FFA control: *p<0.05,  
NS: No significant difference between the groups in comparison  






6.3.3 Effect of low and moderate alcohol on SIRT1 protein expression in FFA- 
 
treated AMPK inhibited HepG2 cells 
 
 
The effect of low and moderate alcohol on the protein expression of SIRT1 
in AMPK inhibited HepG2 cells are shown in Figure 6.3. The FFA-treated control 
cells (n=6) showed a significant (p<0.001) 1.9-fold decrease in SIRT1 protein 
expression when compared to the normal control cells (n=6). On the other hand, 
both the low alcohol-treated (n=6) and moderate alcohol-treated (n=6) groups 
showed a significant increase in SIRT1 protein expression by 1.5-fold (p<0.01) and 
1.8-fold (p<0.001) respectively when compared to the FFA-treated control cells. In 
contrast, both the low alcohol (n=3) and moderate alcohol treatments (n=3) in 
normal cells did not show any change in SIRT1 protein expression when compared 


























































Figure 6.3 Protein expression of SIRT1 in FFA-treated AMPK inhibited HepG2 
cells 
 
SIRT1 protein expression as determined by western blot analysis in AMPK 
inhibited by Compound C 40µM in HepG2 cells treated with 1 mM of FFA for 
24hrs either with normal control cells or FFA (disease control) alone or with low, 
moderate alcohol with FFA and low and moderate alcohol only 
 
Each bar represents the mean ± S.E.M. of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001 Significant 
difference from FFA control: **p<0.01, ***p<0.001 
NS: No significant difference between the groups in comparison  


























6.3.4 Effect of low and moderate alcohol on ACC and its phosphorylation in 
FFA-treated AMPK inhibited HepG2 cells 
 
The expression of ACC protein in AMPK inhibited HepG2 cells are shown in 
Figure 6.4A. The FFA-treated control group (n=6) showed a significant (p<0.001) 
1.3-fold increase in ACC protein expression when compared to the normal control 
group (n=6). On the other hand, the moderate alcohol-treated group (n=6) showed 
a significant 1.1-fold (p<0.01) decrease in ACC protein expression when compared 
to the FFA-treated control group. However, the low alcohol-treated group (n=6) 
showed a mild non-significant (p=0.18) decrease in ACC protein expression when 
compared to the FFA-treated group. In contrast, normal cells treated with either low 
alcohol (n=3) and moderate alcohol (n=3) showed a significant increase in ACC 
protein expression by 1.2-fold (p<0.01) and 1.2-fold (p<0.01) respectively when 
compared to the normal control group. 
 
Figure 6.4B shows the effect of low and moderate alcohol treatment on 
phosphorylation of ACC in AMPK inhibited HepG2 cell. The FFA-treated group 
(n=6) showed a significant (p<0.01) 1.4-fold decrease in phosphorylation of ACC 
protein when compared to the normal control group (n=6). However, the low 
alcohol-treated (n=6) and moderate alcohol-treated (n=6) groups showed a mild 
non-significant (p=0.99 to 0.70) increase in phosphorylation of ACC protein when 
compared to the FFA-treated control group. Furthermore, normal cells treated with 
Low alcohol (n=3) showed a significant (p<0.05) decrease in phosphorylation of 
ACC expression when compared to normal control group. Whereas, moderate 











































































































Figure 6.4 Protein expression of ACC and p-ACC in FFA-treated AMPK 
inhibited HepG2 cells (A) ACC (B) p-ACC protein expression as determined by 
western blot analysis in AMPK inhibited by Compound C 40 µM in HepG2 cells 
treated with 1 mM of FFA for 24hrs either with normal control cells or FFA (disease 




Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001, ##p<0.001 
Significant difference from FFA control: **p<0.01, 
 
Significant difference from normal control group vs normal cells treated with alcohol 
groups: §§p<0.01, §p<0.05, 
 
NS: No significant difference between the groups in comparison  








6.3.5 Effect of low and moderate alcohol on SREBP1 protein expression in 
FFA-treated AMPK inhibited HepG2 cells 
 
The SREBP1 protein expression in different experimental groups is shown in 
Figure 6.5. The FFA-treated group (n=6) showed a significant (p<0.001) 2.0-fold 
increase in SREBP1 expression when compared to the normal control group (n=6). 
The moderate alcohol-treated group (n=6) showed a significant (P<0.01) 1.3-fold 
increase in SREBP1 expression when compared to the FFA- treated control group. 
However, the low alcohol treated group (n=6) showed a 1.2-fold non-significant 
(p=0.11) decrease in SREBP1 protein expression when compared to the FFA-
treated control group. In contrast, the low alcohol treatment in normal cells (n=3) 
showed a non-significant increase SREBP1 protein expression by 1.5-fold (p=0.05) 
when compared to the normal control group. However, moderate alcohol treatment 
in normal cells (n=3) showed a mild non-significant (p=0.82) increase in SREBP1 





















































Figure 6.5 Protein expression of SREBP1 in FFA-treated AMPK inhibited 
HepG2 cells. SREBP1 protein expression as determined by western blot analysis 
in AMPK inhibited by Compound C 40µM in HepG2 cells treated with 1 mM of FFA 
for 24hrs either with normal control cells or FFA (disease control) alone or with low, 
moderate alcohol with FFA and low and moderate alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001 
Significant difference from FFA control: **p<0.001,  
NS: No significant difference between the groups in comparison 
 




























The present study demonstrates the role of low and moderate alcohol 
on protecting FFA induced NAFLD in the absence of AMPK in HepG2 cells. 
The AMPK itself act individually or by SIRT1/LKB1/AMPK pathway in 
regulating the lipid metabolism in the liver. To find the role of SIRT1 and LKB1 
in regulating lipid metabolism via SIRT1, LKB1 and AMPK pathway, AMPK 
was inhibited by using compound C for investigating the role of LKB1 and 
SIRT1in protecting the HepG2 cells. AMPK has multiple effects on lipid 
metabolism; it has been suggested that the impairment of hepatic AMPK 
activity is a key pathological event in the development of many metabolic 
disorders associated with metabolic syndrome including hepatic steatosis[427]. 
In contrast to the impaired active AMPK, the increased AMPK activates the 
ATP producing catabolic pathways, such as fatty acid β oxidation, and inhibits 
ATP consuming processes, such as lipogenesis, directly by phosphorylating 
regulatory proteins and indirectly by affecting expression levels of genes in this 
pathway[366]. The first downstream target of AMPK is ACC, which is involved 
in the synthesis of malonyl-CoA. AMPK inhibits ACC activity by 
phosphorylating ACC hereby stimulating fatty acid oxidation and reducing fatty 
acid synthesis[451]. The important finding of the present study was despite the 
inhibition of AMPK, the low and moderate alcohol increased the SIRT1 and 
LKB1 protein levels in moderate alcohol group in HepG2 cells treated with FFA 
which increase ACC and SREBP1 proteins. 
 
In our study, an increase in SIRT1 was observed in low and moderate 




that heavy alcohol decreases the SIRT1 levels in liver [217, 452]. Min et al. 
have demonstrated that there is no significant change in SIRT1 expression 
when H4IIEC3 cells treated with alcohol from 0-20 mM whereas, a decrease 
in SIRT1 expression after cells treated with 50- 100mM alcohol, this confirms 
that alcohol has no negative effects on SIRT1 at low doses [452]. 
Furthermore, K.J. Thompson et al. (2015) have demonstrated that alcohol 
has no effect on SIRT1 expression in HepG2 cells up 100 mM of alcohol up 
to 48 hours [415]. Based on the results from Min and Thompson it is 
hypothesized that alcohol has no negative effects on SIRT1 at low 
concentrations. A further investigation is required for finding out the 
mechanism behind the increase in SIRT1 levels in alcohol groups. Despite 
the absence of AMPK, results from previous chapters 3 and 4 suggested 
that AMPK/LKB1/SIRT1 regulate each other. 
 
An increase in LKB1 was observed in treatment groups but not the 
phosphorylation of LKB1, the increase in LKB1 may be due to the increase in 
SIRT1 expression via STRAD and MO25 [453]. Furthermore a decrease in 
SREBP1 in low and moderate alcohol might be due to SIRT1, as SIRT1 
responds to fasting and promotes fatty acid oxidation by activating PPARα 
and inhibits fatty acid synthesis by targeting SREBP1c for degradation [430, 
454]. Increased SIRT1 managed to decrease ACC in moderate alcohol with 
FFA but failed to phosphorylate the ACC, a further investigation is required 
to find the role of SIRT1 on phosphorylation of ACC is HepG2 cells. 
 
In conclusion, the present study demonstrated that low and moderate 




regulate each other. Further studies are required for investigating the 













































































Evaluating the mechanistic action of low and 
moderate alcohol on FFA-induced NAFLD in 











































Sirtuins are a group of class III histone/protein deacetylases and the 
members of the family, silent information regulator 2(SIR2). In mammals 7 different 
sirtuins (SIRT1-7), have been identified, which have different localisation and 
expression. SIRT 1, 6, and 7 are localised mainly in the nucleus while SIRT 3, 4 
and 5 are localized in the mitochondrial matrix and SIRT2 predominantly 
cytoplasmic [455]. SIRT1, an NAD+ -dependent protein deacetylase, is an 
important regulator of energy homeostasis in response to nutrient availability. 
Currently, the best known and most studied is SIRT1, which is more commonly 
expressed in metabolic tissues such as liver, skeletal muscle, adipose tissue, 
pancreas and brain. SIRT1 actions in these tissues include regulation of β-cell and 
neuron survival, hepatic gluconeogenesis, insulin secretion and adiposity [314, 
349]. 
 
A decrease in SIRT1 activity would decrease with a decreased level of 
NAD+ as observed in a NAFLD condition [428, 456, 457]. Impairment of SIRT1 in 
liver hepatocytes contributes to the pathogenesis of both alcoholic and non-
alcoholic fatty liver disease [434, 452, 458]. Previous studies reported that deletion 
of SIRT1 in liver showed to cause peroxisome proliferator-activated receptor a 
(PPARα) signal failure and a decrease in fatty acid β-oxidation [430]. At molecular 
level, SIRT1 plays an important role in regulating various transcriptional networks 
regulating various critical metabolic processes in the liver [459, 460]. Along those 
lines, SIRT1 was shown to deacetylate many nonhistone proteins, including p53, 




factors, PGC-1a, liver X-receptor (LXR), CLOCK, PER2 and TORC2 [314, 353, 
461, 462]. Increased expression of SIRT1 decreases the lipogenic genes such as 
SREBP-1c, ACC and FAS, was central to the pathogenesis of metabolic disorders, 
including fatty liver [463]. 
 
Results from previous chapters 3 and 4 proves that apart from AMPK, SIRT1 
also plays a key role in regulating hepatic lipid accumulation. This chapter aims to 
investigate out the role of low and moderate alcohol against FFA induced 













































7.2 Materials and methods 
 
 
7.2.1 Chemical used 
 
 
Electrophoresis and electro-blotting consumables were purchased from Bio-
Rad (Hercules, CA, USA). Primary antibodies of AMPK-α1, p-AMPK-α1, p-ACC, 
LKB1, p-LKB1, and SREBP1 were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) while ACC was obtained from (Abcam, Cambridge, 
United Kingdom). Enhanced chemiluminescence kit was obtained from Bio-Rad 
(Hercules, CA, USA). DMEM ( modified basal medium eagle), low glucose, 
alcohol, Fetal bovine serum (FBS), sodium oleate, sodium palmitate from Sigma 
(Sigma St. Louis, MO, USA). All other chemicals used were of analytical or 
molecular biology grade. 
 
 
7.2.2 Reagents used 
 
(1) Radio immunoprecipitation assay (RIPA) buffer (pH 8.0) 
 
 
Sodium chloride (150 mM), sodium deoxycholate (0.5%), sodium dodecyl sulfate 
(0.1%), tris base (50 mM) and 1 mL of triton X-100 (1%) were added into a 
volumetric flask and made up to 100 mL with distilled water. The solution was 
transferred into a beaker and the pH was adjusted to 8.0 and filtered before use 
through a 0.2 μM membrane. 
 
(2) Running buffer 
 
 
Glycine (14.42 g), tris base (3.03 g) and sodium dodecyl sulfate (1 g) were added 




was transferred into a beaker and the pH was adjusted to 8.3 and filtered before 
use through a 0.2 μM membrane. 
 
(3) Transfer buffer 
 
 
Tris base (3.03 g), glycine (14.41 g) and methanol (200 mL) were added into a 
volumetric flask and made up to 1000 mL with distilled water. The solution was 
filtered before use through a 0.2 μM membrane. 
 
(4) Tris-buffered saline (TBS) 
 
 
Tris-base (2.4 g) and NaCl (8 g) were added into a volumetric flask and made up to 
1000 mL with distilled water. The solution was transferred into a beaker and the pH 
was adjusted to 7.6 and filtered before use through a 0.2 μM membrane. 
 
(5) Phosphate buffered saline (PBS) 
 
 
Sodium chloride (8 g), potassium chloride (0.2 g), disodium hydrogen phosphate 
(1.44 g), and potassium dihydrogen phosphate (0.24 g) were added into a 
volumetric flask and made up to 1000 mL with distilled water. The solution was 
transferred into a beaker and the pH was adjusted to 7.6 and filtered before use 
through a 0.2 μM membrane. 
 
(6)  Stacking gel buffer 
 
Tris base (15.14 g), SDS (1.0 g) were added into volumetric water and made up to 
250 ml with distilled water. The solution was transferred into a beaker and the pH 






(7) Sodium oleate 
 
Sodium oleate (40.58 mg) in 10 mL (13.33 mM) stock of plain DMEM at 37ºC with 
fatty acid-free BSA and filtered with a 0.2 μM membrane and stored in -20°C. 
 
 
(8) Sodium palmitate 
 
 
Sodium palmitate (18.54 mg) in 10 mL of plain DMEM at 50ºC with constant 
shaking with Fatty acid-free BSA and filtered with a 0.2 μM membrane and stored 
in -20°C. 
 
(9) 400 mM alcohol 
 
Alcohol 184.28 mg or 235 μL of alcohol in 10 mL of plain DMEM for 400 mM stock 





Nicotinamide (122.12 mg) in 10 ml of plain DMEM for 100 mM stock and filtered 




7.2.3 Cell culture 
 
HepG2 cells (passage-7) are obtained from the University of Sydney, which 
were previously maintained as per mentioned in ATCC guidelines in DMEM with 
low glucose, 10% FBS, 1% antibiotics (10,000 I.U./mL Penicillin, 10,000 (μg/mL) 
Streptomycin). They were maintained in same incubator conditions, at 37º C with 
5% CO2 changing the growth medium for every two days. After 70-80% confluence 




EDTA. After the cells completely detach, they were added into DMEM to neutralise 
the trypsin and the cells were centrifuged at 300 g for 3 minutes. The subculture 
was done with a ratio of 1:3 or 1:6. The remaining cells were stored with 5% DMSO 
in growth medium and stored in liquid nitrogen vapour phase. 
 
7.2.4 Experimental design and treatments 
 
 
HepG2 cells were grown up to 70% confluence and then transferred into 6 
well plates at 2.5*105 cells per well and divided into six groups. Cells were 
preincubated with 10 mM nicotinamide for 6 hours[346], and then washed with PBS 
and proceeded for alcohol treatment. Control cells were incubated with plain 
medium and free fatty acid group received 1 mM fatty acid mixture (containing 0.66 
mM sodium oleate and 0.33 mM sodium palmitate)[395] whereas the treatment 
groups received low (10 mM) and moderate (20 mM) concentrations of alcohol with 
1 mM fatty acid mixture (0.66 mM sodium oleate and 0.33 mM of sodium palmitate). 
The rest of the groups received 10 mM and 20 mM of alcohol without any FFA 
treatment. Alcohol is a volatile substance in order to maintain a stable alcohol 
concentration inside the 6 well plate, for the cells, double the concentration of 
alcohol was placed in a Petri dish during the 24-hour experiment. After 24-hours of 
treatment, the cells were removed from the incubator and proceeded for lipid 
extraction and cellular protein extraction. 
 
7.2.5 Extraction of lipids from HepG2 cells 
 
 
The total lipids from HepG2 cells were extracted by the modified method of 





homogenized with chloroform-methanol solution (chloroform-methanol-water,8:4:3). 
Further the resulting mixture was shaken at 37ºC for 1hour and then centrifuged at 
1,100 g for 10 minutes. The bottom layer was collected and again centrifuged, the 
supernatant was collected and used for analysis of hepatic lipid. 
 
7.2.6 Cell protein extraction 
 
 
After 24 hours of treatment, 6 well plates with cells were removed from 
incubator and washed with PBS. Radioimmunoprecipitation assay (RIPA) buffer 
(pH 8.0) containing 50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate and 10 l/ml protease and phosphatase 
inhibitors cocktail was added to each well and cells were scraped on ice over an 
orbital shaker for 1hour. The homogenates were collected and then sonicated at 
60AMP of total time for 30 seconds with on time 5 seconds and off time 15 
seconds. The homogenates were centrifuged at 4°C at 10,000 g for 15 minutes, 
and the supernatants were collected. Protein concentrations were measured by the 
Bradford assay using bovine serum albumin as standard. 
 
7.2.7 Western blot analysis 
 
The samples were mixed with loading buffer, proteins were denatured by 
heating at 95 oC for 5 minutes, and 25 g of total protein was electrophoretically 
resolved on 10% Mini-PROTEAN® TGX™ Poured gels (Bio-Rad, Australia) at 135 
V for 90 minutes and then transferred onto a nitrocellulose membrane (Bio-Rad, 
Australia) using a Mini Trans-Blot® Cell (100 V for 60 minutes) or wet transfer (100 





fat dry milk 1hour at room temperature. The membranes were then washed three 
times for 5 minutes each with tris-buffered saline-0.1% Tween-20 (TBST, pH 7.6) 
and incubated for overnight at 4 C with mouse anti-p-ACC reductase (1:1000) or 
mouse anti-AMPK-α1 (1:1000) or mouse anti- LKB1 (1:1000) or mouse anti-
pLKB1(1:1000) or mouse anti-SREBP1(1:1000) antibody (Santa Cruz, 
Biotechnology, CA, USA), rabbit anti-p-AMPK-α1 (1:500) or rabbit anti-
ACC(1:1000) (Abcam, Cambridge, UK) diluted with TBST. Blots were then again 
washed three times for 5 minutes each with TBST and incubated for 1 hour at room 
temperature with an appropriate horseradish peroxidase-conjugated secondary 
antibody (Santa Cruz, Biotechnology, CA, USA) diluted at 1:10,000 with phosphate-
buffered saline (PBS, pH 7.4). The membranes were again washed three times for 
5 minutes each with TBST and incubated with enhanced chemiluminescence 
reagent (Clarity™ Western ECL, Bio-Rad, Australia) for 1 minute at room 
temperature. Immune complexes were detected after exposing the blots to 
ChemiDoc™ XRS system (Bio-Rad, Australia) for various time point. Quantitative 
image analysis was performed using NIH Image software (Image J) to determine 
the intensity of the protein signal, which was expressed relative to the amount of - 
actin used as an internal control. 
 
7.2.8 Data and statistical analysis 
 
The results are expressed as means ± SEM. To analyse the quantitative 
differences among the experimental groups before or after treatments, the data 






(GraphPad Software Inc., California, CA, USA) statistical software. Post-hoc 
 



































































7.3.1 Effect of low and moderate alcohol on triglycerides and total cholesterol 
levels in FFA-treated SIRT1 inhibited HepG2 cells 
 
The levels of triglycerides in different groups are shown in Figure 7.1A. The 
FFA-treated group (n=6) showed a significant (p<0.001) 1.2-fold increase in 
triglycerides levels when compared to the normal control cells (n=6). On the other 
hand, both the low alcohol-treated (n=6) and moderate alcohol-treated (n=6) 
groups showed a non-significant (p=0.15 to 0.10) decrease in triglycerides levels by 
when compared to the FFA-treated control group. In contrast, the low alcohol (n=6) 
and moderate alcohol(n=6) treatment in normal cells showed a non-significant 
(p=0.77 to 0.32) decrease in triglycerides levels when compared to the normal 
control group. 
 
The total cholesterol levels in different groups of SIRT1 inhibited HepG2 cells 
are shown in Figure 7.1B. The FFA-treated (n=6) group showed a significant 
(p<0.001) 1.2-fold increase in cholesterol levels when compared to the normal 
control group (n=6). On the other hand, both the low alcohol-treated (n=6) and 
moderate alcohol-treated (n=6) groups showed a non-significant (p=0.15 to 0.05) 
decrease in total cholesterol levels when compared to the FFA-treated control 
group. In contrast, the normal cells treated with moderate alcohol (n=6) showed a 
significant (p<0.05) decrease in total cholesterol levels when compared to the 
normal control group. Whereas, the normal cells treated with low alcohol group 
(n=6) showed a mild non-significant (p=0.99) increase in total cholesterol levels 










































Figure 7.1 Effect of low and moderate alcohol on triglycerides and total 
cholesterol levels in FFA-treated SIRT1 inhibited HepG2 cells. (A) triglycerides  
(B) total cholesterol accumulation in HepG2 cells incubated with FFA 1mM mixture 
final concentration for 24hrs either with normal control cells or FFA (disease 
control) alone or with low, moderate alcohol with FFA and low and moderate 
alcohol only 
 
Values represent the mean ± SEM of n=6 
 
Significant difference from normal control cells: ###p<0.001 
 
Significant difference from normal control group vs normal cells treated with alcohol 
group: §p<0.005 
 
NS: No significant difference between the groups in comparison 
 










7.3.2 Effect of low and moderate alcohol on AMPK-α1 and its phosphorylation 
in FFA treated SIRT1 inhibited HepG2 cells 
 
The effect of low, moderate alcohol on AMPK-α1 protein expression in 
HepG2 cells are shown in Figure 7.2A. The FFA-treated group (n=6) showed a 
significant (p<0.01) 1.4-fold decrease of AMPK-α1 levels when compared to the 
normal control group (n=6). On the other hand, both the low alcohol-treated (n=6) 
and moderate alcohol-treated (n=6) groups showed a significant increase in 
AMPK-α1 protein expression by 1.2-fold (p<0.05) and 1.3-fold (p<0.01) 
respectively when compared to the FFA-treated control group. In contrast, both the 
low alcohol (n=3) and moderate alcohol (n=3) treatment with normal cells showed 
a non-significant (p=0.80 to 0.99) decrease in AMPK-α1 protein expression when 
compared to the normal control group. 
 
The below Figure 7.2 (B) illustrates the effect of low, moderate alcohol on 
phosphorylation of AMPK-α1 in FFA treated SIRT1 inhibited HepG2 cells. The FFA-
treated control group (n=6) showed a significant (p<0.001) 1.9-fold decrease in 
phosphorylation of AMPK-α1 protein when compared to the normal control cells 
(n=6). On the other hand, both the low alcohol-treated (n=6) and moderate alcohol-
treated (n=6) groups showed a significant increase in phosphorylation of AMPK-α1 
protein by 1.9-fold (p<0.001) and 2.0-fold (p<0.001) respectively when compared to 
the FFA-treated control group. In contrast, the moderate alcohol-treated normal 
cells(n=3) showed a significant 1.6-fold (p<0.05) increase in phospho-AMPK-α1 







treated with low alcohol (n=3) showed a non-significant 1.2-fold (p=0.06) increase 
 







































































































Figure 7.2 Protein expression of AMPK-α1 and p-AMPK-α1 in FFA-treated 
SIRT1 inhibited HepG2 cells. (A) AMPK-α1 (B) p-AMPK-α1 protein expression as 
 
determined by western blot analysis in SIRT1 inhibited by Nicotinamide 10 mM in 
HepG2 cells treated with 1 mM of FFA for 24hrs either with normal control cells or 
FFA (disease control) alone or with low, moderate alcohol with FFA and low and 
moderate alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with low 
and moderate alcohol groups calculated relative β-actin used as internal control. 
 
Significant difference from normal control: ##p<0.01, ###p<0.001 
 
Significant difference from FFA control: *p<0.05, **p<0.01, ***p<0.001 
 
Significant difference from normal control group vs the normal cells treated with 
alcohol group: §p<0.05 
 
NS: No significant difference between the groups in comparison  





7.3.3 Effect of low and moderate alcohol on LKB1 and its phosphorylation in 
FFA-treated SIRT1 inhibited HepG2 cells 
 
 
The effect of low and moderate alcohol treatment on LKB1 protein 
expression was investigated by western blot analysis in SIRT1 inhibited HepG2 
cells and was shown in Figure 7.3A. The FFA-treated group (n=6) showed a 
significant (p<0.001) 1.5-fold decrease in LKB1 protein expression when 
compared to the normal control group (n=6). On the other hand, both the low 
alcohol-treated (n=6) and moderate alcohol-treated (n=6) groups showed a 
significant increase in LKB1 protein expression by 1.4-fold (p<0.001) and 1.5-
fold (p<0.001) respectively when compared to the FFA-treated control group. In 
contrast, the normal cells treated with moderate alcohol treated group (n=3) 
showed a significant (p<0.05) 1.1-fold increase in LKB1 expression when 
compared to normal control group. Whereas, the normal cells treated with low 
alcohol group (n=3) showed a non-significant (p=0.99) decrease in LKB1 
expression when compared to the normal control group. 
 
 
The Figure 7.3B illustrates the effect of low and moderate alcohol on 
phosphorylation of LKB1 in FFA treated SIRT1 inhibited HepG2 cells. The FFA-
treated control group (n=6) showed a significant (p<0.05) 1.2-fold decrease in 
phosphorylation of LKB1 protein when compared to the normal control rats 
(n=6). On the other hand, both the low alcohol-treated (n=6) and moderate 
alcohol-treated (n=6) groups showed a significant increase in phosphorylation of 





when compared to the FFA-treated control group. In contrast both the low 
alcohol (n=3) and moderate alcohol (n=3)- treatment with normal cells showed a 
non-significant (p=0.69 to 0.18) increase in phosphorylation LKB1 protein when 
































































































Figure 7.3 Protein expression of LKB1 and p-LKB1 in FFA-treated SIRT1 
inhibited HepG2 cells. (A) LKB1 (B) p-LKB1 protein expression as determined by 
western blot analysis in SIRT1 inhibited by Nicotinamide 10 mM in HepG2 cells 
treated with 1 mM of FFA for 24hrs either with normal control cells or FFA (disease 
control) alone or with low, moderate alcohol with FFA and low and moderate 
alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: #p<0.05, ###p<0.001 
Significant difference from FFA control: *p<0.05, ***p<0.001 
 
Significant difference from normal control group vs the normal cells treated with 
alcohol group: §p<0.05 
NS: No significant difference between the groups in comparison  







7.3.4 Effect of low and moderate alcohol on ACC and its phosphorylation in 




The effect of low and moderate alcohol treatment on ACC protein 
expression was investigated by western blot analysis in FFA treated SIRT1 
inhibited HepG2 cells and was shown in Figure 7.4A. The FFA-treated control 
group (n=6) showed a significant (p<0.001) 2.0-fold increase in ACC protein 
expression when compared to the normal control group (n=6). On the other hand, 
the moderate alcohol-treated group (n=6) showed a significant 1.2-fold (p<0.05) 
decrease in ACC protein expression when compared to the FFA-treated control 
group. Whereas, the low alcohol-treated group (n=6) showed a non-significant 
(p=0.75) decrease in ACC protein expression when compared to the FFA-treated 
group. In contrast, the low alcohol-treated normal cells (n=3) showed a significant 
1.5-fold (p<0.05) increase in ACC protein expression when compared to the normal 
control group. Whereas, the moderate alcohol-treated normal cells (n=3) showed a 
non-significant 1.2-fold (p=0.25) increase in ACC when compared to normal control 
group. 
 
Figure 7.4B explains the effect of low, and moderate alcohol on 
phosphorylation of ACC in FFA treated SIRT1 inhibited HepG2 cell. The FFA-
treated group (n=6) showed a significant (p<0.001) 1.7-fold decrease in 
phosphorylation of ACC when compared to the normal control group (n=6). On the 
other hand, the moderate alcohol-treated group (n=6) showed a mild non-significant 
(p=0.99) increase in phosphorylation ACC when compared to the FFA-treated 




significant 1.2-fold (p=0.39) decrease in phosphorylation ACC when compared to 
the FFA-treated control group. In contrast, both the low alcohol (n=3) and moderate 
alcohol (n=3) treatment with normal cells showed a significant decrease in 
phosphorylation of ACC protein by 2.8-fold (p<0.001) and 2.3-fold (p<0.001) when 































































































Figure 7.4 Protein expression of ACC and p-ACC in FFA-treated SIRT1 
inhibited HepG2 cells. (A) ACC (B) p-ACC protein expression as determined by 
western blot analysis in SIRT1 inhibited by Nicotinamide 10 mM in HepG2 cells 
treated with 1 mM of FFA for 24hrs either with normal control cells or FFA (disease 
control) alone or with low, moderate alcohol with FFA and low and moderate 
alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001 
Significant difference from FFA control: *p<0.05, 
 
Significant difference from normal control group vs the normal cells treated with 
alcohol group: §p<0.05, §§§p<0.001 
NS: No significant difference between the groups in comparison 
 






7.3.5 Effect of low and moderate alcohol on SREBP1 protein expression in 
FFA treated SIRT1 inhibited HepG2 cells 
 
 
The SREBP1 expression of different experimental groups has been 
shown in Figure 7.5. The FFA-treated group (n=6) showed a significant 
(p<0.001) 2.0-fold increase in SREBP1 protein expression when compared to 
the normal control group (n=6). The moderate alcohol-treated group (n=6) 
showed a significant (P<0.05) 1.2-fold decrease in SREBP1 expression when 
compared to the FFA-treated control group. Whereas, the low alcohol treated 
group (n=6) showed a non-significant (p=0.69) decrease in SREBP1 protein 
when compared to FFA-treated control group. In contrast, both the low alcohol 
(n=3) and moderate alcohol (n=3) treatment with normal cells groups showed a 
non-significant (p=0.69 to 0.52) increase in SREBP1 protein expression when 
























































Figure 7.5 Protein expression of SREBP1 in FFA-treated SIRT1 inhibited 
HepG2 cells. SREBP1 expression as determined by western blot analysis in 
SIRT1 inhibited by Nicotinamide 10 mM in HepG2 cells treated with 1 mM of FFA 
for 24hrs either with normal control cells or FFA (disease control) alone or with low, 
moderate alcohol with FFA and low and moderate alcohol only 
 
Each bar represents the mean ± SEM of n=6 & 3 for normal cells treated with 
low and moderate alcohol groups calculated relative β-actin used as internal 
control. Significant difference from normal control: ###p<0.001 
Significant difference from FFA control: *p<0.05,  
NS: No significant difference between the groups in comparison 
 



























The present study demonstrates the role of low and moderate alcohol on 
protecting FFA induced NAFLD in the absence of SIRT1 in HepG2 cells. The 
SIRT1 itself act individually or by SIRT1/AMPK pathway in regulating the lipid 
metabolism in the liver. To find the role of AMPK/LKB1 in regulating lipid 
metabolism via SIRT1, LKB1 and AMPK pathway, SIRT1 was inhibited by 
Nicotinamide for investigating the role of LKB1 and AMPK in protecting the HepG2 
cells. The present study results demonstrated that low and moderate alcohol 
increase the phosphorylation of AMPK and p-LKB1 expression despite the cells 
treated with FFA which causes an increase in lipid accumulation in HepG2 cells 
which leads to increase in SREBP1, a lipogenic transcription factor in the liver that 
regulate the fatty acid and ACC via de novo lipogenesis. 
 
LKB1 is a protein kinase that plays a major role in phosphorylates and 
activates 13 downstream kinases [464]. Based on the results from previous 
chapters 3 and 4, it is hypothesized that the activation of LKB1 was done by SIRT1. 
SIRT1 overexpression diminished lysine acetylation of LKB1 and concurrently 
increased its activity, cytoplasmic/nuclear ratio, and association with the LKB1 
activator STRAD. In contrast to the above mechanism, in our study, SIRT1 was 
inhibited and an increase in LKB1 was observed in the present study. Carling et al 
(2011) has demonstrated that SIRT1 inhibited showed an HepG2 cells increased 
total LKB1 levels but decreased p-LKB1 [311]. The mechanism behind the increase 
of LKB1 with low and moderate alcohol needs further investigation. Apart from 





alcohol. The possible explanation behind the increase of p-AMPK was LKB1, the 
upstream kinase which activates the AMPK by phosphorylating Thr172. 
 
SREBP-1 is an important transcription factor in the liver that regulates the fatty acid 
respectively, by activating the enzymes involved in the fatty acid pathway including 
ATP citrate lyase (ACL), fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD) 
 
[360] (51). SREBPs are expressed as precursor proteins that span the endoplasmic 
reticulum membrane, are proteolytically cleaved and translocated to the nucleus 
under the influence of SREBP cleavage-activating protein (SCAP) to activate 
transcription. Recent studies have further demonstrated that AMPK activation 
resulted in a decrease in SREBP-1 in the HepG2 cells treated with low and 
moderate alcohol with FFA, suggesting a direct link between AMPK action and 
SREBP transcriptional activity [363] which support our present observations that 
light-to-moderate alcohol treatment tended to increase the liver AMPK-α 
 
phosphorylation and decrease SREBP-1 protein expression leading to increasing 
fatty acid oxidation. 
 
Apart from SREBP1, a decrease in ACC was observed in moderate alcohol 
with FFA treatment group. AMPK activation and phosphorylation of ACC1 at Ser79 
blocks ACC dimerisation, causing a reduction in ACC activity that lowers malonyl-
CoA and leads to the inhibition of DNL and increases in mitochondrial fatty acid 
oxidation [20] 
 
In conclusion, the present investigation demonstrated that low and moderate 
alcohol increased AMPK activation via LKB1 in the absence of SIRT1, which was 







































































































































8.1 An overview of the principal findings 
 
 
In this thesis we demonstrated the role of low and moderate alcohol in protecting 
the liver from non-alcoholic fatty liver disease (NAFLD) via in vitro and in vivo 
models for elucidating the mechanism of action. 
 
NAFLD is an inclusive term for describing a broad range of chronic liver 
pathologies. Several potentially pathogenic mediators are involved during the 
progression of this chronic liver disease [465, 466]. Initially, it starts with steatosis 
and may progress to non-alcoholic steatosis (NASH), which involves hepatocellular 
inflammation and injury which further progresses to hepatic fibrosis [467]. Risk 
factors for NAFLD include obesity, insulin resistance, and other features of 
metabolic syndrome. Steatosis is the initial benign stage, characterised by lipid 
accumulation in hepatocytes due to impaired triglyceride synthesis and export, 
and/or reduced fatty acid beta-oxidation. 
 
Notably, heavy alcohol consumption leads to alcoholic fatty liver disease. In 
contrast to the alcoholic fatty liver disease, evidence shows that moderate alcohol 
consumption has beneficial effects on protection from type II diabetes, protection 
against the risk of major cardiovascular disease events such as myocardial 
infarction and coronary artery disease in healthy populations [183]. Henceforward, 
the purpose of this thesis was to evaluate the beneficial effects of low and 
moderate alcohol in protecting the liver from high fat diet-fed rat model (HFD). 
Moreover, the molecular mechanism responsible for protecting the liver from HFD 
induced dyslipidaemia has been investigated by using in vitro model for different 




Principal finding 1 (outlined in CHAPTER 2): Chronic long-term feeding of low 
and moderate alcohol protects the liver from HFD fed rats causing an 
increase in hepatic lipid accumulation leading to steatosis 
 
Chronic HFD feeding altered the liver functions as evidenced by the 
biochemical studies and the hepatic tissue as evidenced by the histological studies. 
The HFD-control rats lead to augment the metabolic dyslipidaemia. This is 
associated with altered serum lipid profile accompanied by an increase in serum 
insulin and glucose and elevated liver enzymes ALT and AST which are the key 
enzymes involved in the hepatocellular injury. The histological architecture of liver 
tissue in HFD control rats also showed classical features of steatosis. Together with 
the above mentioned biochemical and histological changes, long-term chronic 
feeding of HFD to rats leads to augment the metabolic dyslipidaemia. Thus, long-
term feeding with moderate alcohol reduced the serum glucose, HDL cholesterol 
and liver ALT and AST enzymes in animals with HFD induced NAFLD whereas as 
low alcohol with HFD showed its effects on increasing serum HDL levels. Further 
studies are being undertaken to explain the mechanism behind the lipid regulation 
by low and moderate alcohol. 
 
 
Principal finding 2 (CHAPTER 3): Chronic long-term feeding of low and 
moderate alcohol increases activation of AMPK-α1 and SIRT1 which plays a 
key role in controlling the lipid in HFD rats. 
 
Numerous studies demonstrated that non-alcoholic steatosis arises due to 
 






acid synthesis. The results from chapter-3 revealed that increased hepatic lipid 
accumulation in HFD control rats is mainly due to increase in SREBP-1 and ACC 
which also downregulates AMPK-α1, LKB1 and SIRT1. Moreover, the results of 
chapter 3 also describe that low and moderate alcohol increases the activation of 
AMPK-α1, SIRT and LKB1. Activation of AMPK-α1 inactivates the metabolic 
enzymes involved in lipid metabolism such as SREBP-1. It also controls ACC, the 
key enzyme involved in fatty acid synthesis. Thus, the molecules responsible for 
hepatic lipid accumulation in the HFD control group was regulated in treatment 
groups. 
 
Principal finding 3 (CHAPTER 4): The low and moderate alcohol increases 
activation of AMPK-α1 and SIRT1 which plays a key role in controlling the lipid in 
HepG2 cells treated with FFA (oleic and palmitic acid) induced NAFLD. 
 
Hyperlipidaemia is a hallmark for NAFLD and is largely due to increasing 
triglycerides and total cholesterol which also includes the proteins involved in lipid 
synthesis via de novo lipogenesis induced by the treatment of oleic acid and 
palmitic acid (FFA). The results from chapter- 4 suggest that FFA increases the 
lipid profile and the proteins involved in lipid synthesis (SREBP-1 and ACC) and 
decreases the proteins (AMPK-α1, SIRT1 and LKB1) involved in lipid metabolism. 
On the other hand, low and moderate alcohol failed to decrease the SREBP1 
protein despite the increase in AMPK-α1 and SIRT1 proteins which play a major 
role in regulating the lipids. Thus, the results from chapter-4 indicate that low and 





Principal finding 4 (CHAPTER 5): Identifying the role of LKB1 protein on oleic 
and palmitic acid (FFA) challenged HeLa cells treated with low and moderate 
alcohol. 
 
Based on the results from chapters-3 and 4, low and moderate alcohol 
increases the proteins AMPK-α1, LKB1 and SIRT1 which further regulate each 
other for lipid metabolism regulation. The results from chapter-5 suggest that FFA-
treated HeLa cells showed an increase in lipid synthesis proteins along with 
increase in triglycerides and total cholesterol accumulation. Whereas, the low and 
moderate alcohol failed to regulate the proteins involved in lipid synthesis such as 
SREBP1 and ACC via AMPK-α1 and SIRT1. Thus, the results from chapter-5 
conclude that LKB1 is required for the activation of AMPK-α1, and SIRT1. 
 
Principal finding 5 (CHAPTER 6): Identifying the role of low and moderate 
alcohol in FFA (oleic and palmitic acid) induced NAFLD in HepG2 cells 
(AMPK-inhibited). 
 
The decrease in hepatic AMPK is one of the main protein involved in 
regulating the lipid synthesis. The aim of chapter-6 is to find the role of SIRT1 and 
LKB1 in regulating the lipid synthesis in the absence of AMPK in HepG2 cells 
treated with FFA. The results from this chapter suggest that FFA control group 
showed a similar result of FFA control group from previous chapters. However, the 
alcohol-treated groups showed an increase in LKB1 and SIRT1. SIRT1 plays a 
major role in controlling the post-translation proteins SREBP-1 and ACC. Thus, the 
result from chapter-6 conclude that alcohol treated HepG2 (AMPK-inhibited) cells, 






Principal finding 6 (CHAPTER 7): Identifying the role of low and moderate 
alcohol in FFA (oleic and palmitic acid) induced NAFLD in HepG2 cells 
(SIRT1-inhibited). 
 
The results from chapter-6 suggest that in the absence of 
AMPK, SIRT1 alone can regulate the lipid synthesis. To find the role of AMPK-α1, 
SIRT1 was inhibited in this chapter. In conclusion, the present investigation 
demonstrated that low and moderate alcohol increased AMPK-α1 activation via 
LKB1 in the absence of SIRT1, which was associated with decreased expression of 
SREBP-1 and ACC. So, this study demonstrates that low and moderate alcohol 






































NAFLD is induced by chronic feeding of HFD to rats leading to augmented 
metabolic dyslipidaemia. This is associated with elevated serum lipid profile, 
alongside increased serum insulin and glucose levels, which also includes 
elevated ALT and AST liver enzymes. Long-term feeding with low to moderate 
alcohol decreased the serum glucose, HDL cholesterol and liver ALT and AST 
enzymes in HFD-induced NAFLD. 
 
Long term feeding of HFD leads to up-regulated SREBP-1c protein and 
contributes to the increase de novo fatty acid synthesis. Increased SREBP1c 
triggers the downstream target proteins such as ACC, which was observed in HFD 
fed groups. Increased expression of SREBP1c and ACC proteins, plays a major 
role in regulating the synthesis and β-oxidation of fatty acids . This further leads to 
increase in lipid deposition in liver, which finally results in steatosis, the first stage of 
NAFLD. The low and moderate alcohol-treated groups showed an elevated levels 
of AMPK-α1, p-AMPK-α1, LKB, p-LKB1, and SIRT1 proteins. Apart from AMPK 
itself, the concurrent regulation of SIRT1 and AMPK controls the SREBP-1 
dependent and its downstream proteins by phosphorylating the SREBP1 and ACC 
proteins which are involved in lipid synthesis. 
 
HepG2 cells treated with FFA showed an increase in triglycerides and total 
cholesterol levels, which leads to hepatic steatosis. Whereas, the alcohol-treated 
groups did not show any effect in controlling the hepatic lipids. However, the 








AMPK-α1, LKB1, and SIRT1, the proteins involved in regulating the lipid synthesis 
via controlling the SREBP1c and ACC. 
 
 
From the inhibitory studies, it is concluded that LKB1 is essential for 
activation of AMPK and SIRT1. In contrast to LKB1 inhibition in HeLa cells, HepG2 
cells showed an increased SIRT1 protein levels despite the inhibition of AMPK, 
SIRT1 deacetylates and inhibits SREBP-1c activity, resulting in down-regulation of 
lipogenic SREBP-1c gene expression and subsequently decreased fat storage in 
the liver. Furthermore, the low and moderate alcohol increased AMPK activation via 
LKB1 in the absence of SIRT1, which was associated with decreased expression of 
SREBP-1 and ACC. 
 
Taken all together, these findings demonstrated that the low and moderate 
alcohol protected against the development of HFD induced NAFLD by enhancing 
the proteins such as AMPK-α1, SIRT1 and LKB1 involved in lipid metabolism. 
Further, in vitro studies demonstrated that the consumption/intake of low and 
moderate alcohol reduces the lipid synthesis via increasing AMPK-α1, SIRT1 and 






















8.3  Limitations 
 
Due to time constraints, only protective effects of low to moderate alcohol have been 
evaluated in this thesis. Curative effects of low to moderate alcohol on in vivo studies 
work have not been performed in this thesis. Furthermore, this thesis includes 
information about alcohol with HFD and does not include any experimental groups fed 
with only low to moderate alcohol, which could have delivered information about the 
beneficial effects of low and moderate alcohol in absence of HFD. This thesis provides 
information only about the major proteins involve protecting the liver from NAFLD. The 
enzymatic studies and mRNA expression (RT-PCR) studies work has not been 
performed in this thesis. This thesis includes only information only about the major 
outlined proteins involved in lipid pathways. A further detailed proteins involved in lipid 
pathways need to be quantified, besides those involved in NAFLD. Moreover, this thesis 
does not provide any information on the role of low to moderate alcohol on the 
inflammatory and oxidative stress pathways which plays a major role in pathogenesis of 
NAFLD. 
 
This thesis lacks the information on alcohol metabolism studies in in vitro and in 
vivo models. Furthermore, investigations on blood alcoholic concentrations of low to 
moderate alcohol has not been done. This thesis includes information about the HepG2 
cell line, which cannot metabolise alcohol was used for evaluating the role of low to 
moderate alcohol. This thesis lacks the information about the effects of low to moderate 
alcohol on the genetically modified HepG2 cell line such as VA-13, which has ethanol 
metabolism properties. This thesis lack the detailed information about the role of 
individual protein among AMPK-α1/LKB1/SIRT1 in regulating the lipid metabolism 





8.4  Future directions 
 
 
Future studies on the curative effects of low to moderate alcohol on HFD-induced 
NAFLD are required. Furthermore, extra groups with only alcohol treated rats 
should be included in the experimental procedure with increased sample size, 
which will provide a better understating on beneficial effects of low to moderate 
alcohol on protecting the liver from HFD induced NAFLD. A further detailed 
evaluation on proteins involved in lipid pathways need to be quantified. The effects 
of low to moderate alcohol on inflammatory and oxidative stress pathways which 
plays a major role in pathogenies of NAFLD needs to be investigated. The role of 
low to moderate alcohol on leptin and adiponectin which are the main metabolic 
products of adipose tissue have been implicated in the pathogenies of NAFLD and 
a part of metabolic syndrome needs to be studied. 
 
All the in vitro studies need to be done in VA-13 cell lines, a genetically 
modified HepG2 cell line which has ethanol metabolizing properties and the 
comparison of results will provide the role of alcohol metabolites in protecting the 
liver from NAFLD. Furthermore, detailed multiple protein inhibitory studies need to 
done for evaluating the role of individual proteins in protecting the liver from 
NAFLD. Moreover, a detailed histopathological studies including H&E staining and 

















[1] Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31. 
 
[2] B. SD. Carbohydrates. In Tietze Text book of clinical chemistry. Philadelphia: 
WB Saunders Company; 2005. 
 
[3] Browning LSS, R. Dobbins, P. Nuremberg, J. D. Horton, J. C. Cohen, S. M. 
Grundy, and H. H. Hobbs. . Prevalence of hepatic steatosis in an urban population 
in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95. 
 
[4] Weston SR, W. Leyden, R. Murphy, N. M. Bass, B. P. Bell, M. M. Manos, and N. 
A. Terrault. Racial and ethnic distribution of nonalcoholic fatty liver in persons with 
newly diagnosed chronic liver disease. Hepatology. 2005;41:372–9. 
 
[5] Amarapurkar DN, E. Hashimoto, L. A. Lesmana, J. D. Sollano, P. J. Chen, and 
K. L. Goh. How common is non-alcoholic fattyliver disease in the Asia-Pacific 
region and are there local differences? J Gastroenterol Hepatol. 2007;22:788–93. 
 
[6] Fan JG, T. Saibara, S. Chitturi, B. I. Kim, J. J. Sung, and A. Chutaputti. Asia-
Pacific Working Party for NAFLD.What are the risk factors and settings for non-




[7] Osterreicher CH, and D. A. Brenner. . The genetics of nonalcoholic fatty liver 
disease. Ann Hepatol. 2007;6:83–8. 
 
[8] Zivkovic AM, German, J. B. & Sanyal, A. J. Comparative review of diets for the 
metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J 
ClinNutr. 2007;86:285–300. 
 









[10] Zandbergen FP, J. . PPARalpha in atherosclerosis and inflammation. Biochim 
Biophys Acta. 2007;1771:972–82. 
 
[11] Abid Aea. Soft drink consumption is associated with fatty liver disease 
independent of metabolic syndrome. J Hepatol. 2009;51:918–24. 
 
[12] Ouyang Xea. Fructose consumption as a risk factor for non-alcoholic fatty liver 
disease. J Hepatol. 2008;48:993–9. 
 
[13] Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis 
of non-alcoholic fatty liver disease (NAFLD). Lipids in health and disease. 
2010;9:42. 
 
[14] Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology 
and pathogenesis. Annual review of pathology. 2010;5:145-71. 
 
[15] Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 
1998;114:842-5. 
 
[16] Feldstein WN, Canbay A, Guicciardi ME,Bronk SF, Rydzewski R, et al. Free 
fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a 
lysosomal pathway. Hepatology. 2004;40:185–94. 
 
[17] Tilg HM, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the 
multiple parallel hits hypothesis. Hepatology. 2010;52:1836-46. 
 
[18] Browning, Horton. Molecular mediators of hepatic steatosis and liver injury. J 
Clin Invest. 2004;114::147–52. 
 
[19] Postic GJ. Contribution of de novo fatty acid synthesis to hepatic steatosis and 





[20] Abdelmalek, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. 
Increased fructose consumption is associated with fibrosis severity in patients with 
nonalcoholic fatty liver disease. Hepatology. 2010;51:1961-71. 
 
[21] Jensen-Urstad APLS. Fatty acid synthase and liver triglyceride metabolism: 
housekeeper or messenger? Biochimica et biophysica acta. 2012;1821:747–53. 
 
[22] Zelber-Sagi DN-K, R. Goldsmith et al. Long term nutritional intake and the risk 
for non-alcoholic fatty liver disease (NAFLD): a population based study,. Journal of 
Hepatology. 2007;47:711–7. 
 
[23] Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose 
Consumption as a Risk Factor for Non-alcoholic Fatty Liver Disease. Journal of 
hepatology. 2008;48:993-9. 
 
[24] Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. 
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with 
nonalcoholic fatty liver disease. Journal of Clinical Investigation. 2005;115:1343-51. 
 
[25] Kotronen A, Velagapudi, V. R., Yetukuri, L., Westerbacka, J., Bergholm, R., 
 
Ekroos, K., Makkonen, J., Taskinen, M. R., Oresiˇ cˇ, M. & Yki-Jarvinen ¨ ,. Serum 
saturated fatty acids containing triacylglycerols are better markers of insulin 
resistance than total serum triacylglycerol concentrations. Diabetologia. 
2009b;52,:684–90. 
 
[26] Moon Y-A. The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis. 
Endocrinol Metab. 2017;32:6-10. 
 
[27] Horton GJ, Brown MS. . REBPs: activators of the complete program of 




[28] Shimano H HJ, Shimomura I, Hammer RE, Brown MS, Goldstein JL. . Isoform 
1c of sterol regulatory element binding protein is less active than isoform 1a in 
livers of transgenic mice and in cultured cells. J Clin Invest. 1997;99:846-54. 
 
[29] Moon LG, Xie X, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V, et al. . The 
Scap/SREBP pathway is essential for developing diabetic fatty liver and 
carbohydrateinduced hypertriglyceridemia in animals. Cell Metab. 2012;15:240-6. 
 
[30] Iizuka K BR, Liang G, Horton JD, Uyeda K. . Deficiency of carbohydrate 
response element-binding protein (ChREBP) reduces lipogenesis as well as 
glycolysis. Proceedings of the National Academy of Sciences of the United States 
of America. 2004;101:7281-6. 
 
[31] Kabashima T KT, Wadzinski BE, et al. ylulose 5-phosphate mediates glucose-
induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat 
liver. X Proc Natl Acad Sci. 2003;100:5107–12. 
 
[32] Arden C PJ, Tudhope SJ, et al. Elevated glucose represses liver glucokinase 
and induces its regulatory protein to safeguard hepatic phosphate homeostasis. 
Diabetes. 2011;60:3110–20. 
 
[33] de la Iglesia N MM, Seoane J, Guinovart JJ, Agius L. The role of the regulatory 
protein of glucokinase in the glucose sensory mechanism of the hepatocyte. J Biol 
Chem. 2000;275:10597–603. 
 
[34] Dentin R, Benhamed, F., Hainault, I., Fauveau, V., Foufelle, F., Dyck, J.R., 
Girard, J. and Postic, C. Liver-specific inhibition of ChREBP improves hepatic 
steatosis and insulin resistance in ob/ob. Mice Diabetes. 2006;55:2159–70. 
 





[36] Kasinath F, D, Sataranatarajan, K, Choudhury, GG, Lee MJ, Mariappan, MM: . 
Regulation of mRNA translation in renal physiology and disease. Am J Physiol 
Renal Physiol. 2009;297:F1153–F65,. 
 
[37] Kasinath BS MM, Sataranatarajan K, Lee MJ, Feliers D. mRNA translation: 
Unexplored territory in renal science. J Am Soc Nephrol. 2006;17:3281–92. 
 
[38] Sharma JHIaK. Mechanisms Linking Obesity, Chronic Kidney Disease, and 
Fatty Liver Disease: The Roles of Fetuin-A, Adiponectin, and AMPK. J Am Soc 
Nephrol. 2010;21:406–12. 
 
[39] Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, Thorens B, 
Vaulont S & Viollet B ,. Short-term overexpression of a constitutively active form of 
AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. 
Diabetes Care. 2005;54:1331–9. 
 
[40] Xu A, Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. & Cooper, . The fat-derived 
hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in 
mice. J Clin Invest,. 2003;112:91-100. 
 
[41] Yamaguchi K, Yang ,L, McCall, S, Huang, J, Yu ,XX, Pandey ,SK, et al. . 
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver 
damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 
2007;45:1366–74. 
 
[42] Bergeron R. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-
ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese 
Zucker rats. Diabetes,. 2001;50:1076-82. 
 
[43] Baur JA, ., et al. . Resveratrol improves health and survival of mice on a high-




[44] Ruderman N, Xu ,XJ, Nelson L, et al. AMPK and SIRT1: a long-standing 
partnership? Am J Physiol Endocrinol Metab. 2010;298:E751-60. 
 




[46] Bergheim I, Weber S, Vos M, Kramer S, Volynets V, Kaserouni S, et al. 
Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role 
of endotoxin. J Hepatol. 2008;48:983-92. 
 
[47] Zhang H, Wu MR. . IRT1 regulates Tat-induced HIV-1 transactivation through 
activating AMP-activated protein kinase. S Virus Res. 2009;146:51-7. 
 
[48] Cantó C, Gerhart-Hines ,Z, Feige, JN, et al. . AMPK regulates energy 
expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 
2009;458:1056-60. 
 
[49] D.E. Jenne ea. Peutz-Jeghers syndrome is caused by mutations in a novel 
serine threonine kinase. Nat Genet. 1998;18:38-43. 
 
[50] Martínez-López N. Activation of LKB1-Akt pathway independent of PI3 Kinase 
plays a critical role in the proliferation of hepatocellular carcinoma from NASH. 
Hepatology. 2010;52:1621–31. 
 
[51] Hong SP. Activation of yeast SNF1 and mammalian AMP-activated protein 
kinase by upstream kinases. Proc Natl Acad Sci. 2003;100:8839–43. 
 
[52] Woods AC. LKB1 is the upstream kinase in the AMP-activated protein kinase 
cascade. Curr Biol. 2003;13:2004-8. 
 
[53] Cameron A, Shaw JE, Zimmet PZ. . The metabolic syndrome: Prevalence in 
worldwide populations. Endocrinol Metab Clin N AM. 2004;33:351-76. 
 




Advances in clinical chemistry. 2015;70:247-314. 
 
[55] Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of 
PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. 
Hepatology. 2003;38:123-32. 
 
[56] Kashireddy PV, Rao MS. Lack of peroxisome proliferator-activated receptor 
alpha in mice enhances methionine and choline deficient diet-induced 
steatohepatitis. Hepatology research : the official journal of the Japan Society of 
Hepatology. 2004;30:104-10. 
 
[57] Kadayifci A MR, Bass N. Medical treatment of non-alcoholic steatohepatitis. 
Clin Liver Dis. 2007;11:119-40. 
 
[58] Palmer M SF. Effect of weight reduction on hepatic abnormalities in overweight 
patients. Gastroenterology. 1990;99:1408–13. 
 
[59] Vajro P FA, Perna C, Orso G, Tedesco M, De VincenZo A. Persistent 
hyperaminotransferasemia resolving after weight reduction in obese children. J 
Pediatr. 1994;125:239–41. 
 
[60] BLOOD ALCOHOL CONCENTRATION LIMITS WORLDWIDE. ICAP 
REPORTS 112002. 
 
[61] Sjostrom L LA, Peltonen M,et al. Lifestyle, diabetes, and cardiovascular risk 
factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93. 
 
[62] Kral JG TS, Biron S, et al. Effects of surgical treatment of the metabolic 
syndrome on liver fibrosis and cirrhosis. Surgery. 2004;135:48–58. 
 
[63] Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic 





[64] Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, 
Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in 
obese patients. Cochrane Database Syst Rev. 2010:Cd007340. 
 
[65] Musso G. A meta-analysis of randomized trials for the treatment of 
nonalcoholic fatty liver disease. Hepatology. 2010;52:79-104. 
 
[66] Caldwell SH AC, Al-Osaimi Therapy of NAFLD: insulin sensitizing agents. J 
Clin Gastroenterol. 2006;40:61–6. 
 
[67] RS A. Insulin resistance: cause or consequence of nonalcoholic 
steatohepatitis? Gastroenterology. 2007;132:444-6. 
 
[68] Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty 
L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the 
randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone 
Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-10. 
 
[69] Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A 
placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. 
N Engl J Med. 2006;355:2297-307. 
 
[70] Chang CY AC, Al-Osaimi AM, Caldwell S. Therapy of NAFLD: antioxidants and 
cytoprotective agents. J Clin Gastroenterology. 2006;40:S51-60. 
 
[71] Shu X ZL, Ji G. Vitamin E therapy in non-alcoholic fatty liver disease. Int J Clin 
Med. 2014;5:87-92. 
 
[72] Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where 
do we stand? an overview. Saudi journal of gastroenterology : official journal of the 
Saudi Gastroenterology Association. 2016;22:91-105. 
 





regulation, glutathione metabolism and bile formation in the obese Zucker rat. J 
Hepatol. 2005;43:1021–30. 
 
[74] Pizarro M BN, Solis N, et al. Bile secretory function in the obese Zucker rat: 
evidence of cholestasis and altered canalicular transport function. Gut. 
2004;53:1837–43. 
 
[75] Okan A AH, Tankurt E, et al. Effect of ursodeoxycholic acid on hepatic 
steatosis in rats. Dig Dis Sci. 2002;47:2389–97. 
 
[76] Kiyici M GM, Gurel S, et al. . Ursodeoxycholic acid and atorvastatin in the 
treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003;17:713–8. 
 
[77] Laurin J LK, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the 
treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 
1996;23:1464–7. 
 
[78] Lindor KD KK, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of 
nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 
2004;39:770–8. 
 
[79] Mendez-Sanchez N GV, Chavez-Tapia N, Ramos. Weight reduction and 
ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-
blind, placebo-controlled trial. Ann Hepatol. 2004;3:108-12. 
 
[80] Buang Y WY, Cha JY, Nagao K, Yanagita T. Dietary phosphatidylcholine 
alleviates fatty liver induced by orotic acid. Nutrition. 2005;21:867-73. 
 
[81] Dajani AI AHA, Zakaria MA, Al Jaberi M, Nounou MA. Essential phospholipids 
as a supportive adjunct to the management of patients with primary NAFLD and 





[82] Dudley R. Ethanol, fruit ripening, and the historical origins of human alcoholism 
in primate frugivory. Integrative and comparative biology. 2004;44:315-23. 
 
[83] Sylva Leblová ES, Věra Vaníčková. Pyruvate metabolism in germinating seeds 
 
during natural anaerobiosis. Biologia Plantarum. 1974;16:406-11. 
 
[84] Paton. Alcohol in the body. BMJ. 2005;330:85-7. 
 
[85] Sadler. Alcohol and alcoholism. 2007. 
 
[86] Fraser. Pharmacokinetic interactions between alcohol and other drugs. Clin 
Pharmacokinet. 1997;33:79-90. 
 
[87] Ferreira M, Willoughby D. Alcohol consumption: the good, the bad, and the 
indifferent. Appl Physiol Nutr Metab. 2008;33:12-20. 
 
[88] Smart L. Alcohol and Human Health. Oxford University Press. 2007. 
 
[89] AW. J. Body mass index and blood-alcohol calculations. Anal Toxicol. 
2007;31:177-8. 
 
[90] Paton A. Alcohol in the body. BMJ. 2005;330:85-7. 
 
[91] Vonghia L, Leggio L, Ferrulli A, Bertini M, Gasbarrini G, Addolorato G. . Acute 
alcohol intoxication. Eur J Intern Med. 2008;19:561-7. 
 
[92] Lieber C. Hepatic, metabolic and toxic effects of ethanol: 1991 update. 
Alcoholism, clinical and experimental research. 1991;15:573-92. 
 
[93] Zakhari S. Alcohol metabolism and epigenetics changes. Alcohol research 
:current reviews. 2013;35:6-16. 
 
[94] Samir Z. How Is Alcohol Metabolized by the Body? Alcohol Research & Health. 
2006;29:245-54. 
 
[95] BOSRON WFE, T.; AND LI, T.K. . Genetic factors in alcohol metabolism and 




[96] HANDLER JA, AND THURMAN, R.G. . Redox interactions between catalase 
and alcohol dehydrogenase pathways of ethanol metabolism in the perfused rat 
liver. Journal of Biological Chemistry. 1990;265:1510–5. 
 
[97] WERNER JS, M. WARSHAW, A.L. ET AL. Alcoholic pancreatitis in rats: Injury 
from nonoxidative metabolites of ethanol. American Journal of Physiology. 
2002;283:G65–G73. 
 
[98] Randall I. Disposition of Toxic Drugs and Chemicals in Man. California: 
Biomedical Pubilcations; 2011. 
 
[99] NHMR. Is there a safe level of daily consumption of alcohol for men and 
women. 1992. 
 
[100] NHMRC. Australian Alcohol Guidelines: Health Risks and Benefits. In: Care 
CDoHaA, editor. Canberra2001. 
 
[101] REPORTS I. BLOOD ALCOHOL CONCENTRATION LIMITS WORLDWIDE. 
ICAP REPORTS 112002. 
 




[103] Ginsburg BC, Javors MA, Friesenhahn G, Frontz M, Martinez G, Hite T, et al. 
Mouse breathalyzer. Alcoholism, clinical and experimental research. 2008;32:1181-
5. 
 
[104] Dilley JE, Nicholson ER, Fischer SM, Zimmer R, Froehlich JC. Alcohol 
Drinking and Blood Alcohol Concentration Revisited. Alcoholism, clinical and 
experimental research. 2018;42:260-9. 
 
[105] Lemmens. Individual risk and population distribution of alcohol consumption,: 




[106] Dunbar RIM, Launay J, Wlodarski R, Robertson C, Pearce E, Carney J, et al. 
Functional Benefits of (Modest) Alcohol Consumption. Adaptive Human Behavior 
and Physiology. 2017;3:118-33. 
 
[107] Beaglehole JR. Alcohol, cardiovascular diseases and all causes of death: A 
review of the epidemiological evidence. Drug Alcohol Review. 1992;11:275-90. 
 
[108] Corrao G, Rubbiati L, Bagnardi V, Zambon A, Poikolainen K. Alcohol and 
coronary heart disease: a meta-analysis. Addiction (Abingdon, England). 
2000;95:1505-23. 
 
[109] Friesema IHM, Zwietering PJ, Veenstra MY, Knottnerus JA, Garretsen HFL, 
Lemmens PHHM. Alcohol intake and cardiovascular disease and mortality: the role 
of pre-existing disease. Journal of epidemiology and community health. 
2007;61:441-6. 
 
[110] Edwards. The individual’s drinking and degree of risk Alcohol Policy and the 
Public Good. Oxford, Oxford University Press. 1994:41-74. 
 
[111] Bondy. Overview of studies on drinking patterns and consequences. 
Addiction Biology. 1996;91:1663-74. 
 
[112] Jackson. Cardiovascular disease and alcohol consumption: Evidence of 
benefit from epidemiological studies. Contemp Drug Probl. 1994:215-24. 
 
[113] Streissguth AP SP, Barr HM. Neurobehavioral doseresponse effects of 
prenatal alcohol exposure in humans from infancy to adulthood. Ann N Y Acad Sci. 
1989;562:145-58. 
 
[114] Shaper AG WG, Walker M. Alcohol and coronary heart disease: A 
perspective from the British Regional Heart Study. Int J Epidemiol. 1994;23:482-94. 
 




women. N Engl J Med. 1995;332:1245-50,. 
 
[116] Holman CDJ ED, Milne E, Winter MG: . Meta-analysis of alcohol and all-
cause mortality: A validation of NHMRC recommendations. Med J Aust. 
1996;164:141-5. 
 
[117] Anderson. Alcohol and risk of physical harm,: Oxford, Oxford University 
Press; 1995. 
 
[118] Rimm EB, Giovannucci EL, Willett WC, Colditz GA, Ascherio A, Rosner B, et 
al. Prospective study of alcohol consumption and risk of coronary disease in men. 
Lancet. 1991;338:464-8. 
 
[119] F. B. Hu JEM, M. J. Stampfer et al. “Diet, lifestyle, and the risk of type 2 
 




[120] S. G. Wannamethee CACJ, J. E. Manson, W. C. Willett, and E. B. Rimm, . 
“Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger 
women,”. Archives of Internal Medicine. 2003;163:1329–36. 
 
[121] Davies MJ. Effects of Moderate Alcohol Intake on Fasting Insulin and Glucose 
Concentrations and Insulin Sensitivity in Postmenopausal Women A Randomized 
Controlled Trial. JAMA. 2002;287:2559-62. 
 
[122] Schrieks. The Effect of Alcohol Consumption on Insulin Sensitivity and 
Glycemic Status: A Systematic Review and Meta-analysis of Intervention Studies. 
Diabetes Care. 2015;38:723-32. 
 
[123] McCarty. “Does regular ethanol consumption promote insulin sensitivity and 





[124] Stampfer M, Kang JH, Chen J et al. Effects of moderate alcohol consumption 
on cognitive function in women. N Engl J Med. 2005;253:352:245. 
 
[125] Ganguli M VB, Saxton JA et al. Alcohol consumption and cognitive functio in 
late life: A longitudinal community study. Neurology. 2005;65:1210–7. 
 
[126] Luchsinger JA TM, Siddiqui M et al. . Alcohol intake and risk of dementia. J 
Am Geriatr Soc. 2004;52:540–6. 
 
[127] Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol 
intake and lower risk of coronary heart disease: meta-analysis of effects on lipids 
and haemostatic factors. Bmj. 1999;319:1523-8. 
 
[128] Kaptoge S WI, Thompson SG. Associations of plasma fibrinogen levels with 
established cardiovascular disease risk factors, inflammatory markers, and other 
characteristics: Individual participant meta-analysis of 154,211 adults in 31 
prospective studies: The fibrinogen studies collaboration. Am J Epidemiol. 
2007;166:867–79. 
 
[129] Fenn LJ. Inhibition of platelet aggregation by ethanol in vitro shows specificity 
for aggregating agent used and is influenced by platelet lipid composition. 
Thrombosis Haemostasis. 1982;48:49–53. 
 
[130] Rajdl D RJ, Trefil L et al. Effect of white wine consumption on oxidative stress 
markers and homocysteine levels. Physiol Res. 2007;56:203–12. 
 
[131] Tilg H MA. Evolution of inflammation in nonalcoholic fatty liver disease: the 
multiple parallel hits hypothesis. Hepatology. 2010;52:1836–46. 
 
[132] Kanuri G, Bergheim I. In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver 
Disease (NAFLD). International Journal of Molecular Sciences. 2013;14:11963. 
 








[134] Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, et al. Model of 
nonalcoholic steatohepatitis. Am J Clin Nutr. 2004;79:502-9. 
 
[135] Rosenstengel S, Stoeppeler S, Bahde R, Spiegel HU, Palmes D. Type of 
steatosis influences microcirculation and fibrogenesis in different rat strains. 
Journal of investigative surgery : the official journal of the Academy of Surgical 
Research. 2011;24:273-82. 
 
[136] Zou Y, Li J, Lu C, Wang J, Ge J, Huang Y, et al. High-fat emulsion-induced 
rat model of nonalcoholic steatohepatitis. Life sciences. 2006;79:1100-7. 
 
[137] Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-
like receptor 4 is involved in the development of fructose-induced hepatic steatosis 
in mice. Hepatology. 2009;50:1094-104. 
 
[138] Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of 
fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nature 
reviews Gastroenterology & hepatology. 2010;7:251-64. 
 
[139] Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, et al. 
High-fructose, medium chain trans fat diet induces liver fibrosis and elevates 
plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic 
steatohepatitis. Hepatology. 2010;52:934-44. 
 
[140] Anstee QMG, R. D. Mouse models in non-alcoholic fatty liver disease and 
steatohepatitis research. International journal of experimental pathology. 
2006;87:1-16. 
 




deficiency. Critical reviews in biochemistry and molecular biology. 1995;30:263-73. 
 
[142] Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and 
steatohepatitis research. International journal of experimental pathology. 
2006;87:1-16. 
 
[143] Larter CZ. Not all models of fatty liver are created equal: Understanding 
mechanisms of steatosis development is important. Journal of Gastroenterology 
and Hepatology. 2007;22:1353-4. 
 
[144] Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. 
Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and 
adipose tissue of transgenic mice overproducing sterol regulatory element-binding 
protein-2. Journal of Clinical Investigation. 1998;101:2331-9. 
 
[145] Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein 
JL. Decreased IRS-2 and Increased SREBP-1c Lead to Mixed Insulin Resistance 
and Sensitivity in Livers of Lipodystrophic and ob/ob Mice. Molecular Cell. 
2000;6:77-86. 
 
[146] Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, 
Goldstein JL, et al. Insulin resistance and diabetes mellitus in transgenic mice 
expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized 
lipodystrophy. Genes Dev. 1998;12:3182-94. 
 
[147] Nakayama H, Otabe S, Ueno T, Hirota N, Yuan X, Fukutani T, et al. 
Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in 
adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. 
Metabolism: clinical and experimental. 2007;56:470-5. 
 




mice and man. Digestive diseases (Basel, Switzerland). 2010;28:247-54. 
 
[149] Chalasani NC, D.W.; Cummings, O.W. . Does leptin play a role in the 
pathogenesis of human nonalcoholic steatohepatitis? Gastroenterol Hepatol. 
2003;98:2771–6. 
 
[150] Machado MVC-P, H. . Gut microbiota and nonalcoholic fatty liver disease. 
Ann Hepatol. 2012;11:440–9. 
 
[151] Zelber-Sagi S, Ratziu V, Zvibel I, Goldiner I, Blendis L, Morali G, et al. The 
association between adipocytokines and biomarkers for nonalcoholic fatty liver 
disease-induced liver injury: a study in the general population. Eur J Gastroenterol 
Hepatol. 2012;24:262-9. 
 
[152] Mayer J, Bates MW, Dickie MM. Hereditary diabetes in genetically obese 
mice. Science. 1951;113:746-7. 
 
[153] Bray GA, York DA. Hypothalamic and genetic obesity in experimental 
animals: an autonomic and endocrine hypothesis. Physiol Rev. 1979;59:719-809. 
 
[154] Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases 
sensitivity to endotoxin liver injury: implications for the pathogenesis of 
steatohepatitis. Proceedings of the National Academy of Sciences of the United 
States of America. 1997;94:2557-62. 
 
[155] Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and 
antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver 
disease. Hepatology. 2003;37:343-50. 
 
[156] Diehl AM. Lessons from animal models of NASH. Hepatology research : the 
official journal of the Japan Society of Hepatology. 2005;33:138-44. 
 





Leptin deficiency enhances sensitivity to endotoxin-induced lethality. The American 
journal of physiology. 1999;276:R136-42. 
 
[158] Brix AE, Elgavish A, Nagy TR, Gower BA, Rhead WJ, Wood PA. Evaluation 
of liver fatty acid oxidation in the leptin-deficient obese mouse. Molecular genetics 
and metabolism. 2002;75:219-26. 
 
[159] Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for 
the hepatic fibrogenic response to chronic liver injury. J Hepatol. 2002;37:206-13. 
 
[160] Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, et al. Evidence 
that the diabetes gene encodes the leptin receptor: identification of a mutation in 
the leptin receptor gene in db/db mice. Cell. 1996;84:491-5. 
 
[161] Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the 
mouse. Science. 1966;153:1127-8. 
 
[162] Wortham M, He L, Gyamfi M, Copple BL, Wan YJ. The transition from fatty 
liver to NASH associates with SAMe depletion in db/db mice fed a methionine 
choline-deficient diet. Dig Dis Sci. 2008;53:2761-74. 
 
[163] Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, et al. Obese 
and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic 
steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol 
Gastrointest Liver Physiol. 2004;287:G1035-43. 
 
[164] Shen L, Hillebrand A, Wang DQH, Liu M. Isolation and Primary Culture of Rat 
Hepatic Cells. Journal of Visualized Experiments : JoVE. 2012:3917. 
 
[165] Berry MN, Friend DS. HIGH-YIELD PREPARATION OF ISOLATED RAT 
LIVER PARENCHYMAL CELLS : A Biochemical and Fine Structural Study. The 




[166] Seglen P, O. Preparation of isolated rat liver cells. Methods Cell Biol. 
1976;13:29-83. 
 
[167] De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-Dall'Antonia F, 
Pazienza V, et al. Microarray analyses and molecular profiling of steatosis induction 
in immortalized human hepatocytes. Lab Invest. 2007;87:792-806. 
 
[168] Gómez-Lechón MJ, Donato MT, Martínez-Romero A, Jiménez N, Castell JV, 
 
O’Connor  J-E.  A  human  hepatocellular  in  vitro  model  to  investigate  steatosis. 
 
Chemico-Biological Interactions. 2007;165:106-16. 
 
[169] Tang Y, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, et al. Interleukin-17 
exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. 
Clinical & Experimental Immunology. 2011;166:281-90. 
 
[170] Lin Y, Smit MJ, Havinga R, Verkade HJ, Vonk RJ, Kuipers F. Differential 
effects of eicosapentaenoic acid on glycerolipid and apolipoprotein B metabolism in 
primary human hepatocytes compared to HepG2 cells and primary rat hepatocytes. 
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1995;1256:88-
96. 
 
[171] Guguen-Guillouzo C, Guillouzo A. General Review on In Vitro Hepatocyte 
Models and Their Applications. In: Maurel P, editor. Hepatocytes: Methods and 
Protocols. Totowa, NJ: Humana Press; 2010. p. 1-40. 
 
[172] Donato MT, Jiménez N, Serralta A, Mir J, Castell JV, Gómez-Lechón MJ. 
Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. 
Toxicology in Vitro. 2007;21:271-6. 
 
[173] Van Remmen H, Williams MD, Heydari AR, Takahashi R, Chung HY, Yu BP, 
et al. Expression of genes coding for antioxidant enzymes and heat shock proteins 
 
238 




[174] Rodriguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell 
JV, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell 
lines: molecular mechanisms that determine lower expression in cultured cells. 
Xenobiotica; the fate of foreign compounds in biological systems. 2002;32:505-20. 
 
[175] Donato T, Ramiro J, Gómez-Lechón MJ. Hepatic Cell Lines for Drug 
Hepatotoxicity Testing: Limitations and Strategies to Upgrade their Metabolic 
Competence by Gene Engineering. Current Drug Metabolism. 2013;14:946-68. 
 
[176] Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines 
secrete the major plasma proteins and hepatitis B surface antigen. Science. 
1980;209:497-9. 
 
[177] Dashti N, Wolfbauer G. Secretion of lipids, apolipoproteins, and lipoproteins 
by human hepatoma cell line, HepG2: effects of oleic acid and insulin. J Lipid Res. 
1987;28:423-36. 
 
[178] Cui W, Chen SL, Hu KQ. Quantification and mechanisms of oleic acid-
induced steatosis in HepG2 cells. American journal of translational research. 
2010;2:95-104. 
 
[179] Yecies JL ZH, Menon S, Liu S, Yecies D, Lipovsky AI. Akt stimulates hepatic 
SREBP1c and lipogenesis through parallel mTORC1-dependent and independent 
pathways. Cell Metab. 2011;14:21-32. 
 
[180] Hewitt NJ, Hewitt P. Phase I and II enzyme characterization of two sources of 





[181] Garcia MC, Amankwa-Sakyi M, Flynn TJ. Cellular glutathione in fatty liver in 
vitro models. Toxicology in Vitro. 2011;25:1501-6. 
 
[182] Anthérieu S, Rogue A, Fromenty B, Guillouzo A, Robin M-A. Induction of 
vesicular steatosis by amiodarone and tetracycline is associated with up-regulation 
of lipogenic genes in heparg cells. Hepatology. 2011;53:1895-905. 
 
[183] Nammi SR, B. D. Light-to-moderate ethanol feeding augments AMPK-alpha 
phosphorylation and attenuates SREBP-1 expression in the liver of rats. J Pharm 
Pharm Sci. 2013;16:342-51. 
 
[184] Metcalf PA, Scragg RKR, Jackson R. Light to Moderate Alcohol Consumption 
Is Protective for Type 2 Diabetes Mellitus in Normal Weight and Overweight 
Individuals but Not the Obese. Journal of Obesity. 2014;2014:634587. 
 
[185] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-
alcoholic fatty liver disease (NAFLD). Metabolism: clinical and experimental. 
2016;65:1038-48. 
 
[186] Younossi ZM, et al. . Global epidemiology of nonalcoholic fatty liver disease 
 
— meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 
2016;64:73-84. 
 
[187] Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global 
burden of NAFLD and NASH: trends, predictions, risk factors and prevention. 
Nature Reviews Gastroenterology &Amp; Hepatology. 2017;15:11. 
 
[188] Anstee QM, Targher, G. & Day, C. P. Progression of NAFLD to diabetes 
mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 
2013;10:330–44. 
 





NASH: Beyond Steatosis and Inflammation. International Journal of Molecular 
Sciences. 2014;15:8591-638. 
 
[190] Moschen HTaAR. Evolution of inflammation in nonalcoholic fatty liver 
disease: the multiple parallel hits hypothesis,. Hepatology. 2010;52:1836–46. 
 
[191] London RMG, J. Pathogenesis of NASH: animal models. Clin Liver Dis. 
2007;11:55-74, viii. 
 
[192] Feng L, Gao L, Guan Q, Hou X, Wan Q, Wang X, et al. Long-term moderate 
ethanol consumption restores insulin sensitivity in high-fat-fed rats by increasing 
SLC2A4 (GLUT4) in the adipose tissue by AMP-activated protein kinase activation. 
Journal of Endocrinology. 2008;199:95-104. 
 
[193] Lelbach. Cirrhosis in the alcoholic and its relation to the volume of alcohol 
abuse. Ann N Y Acad Sci. 1975;252:85–105. 
 
[194] Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, et 
al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective 
population study. Hepatology. 1996;23:1025-9. 
 
[195] Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. 
Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos 
Study Group. Gut. 1997;41:845-50. 
 
[196] Dunn W, Sanyal AJ, Brunt EM, Unalp-Arida A, Donohue M, McCullough AJ, 
et al. Modest alcohol consumption is associated with decreased prevalence of 
steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 
2012;57:384-91. 
 
[197] Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, et 
al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. 
 
241 
Aliment Pharmacol Ther. 2011;33:378-88. 
 
[198] White IR, Altmann DR, Nanchahal K. Alcohol consumption and mortality: 
modelling risks for men and women at different ages. Bmj. 2002;325:191. 
 
[199] Gao , Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic 
targets. Gastroenterology. 2011;141:1572-85. 
 
[200] Brenner DA. Moderate alcohol drinking: effects on the heart and liver. 
Gastroenterology. 2000;119:1399-401. 
 
[201] Yokoyama H. Beneficial Effects of Ethanol Consumption on Insulin 
Resistance Are Only Applicable to Subjects Without Obesity or Insulin Resistance; 
Drinking is not Necessarily a Remedy for Metabolic Syndrome. International 
Journal of Environmental Research and Public Health. 2011;8:3019-31. 
 
[202] Kim SH, Abbasi F, Lamendola C, Reaven GM. Effect of Moderate Alcoholic 
Beverage Consumption on Insulin Sensitivity in Insulin Resistant, Nondiabetic 
individuals. Metabolism: clinical and experimental. 2009;58:387-92. 
 
[203] Koppes LLJ, Dekker JM, Hendriks HFJ, Bouter LM, Heine RJ. Moderate 
Alcohol Consumption Lowers the Risk of Type 2 Diabetes. A meta-analysis of 
prospective observational studies. 2005;28:719-25. 
 
[204] Hines LMR, E B. Moderate alcohol consumption and coronary heart disease: 
a review. Postgraduate Medical Journal. 2001;77:747-52. 
 
[205] Gaziano JM, Gaziano TA, Glynn RJ, Sesso HD, Ajani UA, Stampfer MJ, et al. 
Light-to-moderate alcohol consumption and mortality in the Physicians' Health 
Study enrollment cohort. J Am Coll Cardiol. 2000;35:96-105. 
 
[206] Albert vdW. Diabetes mellitus and alcohol. Diabetes/Metabolism Research 




[207] Diem P, Deplazes M, Fajfr R, Bearth A, Müller B, Christ E, et al. Effects of 
alcohol consumption on mortality in patients with Type 2 diabetes mellitus2003. 
 
[208] Beulens JW, Rimm EB, Ascherio A, Spiegelman D, Hendriks HF, Mukamal 
KJ. Alcohol consumption and risk for coronary heart disease among men with 
hypertension. Ann Intern Med. 2007;146:10-9. 
 
[209] Malinski MK, Sesso HD, Lopez-Jimenez F, Buring JE, Gaziano JM. Alcohol 
consumption and cardiovascular disease mortality in hypertensive men. Arch Intern 
Med. 2004;164:623-8. 
 
[210] Zuccala G, Onder G, Pedone C, Cesari M, Landi F, Bernabei R, et al. Dose-
related impact of alcohol consumption on cognitive function in advanced age: 
results of a multicenter survey. Alcoholism, clinical and experimental research. 
2001;25:1743-8. 
 
[211] Standridge JB, Zylstra RG, Adams SM. Alcohol consumption: an overview of 
benefits and risks. South Med J. 2004;97:664-72. 
 
[212] La Vecchia C, Negri E, Franceschi S, D'Avanzo B. Moderate beer 
consumption and the risk of colorectal cancer. Nutr Cancer. 1993;19:303-6. 
 
[213] Fromenty B. Chronic Ethanol Consumption Lessens the Gain of Body Weight, 
Liver Triglycerides, and Diabetes in Obese ob/ob Mice. Journal of Pharmacology 
and Experimental Therapeutics. 2009;331:23-34. 
 
[214] Chen L, Wang F, Sun X, Zhou J, Gao L, Jiao Y, et al. Chronic ethanol feeding 
impairs AMPK and MEF2 expression and is associated with GLUT4 decrease in rat 
myocardium. Experimental &Amp; Molecular Medicine. 2010;42:205. 
 







[216] Shearn CT. Increased dietary fat contributes to dysregulation of the LKB1/ 
AMPK pathway and increased damage in a mouse model of early stage ethanol-
mediated steatosis. The Journal of nutritional biochemistry. 2013;24:1436-45. 
 
[217] Ruan X, Li Z, Zhang Y, Yang L, Pan Y, Wang Z, et al. Apolipoprotein A-I 
possesses an anti-obesity effect associated with increase of energy expenditure 
and up-regulation of UCP1 in brown fat. Journal of Cellular and Molecular 
Medicine. 2011;15:763-72. 
 
[218] Assunção M, Santos-Marques MJ, Monteiro R, Azevedo I, Andrade JP, 
Carvalho F, et al. Red Wine Protects against Ethanol-Induced Oxidative Stress in 
Rat Liver. Journal of Agricultural and Food Chemistry. 2009;57:6066-73. 
 
[219] Chiva-Blanch G, Urpi-Sarda M, Ros E, Valderas-Martinez P, Casas R, Arranz 
S, et al. Effects of red wine polyphenols and alcohol on glucose metabolism and 
the lipid profile: a randomized clinical trial. Clinical nutrition (Edinburgh, Scotland). 
2013;32:200-6. 
 
[220] Gronbaek M, Jensen MK, Johansen D, Sorensen TI, Becker U. Intake of 
beer, wine and spirits and risk of heavy drinking and alcoholic cirrhosis. Biol Res. 
2004;37:195–200. 
 
[221] Konrat C, Mennen LI, Cacès E, Lepinay P, Rakotozafy F, Forhan A, et al. 
Alcohol intake and fasting insulin in French men and women. The D.E.S.I.R. Study. 
Diabetes & metabolism. 2002;28:116-23. 
 
[222] Fossati P, Lorenzo, P. Serum triglycerides determined colorimetrically with an 
enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077-80. 
 
[223] Roeschlau P, et al,. Enzymatic determination of total cholesterol in serum. Z 




[224] Warnick G. Russell WPD. National Cholesterol Education Program 
Recommendations for Measurement of High-Density Lipoprotein Cholesterol;. 
Executive Summary Clinical Chemistry,. 1995;41. 
 
[225] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of 
low-density lipoprotein cholesterol in plasma, without use of the preparative 
ultracentrifuge. Clin Chem. 1972;18:499-502. 
 
[226] Stone NJ, et al.,. ACC/AHA guideline on the treatment of blood cholesterol to 
reduce atherosclerotic cardiovascular risk in adults: a report of the American 
College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. Circulation. 2014;129:S1-45. 
 
[227] Trinder P. Determination of blood glucose using an oxidase-peroxidase 
system with a non-carcinogenic chromogen. J Clin Pathol 1969;22:158-61. 
 
[228] Pradelles GJ. Compounds labelled by the acetylcholinesterase of 
Electrophorus Electricus. Its preparation process and 
 
its use as a tracer or marquer in enzymo-immunological determinations. United 
States patent1991. 
 
[229] Maehata E YM, Shiba T, Yamakado M, Inoue M, Suzuki S. . Insulin 
resistance index (HOMA-R) method. . Nippon Rinsho. 2002;60::341–50. 
 
[230] Jung K, Bohm, M. Relative Stimulation of Aspartate Aminotransferase Activity 
in Human Serum by Pyridoxal 5'-Phosphate in Myocardial Infarction. Enzyme. 
1978;23 201–5. 
 
[231] Hafkenscheid. Determination of serum aminotransferases: activation by 






[232] Henry RJ, et al, . Revised spectrophotometric methods for the determination 
of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid 
dehydrogenase. Am J Clin Pathol. 1960;34. 
 
[233] Hara A, Radin ,NS, . Lipid extraction of tissues with a low-toxicity solvent. 
Anal Biochem. 1978;90:420. 
 
[234] Alturkistani HA, Tashkandi FM, Mohammedsaleh ZM. Histological Stains: A 
Literature Review and Case Study. Glob J Health Sci. 2015;8:72-9. 
 
[235] Crookham J, Dapson,R, . Hazardous Chemicals in the Histopathology 
Laboratory: Anatech; 1991. 
 
[236] Sheehan DCaH, B.B. Theory and practice of histotechnology. 1980. 
 
[237] Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and 
risk factors of non-alcoholic fatty liver disease among Korean adults. J 
Gastroenterol Hepatol. 2006;21:138-43. 
 
[238] Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 
diabetes mellitus. The American journal of medicine. 2000;108 Suppl 6a:9s-14s. 
 
[239] Edelman SV. Type II diabetes mellitus. Advances in internal medicine. 
1998;43:449-500. 
 
[240] Fernandez. The metabolic syndrome. Nutr Rev. 2007;65:30-4. 
 
[241] Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, 
Scholmerich J, et al. Defining high-fat-diet rat models: metabolic and molecular 
effects of different fat types. Journal of molecular endocrinology. 2006;36:485-501. 
 
[242] Buettner R. High-fat diets: modeling the metabolic disorders of human obesity 




[243] Hebbard LG, J. Animal models of nonalcoholic fatty liver disease. Nature 
reviews Gastroenterology & hepatology. 2011;8:35-44. 
 
[244] Lau JK, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: 
current perspectives and recent advances. J Pathol. 2017;241:36-44. 
 
[245] Hidestrand M, Shankar K, Ronis MJ, Badger TM. Effects of light and dark 
beer on hepatic cytochrome P-450 expression in male rats receiving alcoholic 
beverages as part of total enteral nutrition. Alcoholism, clinical and experimental 
research. 2005;29:888-95. 
 
[246] Ramalho L, da Jornada MN, Antunes LC, Hidalgo MP. Metabolic 
disturbances due to a high-fat diet in a non-insulin-resistant animal model. Nutrition 
&Amp; Diabetes. 2017;7:e245. 
 
[247] Bai T, Yang, Y., Wu, Y.L., Jiang, S., Lee, J.J., Lian, L.H., Nan, J.X. 
Thymoquinone alleviates thioacetamide-induced hepatic fibrosis and inflammation 
by activating LKB1–AMPK signaling pathway in mice. Int Immunopharmacol. 
2014;19:351–7. 
 
[248] Wilkes JJ, Bonen A, Bell RC. A modified high-fat diet induces insulin 
resistance in rat skeletal muscle but not adipocytes. The American journal of 
physiology. 1998;275:E679-86. 
 
[249] Panchal SKB, Lindsay. Rodent Models for Metabolic Syndrome Research. 
Journal of Biomedicine and Biotechnology. 2011;2011. 
 
[250] Axelsen LN, Lademann JB, Petersen JS, Holstein-Rathlou NH, Ploug T, Prats 
C, et al. Cardiac and metabolic changes in long-term high fructose-fat fed rats with 
severe obesity and extensive intramyocardial lipid accumulation. American journal 
 






[251] Niemeijer-Kanters SDB, J. D. Erkelens, D. W. Lipid-lowering therapy in 
diabetes mellitus. Neth J Med. 2001;58:214-22. 
 
[252] Adiels M, Olofsson S-O, Taskinen M-R, Borén J. Overproduction of Very 
Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic 
Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1225-36. 
 
[253] Choi SSD, A. M. Hepatic triglyceride synthesis and nonalcoholic fatty liver 
disease. Current opinion in lipidology. 2008;19:295-300. 
 
[254] Osaki A, Okazaki Y, Kimoto A, Izu H, Kato N. Beneficial effect of a low dose 
of ethanol on liver function and serum urate in rats fed a high-fat diet. Journal of 
nutritional science and vitaminology. 2014;60:408-12. 
 
[255] Kanuri G, Landmann M, Priebs J, Spruss A, Löscher M, Ziegenhardt D, et al. 
Moderate alcohol consumption diminishes the development of non-alcoholic fatty 
liver disease (NAFLD) in ob/ob mice. European Journal of Nutrition. 2016;55:1153-
64. 
 
[256] Webb JC, Patel DD, Jones MD, Knight BL, Soutar AK. Characterization and 
tissue-specific expression of the human ‘very low density lipoprotein (VLDL) 
receptor’ mRNA. Human Molecular Genetics. 1994;3:531-7. 
 
[257] Kazuhiro O, Kazumi IO, Mei‐jin C, Merry S, Julia K, Wen‐Hsiung L, et al. Mouse Very‐Low‐Density‐Lipoprotein Receptor (VLDLR) cDNA Cloning, Tissue‐ 
 
 
specific Expression and Evolutionary Relationship with the Low‐density‐lipoprotein Receptor. European Journal of 
Biochemistry. 1994;224:975-82. 
 
[258] Cano A, Ciaffoni F, Safwat GM, Aspichueta P, Ochoa B, Bravo E, et al. 
Hepatic VLDL assembly is disturbed in a rat model of nonalcoholic fatty liver 
 
248 




[259] Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, 
Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased 
liver fat content in man. Diabetologia. 2006;49:755-65. 
 
[260] Mensenkamp AR, Havekes LM, Romijn JA, Kuipers F. Hepatic steatosis and 
very low density lipoprotein secretion: the involvement of apolipoprotein E. J 
Hepatol. 2001;35:816-22. 
 
[261] Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty 
liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes 
Care. 2006;29:1845-50. 
 
[262] Irondi E, Oboh G, Akindahunsi A. Antidiabetic effects of Mangifera indica 
Kernel Flour-supplemented diet in streptozotocin-induced type 2 diabetes in 
rats2016. 
 
[263] Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of 
cholesterol in non-alcoholic fatty liver disease. Biochimica et biophysica acta. 
2015;1852:1765-78. 
 
[264] Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol 
metabolism by proteolysis of a membrane-bound transcription factor. Cell. 
1997;89:331-40. 
 
[265] Flamment M, Hajduch E, Ferre P, Foufelle F. New insights into ER stress-
induced insulin resistance. Trends in endocrinology and metabolism: TEM. 
2012;23:381-90. 
 





extract of Zingiber officinale rhizome on the development of metabolic syndrome in 
high-fat diet-fed rats. Basic & clinical pharmacology & toxicology. 2009;104:366-73. 
 
[267] Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol 
homeostasis. Science. 1986;232:34-47. 
 
[268] FAN F. Impact of chronic low to moderate alcohol consumption on blood lipid 
and heart energy profile in acetaldehyde dehydrogenase 2-deficient mice. Acta 
Pharmacologica Sinica. 2014;35:1015–22. 
 
[269] Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in Patients with 
Nonalcoholic Fatty Liver Disease. Seminars in liver disease. 2012;32:22-9. 
 
[270] Bhandari U, Kumar V, Khanna N, Prasad Panda B. The effect of high-fat diet-
induced obesity on cardiovascular toxicity in Wistar albino rats2010. 
 
[271] Agarwal S, Fulgoni VL, Lieberman HR. Assessing alcohol intake & its dose-
dependent effects on liver enzymes by 24-h recall and questionnaire using 
NHANES 2001-2010 data. Nutrition Journal. 2016;15:62. 
 




[273] Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin 
resistance in hepatocytes and sinusoidal liver cells: mechanisms and 
consequences. J Hepatol. 2007;47:142-56. 
 
[274] Petta S, Muratore C, Craxi A. Non-alcoholic fatty liver disease pathogenesis: 
the present and the future. Dig Liver Dis. 2009;41:615-25. 
 
[275] Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and 
non-alcoholic fatty liver disease. Nutrition, metabolism, and cardiovascular diseases 




[276] Zabielski P, Hady HR, Chacinska M, Roszczyc K, Gorski J, Blachnio-
Zabielska AU. The effect of high fat diet and metformin treatment on liver lipids 
accumulation and their impact on insulin action. Scientific Reports. 2018;8:7249. 
 
[277] Huang XD FY, Zhang H, Wang P, Yuan JP, Li MJ, et al. Serum leptin and 
soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol. 
2008;;14:2888–93. 
 
[278] Nilsson NO, Belfrage P. Effects of acetate, acetaldehyde, and ethanol on 
lipolysis in isolated rat adipocytes. J Lipid Res. 1978;19:737-411. 
 
[279] Patsch, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, et 
al. Relation of triglyceride metabolism and coronary artery disease. Studies in the 
postprandial state. Arteriosclerosis and thrombosis : a journal of vascular biology. 
1992;12:1336-45. 
 
[280] Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: 
unravelling the mechanism. Lancet. 2010;375:2267-77. 
 
[281] Azzout-Marniche D, Bécard D, Guichard C, Foretz M, Ferré P, Foufelle F. 
Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) 
transcriptional activity in rat hepatocytes. Biochemical Journal. 2000;350:389-93. 
 
[282] Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and 
mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr 
Rev. 2002;23:201-29. 
 
[283] Radikova Z, Koska J, Huckova M, Ksinantova L, Imrich R, Vigas M, et al. 
Insulin sensitivity indices: a proposal of cut-off points for simple identification of 
insulin-resistant subjects. Experimental and clinical endocrinology & diabetes : 





[284] Facchini F, Chen YD, Reaven GM. Light-to-moderate alcohol intake is 
associated with enhanced insulin sensitivity. Diabetes Care. 1994;17:115-9. 
 
[285] Lazarus R, Sparrow D, Weiss ST. Alcohol intake and insulin levels. The 
Normative Aging Study. Am J Epidemiol. 1997;145:909-16. 
 
[286] Kiechl S, Willeit J, Poewe W, Egger G, Oberhollenzer F, Muggeo M, et al. 
Insulin sensitivity and regular alcohol consumption: large, prospective, cross 
sectional population study (Bruneck study). Bmj. 1996;313:1040-4. 
 
[287] Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin 
and adiponectin receptors in insulin resistance, diabetes, and the metabolic 
syndrome. J Clin Invest. 2006;116:1784-92. 
 
[288] Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in 
NASH: causes, consequences and possible means to prevent it. Mitochondrion. 
2006;6:1-28. 
 
[289] Angela BF, Giorgia Anna Garinis, Stefania Giuliano, Roberta Malaguarnera, 
and Antonino Belfiore. The Role of Metformin in the Management of NAFLD. 
Experimental Diabetes Research. 2012:13. 
 
[290] Bais S, Singh GS, Sharma R. Antiobesity and Hypolipidemic Activity of 
Moringa oleifera Leaves against High Fat Diet-Induced Obesity in Rats. Advances 
in Biology. 2014;2014:9. 
 
[291] Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features 
and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 
2001;21:17-26. 
 





Association Between Elevated Liver Enzymes and C-Reactive Protein. Possible 
Hepatic Contribution to Systemic Inflammation in the Metabolic Syndrome. 
2005;25:193-7. 
 
[293] Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic 
steatohepatitis and alcoholic hepatitis. Am J Gastroenterol. 1987;82:650-4. 
 
[294] Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to 
alanine aminotransferase: potential value in differentiating nonalcoholic 
steatohepatitis from alcoholic liver disease. American Journal Of Gastroenterology. 
1999;94:1018. 
 
[295] RB Gurung BP, P Gyawali, P Risal. The Ratio of Aspartate Aminotransferase 
to Alanine Aminotransferase (AST/ALT): the Correlation of Value with Underlying 
Severity of Alcoholic Liver Disease. Kathmandu Univ Med J. 2013;43:233-6. 
 
[296] Duly AMP, Alani B, Huang EYW, Yee C, Haber PS, McLennan SV, et al. 
Effect of multiple binge alcohol on diet-induced liver injury in a mouse model of 
obesity. Nutrition &Amp; Diabetes. 2015;5:e154. 
 
[297] Brown JD, Naples SP, Booth FW. Effects of voluntary running on oxygen 
consumption, RQ, and energy expenditure during primary prevention of diet-
induced obesity in C57BL/6N mice. Journal of Applied Physiology. 2012;113:473-8. 
 
[298] Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarim-
de-Lacerda CA. A Mouse Model of Metabolic Syndrome: Insulin Resistance, Fatty 
Liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 Mice Fed a 
High Fat Diet. Journal of clinical biochemistry and nutrition. 2010;46:212-23. 
 
[299] Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA. Infliximab reverses 
steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. 
 
253 
The Journal of endocrinology. 2007;194:539-50. 
 
[300] Everitt H, Hu M, Ajmo JM, Rogers CQ, Liang X, Zhang R, et al. Ethanol 
administration exacerbates the abnormalities in hepatic lipid oxidation in genetically 
obese mice. American Journal of Physiology - Gastrointestinal and Liver 
Physiology. 2013;304:G38-G47. 
 
[301] Rozman D. From nonalcoholic Fatty liver disease to hepatocellular 
carcinoma: a systems understanding. Dig Dis Sci. 2014;59:238-41. 
 
[302] Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, 
Marzioni M, et al. A model of insulin resistance and nonalcoholic steatohepatitis in 
rats: role of peroxisome proliferator-activated receptor-alpha and n-3 
polyunsaturated fatty acid treatment on liver injury. Am J Pathol. 2006;169:846-60. 
 
[303] Abu-Shanab AQ, E. M. The role of the gut microbiota in nonalcoholic fatty 
liver disease. Nature reviews Gastroenterology & hepatology. 2010;7:691-701. 
 
[304] Angulo. Long-term mortality in nonalcoholic fatty liver disease: Is liver 
histology of any prognostic significance? Hepatology. 2010;51:373-5. 
 
[305] Demir SL, and H. Steffen, . Nonalcoholic fatty liver disease: current status 
and future directions. Journal of Digestive Diseases. 2015;16:541-57. 
 
[306] Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty 
liver disease. Therapeutic Advances in Gastroenterology. 2012;5:199-207. 
 
[307] Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo 
lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver 
disease. Gastroenterology. 2014;146:726-35. 
 
[308] Zelber-Sagi DN-K, R. Goldsmith et al. . Long term nutritional intake and the 
risk for non-alcoholic fatty liver disease (NAFLD): a population based study. Journal 
 
254 
of Hepatology. 2007;47:711–7. 
 
[309] Anstee QM, Day CP. The genetics of NAFLD. Nature reviews 
Gastroenterology & hepatology. 2013;10:645-55. 
 
[310] Brennan KM. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am 
J Physiol Endocrinol Metab. 2016;311:E730–E40. 
 
[311] Carling D, Mayer FV, Sanders MJ, Gamblin SJ. AMP-activated protein 
kinase: nature's energy sensor. Nature chemical biology. 2011;7:512-8. 
 
[312] Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all 
aspects of cell function. Genes Dev. 2011;25:1895-908. 
 
[313] Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, Billaud M, et al. AMPK 
inhibition in health and disease. Critical reviews in biochemistry and molecular 
biology. 2010;45:276-95. 
 
[314] Colak Y. SIRT1 as a potential therapeutic target for treatment of nonalcoholic 
fatty liver disease. Med Sci Monit. 2011;17:HY5-9. 
 
[315] Nova E. Potential health benefits of moderate alcohol consumption: current 
perspectives in research. Proceedings of the Nutrition Society. 2012;71:307–15. 
 
[316] Wakabayashi I. Influence of age on the relationship between alcohol 
consumption and metabolic syndrome. Gerontology. 2012;58:24-31. 
 
[317] Petta S, Gastaldelli A, Rebelos E, Bugianesi E, Messa P, Miele L, et al. 
Pathophysiology of Non Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. 
 
[318] Giugliano D, Ceriello A, Esposito K. Are there specific treatments for the 
metabolic syndrome? Am J Clin Nutr. 2008;87:8-11. 
 
[319] Mohamed HA, MD, PhD. The Road Map for the Diagnosis of Nonalcoholic 




[320] Sanal MG. Biomarkers in nonalcoholic fatty liver disease-the emperor has no 
clothes? World J Gastroenterol. 2015;21:3223-31. 
 
[321] Jiang SL, Hu XD, Liu P. Immunomodulation and liver protection of 
Yinchenhao decoction against concanavalin A-induced chronic liver injury in mice. 
Journal of integrative medicine. 2015;13:262-8. 
 
[322] Carling D. The AMP-activated protein kinase cascade--a unifying system for 
energy control. Trends in biochemical sciences. 2004;29:18-24. 
 
[323] Winder WW. Energy-sensing and signaling by AMP-activated protein kinase 
in skeletal muscle. Journal of applied physiology (Bethesda, Md : 1985). 
2001;91:1017-28. 
 
[324] Hardie G. Regulation of fatty acid and cholesterol metabolism by the AMP-
activated protein kinase. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid 
Metabolism. 1992;1123:231-8. 
 
[325] Kim KH. Regulation of mammalian acetyl-coenzyme A carboxylase. Annu 
Rev Nutr. 1997;17:77-99. 
 
[326] McGarry JDB, N. F. The mitochondrial carnitine palmitoyltransferase system. 
From concept to molecular analysis. Eur J Biochem. 1997;244:1-14. 
 
[327] Ruderman NB, Saha AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, 
and insulin resistance. The American journal of physiology. 1999;276:E1-e18. 
 
[328] Asish K, Saha , Neil B, Ruderman. Malonyl-CoA and AMP-activated protein 
kinase: An expanding partnership. Molecular and Cellular Biochemistry. 
2003;253:65–70. 
 
[329] Kwon E-B, Kang M-J, Kim S-Y, Lee Y-M, Lee M-K, Yuk HJ, et al. 




through an Activation of LKB1/AMPK Pathway in HepG2 Cells. Evidence-Based 
Complementary and Alternative Medicine. 2018;2018:11. 
 
[330] Kraegen EW, Saha AK, Preston E, Wilks D, Hoy AJ, Cooney GJ, et al. 
Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity 
accompany insulin resistance induced by glucose infusion in muscle and liver of 
rats. Am J Physiol Endocrinol Metab. 2006;290:E471-9. 
 
[331] García-Ruiz C, Colell A, Marí M, Morales A, Calvo M, Enrich C, et al. 
Defective TNF-α–mediated hepatocellular apoptosis and liver damage in acidic 
sphingomyelinase knockout mice. Journal of Clinical Investigation. 2003;111:197-
208. 
 
[332] Liangpunsakul S, Wou SE, Zeng Y, Ross RA, Jayaram HN, Crabb DW. Effect 
of ethanol on hydrogen peroxide-induced AMPK phosphorylation. Am J Physiol 
Gastrointest Liver Physiol. 2008;295:G1173-81. 
 
[333] Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating 
the mechanism for AMP activation of the AMP-activated protein kinase cascade. 
The Biochemical journal. 2007;403:139-48. 
 
[334] Lieber CS. Alcohol and the liver: 1994 update. Gastroenterology. 
1994;106:1085-105. 
 
[335] McCarty MF. Toward practical prevention of type 2 diabetes. Medical 
hypotheses. 2000;54:786-93. 
 
[336] Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA. 
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein 
kinase kinases. J Biol Chem. 2005;280:29060-6. 
 




al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. 
 
Current biology : CB. 2003;13:2004-8. 
 
[338] Jenne ea. Peutz-Jeghers syndrome is caused by mutations in a novel serine 
threonine kinase. Nat Genet,. 1998;18:38-43. 
 
[339] Tiainen M, Vaahtomeri K, Ylikorkala A, Makela TP. Growth arrest by the LKB1 
tumor suppressor: induction of p21(WAF1/CIP1). Hum Mol Genet. 2002;11:1497-
504. 
 
[340] Tiainen M, Ylikorkala A, Mäkelä TP. Growth suppression by Lkb1 is mediated 
by a G<sub>1</sub> cell cycle arrest. Proceedings of the National Academy of 
Sciences. 1999;96:9248-51. 
 
[341] Auwerx CCaJ. AMP-activated protein kinase and its downstream 
transcriptional pathways. Cell Mol Life Sci. 2010;67:3407–23. 
 
[342] Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, et al. 
MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, 
activate and localize LKB1 in the cytoplasm. The EMBO journal. 2003;22:5102-14. 
 
[343] Santamarina AB, Oliveira JL, Silva FP, Carnier J, Mennitti LV, Santana AA, et 
al. Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by 
AMPK Activation via LKB1 in Mice Fed a High-Fat Diet. PLoS ONE. 
2015;10:e0141227. 
 
[344] Xie Z, Dong Y, Scholz R, Neumann D, Zou M-H. Phosphorylation of LKB1 at 
Serine 428 by Protein Kinase C-ζ Is Required for Metformin-Enhanced Activation of 
the AMP-Activated Protein Kinase in Endothelial Cells. Circulation. 2008;117:952-
62. 
 




Analysis of the LKB1-STRAD-MO25 complex. J Cell Science. 2004;117:6365-75. 
 
[346] Suchankova G, Nelson LE, Gerhart-Hines Z, Kelly M, Gauthier M-S, Saha 
AK, et al. Concurrent regulation of AMP-activated protein kinase and SIRT1 in 
mammalian cells. Biochemical and biophysical research communications. 
2009;378:836-41. 
 
[347] Finkel DC, Mostoslavsky Recent progress in the biology and physiology of 
sirtuins. R Nature. 2009;460:587-91. 
 
[348] Kwon OM. The ups and downs of SIRT1. Trends in biochemical sciences. 
2008;33:517–25. 
 
[349] Lee SL, Chau GY, Yao CT, Wu CW, Yin SJ. Functional assessment of human 
alcohol dehydrogenase family in ethanol metabolism: significance of first-pass 
metabolism. Alcoholism, clinical and experimental research. 2006;30:1132-42. 
 
[350] Rodgers JT, Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., Puigserver, 
P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and 
SIRT1. Nature. 2005;434:113–8. 
 
[351] Heilbronn L, Civitarese AE, Bogacka I, et al. Glucose tolerance and skeletal 
muscle gene expression in response to alternate day fasting. Obes Res. 
2005;13:574–81. 
 
[352] Lopez-Lluch G, Hunt N, Jones B, et al. . Calorie restriction induces 
mitochondrial biogenesis and bioenergetic efficiency. Proceedings of the National 
Academy of Sciences of the United States of America. 2006;103:1768-73. 
 
[353] Rodgers J, Lerin C, Haas W, et al. . Nutrient control of glucose homeostasis 
through a complex of PGC-1alpha and SIRT1. Nature. 2005;434:113–8. 
 




A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. 
 
Journal of Gastrointestinal and Liver Diseases. 2014;23:311-9. 
 
[355] Pfluger PT. Sirt1 protects against high-fat diet-induced metabolic damage. 
PNAS. 2008;105:9793-8. 
 
[356] Fellmann, Nascimento AR, Tibirica E, Bousquet P. Murine models for 
pharmacological studies of the metabolic syndrome. Pharmacology & therapeutics. 
2013;137:331-40. 
 
[357] Kim KE. Myeloid-specific SIRT1 Deletion Aggravates Hepatic Inflammation 




[358] Deng X, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver 
disease induced by high-fat diet in rats. Liver Int. 2007;27:708-15. 
 
[359] Ahn J, Lee H, Jung CH, Ha TY, Jang YJ. Effect of a new dietary SIRT1 
activator on high fat diet-induced obesity and the involvement of microRNAs. The 
FASEB Journal. 2015;29:405.8. 
 
[360] Horton J, Goldstein JL, Brown MS. SREBPs: activators of the complete 
program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 
2002;109:1125-31. 
 
[361] Horton J, Shah NA, Warrington JA, Anderson NN, Park SW, et al. . 
Combined analysis of oligonucleotide microarray data from transgenic and 
knockout mice identifies direct SREBP target genes. Proceedings of the National 
Academy of Sciences of the United States of America. 2003;100:12027-32. 
 
[362] Lin H, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. . Metformin 





[363] Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in 
mechanism of metformin action. J Clin Invest. 2001;108:1167-74. 
 
[364] Munday MR. Regulation of mammalian acetyl-CoA carboxylase. Biochemical 
society transactions. 2002;30:1059-64. 
 
[365] Hardie DG. AMPK: a key regulator of energy balance in the singlecell and the 
whole organism. International journal of obesity. 2008;32:7-12. 
 
[366] Browning H. Molecular mediators of hepatic steatosis and liver injury. J Clin 
Invest. 2004;114:147-52. 
 
[367] Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to 
cirrhosis. Hepatology. 2006;43:S99-s112. 
 
[368] M.E. Dumas JK, and J. K. Nicholson, . Metabolic phenotyping and systems 
biology approaches to understanding metabolic syndrome and fatty liver disease. 
Gastroenterology. 2014;146:46–62. 
 
[369] Schattenberg DSaJM. Non-alcoholic steatohepatitis: pathogenesis and novel 




[370] A. Berson VDB, P. Letteron et al. Steatohepatitis-inducing drugs cause 
mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. 
Gastroenterology,. 1998;114:764–74. 
 
[371] Wobser DC, Weiss TS, Amann T, Bollheimer C, Buttner R, Scholmerich J, 
Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of 
hepatic stellate cells. Cell Res. 2009;19:996-1005. 
 





SW. J. Magnolia officinalis attenuates free fatty acid-induced lipogenesis via AMPK 
phosphorylation in hepatocytes. Ethnopharmacol. 2014;157:140-8. 
 
[373] Leamy AK ER, Young JD. Molecular mechanisms and the role of saturated 
fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res. 
2013;52:165–74. 
 
[374] Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic Fatty Liver Disease: 
Pathogenesis and Disease Spectrum. Annual Review of Pathology: Mechanisms of 
Disease. 2016;11:451-96. 
 
[375] Feldstein AC, M.E. Guicciardi, H. Higuchi, S.F. Bronk, G.J. Gores. Diet 
associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J 
Hepatol. 2003;39:978-83. 
 
[376] Donato AL, N. Jiménez, G. Pérez, A. Serralta, J. Mir, J.V. Castell, M.J. 
Gómez-Lechón. Potential impact of steatosis on cytochrome P450 enzymes of 
human hepatocytes isolated from fatty liver grafts. Drug Metab Disp. 2006;34:1556-
62. 
 
[377] Steenbergen RH, Joyce MA, Thomas BS, Jones D, Law J, Russell R, et al. 
Human serum leads to differentiation of human hepatoma cells, restoration of very-
low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese 
fulminant hepatitis type 1 titers. Hepatology. 2013;58:1907-17. 
 
[378] Green CJ, Johnson D, Amin HD, Sivathondan P, Silva MA, Wang LM, et al. 
Characterization of lipid metabolism in a novel immortalized human hepatocyte cell 
line. Am J Physiol Endocrinol Metab. 2015;309:E511-22. 
 
[379] Zhang MY LP, Hung PJ, Johnson T, Lee LP, Mofrad MR Microfluidic 





[380] NB J. Hep G2 cells as a resource for metabolic studies: lipoprotein, 
cholesterol, and bile acids. FASEB J. 1990;4:161–8. 
 
[381] Garcia-Canaveras JC, Jimenez N, Gomez-Lechon MJ, Castell JV, Donato 
MT, Lahoz A. LC-MS untargeted metabolomic analysis of drug-induced 
hepatotoxicity in HepG2 cells. Electrophoresis. 2015;36:2294-302. 
 
[382] Sassa S SO, Galbraith RA, Kappas A Drug metabolism by the human 
hepatoma cell, HepG2. Biochem Biophys Res Commun. 1987;143:52-7. 
 
[383] Grishko V RL, Musiyenko S, Ledoux SP and Wilson GL. . Involvement of 
mtDNA damage in free fatty acid-induced apoptosis. Free Radic Biol Med. 
2005;38:755-62. 
 
[384] Chiu HC KA, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE and Schaffer 
JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest. 2001:813-22. 
 
[385] Joshi-Barve S BS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P, 
McClain CJ. Palmitic acid induces production of proinflammatory cytokine 
interleukin-8 from hepatocytes. Hepatology. 2007;46:823-30. 
 
[386] Berthiaume F, Barbe L, Mokuno Y, MacDonald AD, Jindal R, Yarmush ML. 
Steatosis reversibly increases hepatocyte sensitivity to hypoxia-reoxygenation 
injury. The Journal of surgical research. 2009;152:54-60. 
 
[387] Mei S, Ni HM, Manley S, Bockus A, Kassel KM, Luyendyk JP, et al. 
Differential roles of unsaturated and saturated fatty acids on autophagy and 
apoptosis in hepatocytes. J Pharmacol Exp Ther. 2011;339:487-98. 
 
[388] Berk PDaDDS. Mechanisms of Cellular Uptake of Long Chain Free Fatty 




[389] Held P. Lipid Accumulation in HepG2 Cells Exposed to Free Fatty Acids. 
Image-Based Assay to Model Non-Alcoholic Steatohepatitis (NASH)2014. 
 
[390] Song Z, Deaciuc I, Song M, Lee DY, Liu Y, Ji X, et al. Silymarin protects 
against acute ethanol-induced hepatotoxicity in mice. Alcoholism, clinical and 
experimental research. 2006;30:407-13. 
 
[391] Majano PL, Medina, J., Zubia, I., Sunyer, L., Pezzi, E.L., Rodriguez, A.M., 
Cabrera, M.L., Otero, R.M., . N-acetyl-cysteine modulates inducible nitric oxide 
synthase gene expression in human hepatoma cells. J Hepatol. 2004;40:632–7. 
 
[392] Neuman MG, Cameron RG, Shear NH, Bellentani S, Tiribelli C. Effect of 
tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in 
the human Hep G2 cell line. Gastroenterology. 1995;109:555-63. 
 
[393] Woods JRW, P.J. Muckett, F.V. Mayer, M. Liljevald, Y. Bohlooly, et al. Liver-
specific activation of AMPK prevents steatosis on a high-fructose diet. Cell Rep. 
2017;18:3043-51. 
 
[394] B.S. Henriksen MEC, N. Fillmore, B.R. Cardon, D.M. Thomson, C.R. 
Hancock. The effects of chronic AMPK activation on hepatic triglyceride 
accumulation and glycerol 3-phosphate acyltransferase activity with high fat 
feeding. Diabetol Metab Syndr. 2013;5:29. 
 
[395] Ricchi OM, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, 
Bertolotti M, Banni S, et al. . Differential effect of oleic and palmitic acid on lipid 
accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol. 
2009;24:830–40. 
 
[396] Bligh EG, and W. J. Dyer. A rapid method of total lipid extraction and 




[397] Lin CLH, H. C. Lin, J. K. Theaflavins attenuate hepatic lipid accumulation 
through activating AMPK in human HepG2 cells. J Lipid Res. 2007;48:2334-43. 
 
[398] Y. Ogawa KI, M. Yoneda, A. Nakajima Pathophysiology of NAsh/NAFLD 
associated with high levels of serum triglycerides. Nihon Rinsho. 2013;71:1623-9. 
 
[399] C. Sun JGF, L. Qiao. Potential epigenetic mechanism in non-alcoholic fatty 
liver disease. Int J Mol Sci. 2015;16:5161-79. 
 
[400] S. Rouabhia NM, L. Abenavoli. Metformin in the treatment of non-alcoholic 
fatty liver disease: safety, efficacy and mechanism. Expert Rev Gastroenterol 
Hepatol. 2014;8:343-9. 
 
[401] Gómez-Lechón MJ DM, Martínez-Romero A, Jiménez N, Castell JV and 
O'Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chem 
Biol Interact. 2007;165:106-16. 
 
[402] Matteo Ricchi ea. Differential effect of oleic and palmitic acid on lipid 
accumulation and apoptosis in cultured hepatocytes. Journal of Gastroenterology 
and Hepatology. 2009;24:830–40. 
 
[403] YUN WAN L-YL, ZHEN-FENG HONG and JUN PENG Ethanol extract of 
Cirsium japonicum attenuates hepatic lipid accumulation via AMPK activation in 
human HepG2 cells. EXPERIMENTAL AND THERAPEUTIC MEDICINE. 
2014;8:79-84. 
 
[404] Hong Rui Yao JL. Lipotoxicity in HepG2 cells triggered by free fatty acids. 
American journal of translational research. 2011;3:284-91. 
 
[405] Jimenez-Lopez JM, Carrasco MP, Segovia JL, Marco C. Resistance of 
HepG2 cells against the adverse effects of ethanol related to neutral lipid and 




[406] Srivastava RA, S.L. Pinkosky, S. Filippov, J.C. Hanselman, C.T. Cramer, R.S. 
Newton. AMP-activated protein kinase: an emerging drug target to regulate 
imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic 
diseases. J Lipid Res. 2012;53:2490-514. 
 
[407] Lee M-R. Leonurus japonicus Houtt Attenuates Nonalcoholic Fatty Liver 
Disease in Free Fatty Acid-Induced HepG2 Cells and Mice Fed a High-Fat Diet. 
Nutrients 2018, 10(1), 20. 2018;10:20. 
 
[408] Donohue TM, Osna NA, Clemens DL. Recombinant Hep G2 cells that 
express alcohol dehydrogenase and cytochrome P450 2E1 as a model of ethanol-
elicited cytotoxicity. The international journal of biochemistry & cell biology. 
2006;38:92-101. 
 
[409] Ding WX LM, Chen X, Ni HM, Lin CW, Gao W, Lu B, Stolz DB, Clemens DL, 
Yin XM. Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in 
mice. Gastroenterology. 2010;139:1740-52. 
 
[410] Kovar KBJ. Alcohol dehydrogenase and cytochrome P450 2E1 can be 
induced by long-term exposure to ethanol in cultured liver HEP-G2 cells. In Vitro 
CellDevBiol. 2013;49:619–25. 
 
[411] R.Thadhani CACJ, M. J. Stampfer,G.C.Curhan,W. C.Willett, and E. B.Rimm, . 
Prospective study ofmoderate alcohol consumption and risk of hypertension in 
young women. Archives of Internal Medicine. 2002;162:569–74. 
 
[412] Woods A. Ca2+/calmodulin-dependent protein kinase kinase-β acts upstream 
 
of AMP-activated protein kinase in mammalian cells. cell press. 2005;2:21-33. 
 
[413] al SAe. The biochemistry of sirtuins. Annu Rev Biochem. 2006;75. 
 




NAD(+)? Pharmacol Rev. 2012;64:166–87. 
 
[415] Thompson KJ, John R. Humphries , David J. Niemeyer , David Sindram , and 
Iain H. McKillop. The Effect of Alcohol on Sirt1 Expression and Function in Animal 
and Human Models of Hepatocellular Carcinoma (HCC). In: al. VVe, editor. 
Switzerland: Springer International Publishing; 2015. p. 361-73. 
 
[416] Hardie D, Pan DA. Regulation of fatty acid synthesis and oxidation by the 
AMP-activated protein kinase. Biochem Soc Trans. 2002;30:1064-70. 
 
[417] Goldstein J, Brown MS. From fatty streak to fatty liver: 33 years of joint 
publications in the JCI. J Clin Invest. 2008;118:1220-2. 
 
[418] Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you 
should care, when you should worry, what you should do. Diabetes Metab Res 
Rev. 2011;27:419-24. 
 
[419] A. Woods JRW, P.J. Muckett, F.V. Mayer, M. Liljevald, Y. Bohlooly, et al. 
Liver-specific activation of AMPK prevents steatosis on a high-fructose diet. Cell 
Rep. 2017;18:3043-51. 
 
[420] Mark Benedict XZ. Non-alcoholic fatty liver disease: An expanded review. 
World J Hepatol Non-alcoholic fatty liver disease: An expanded review. 2017;9:715-
32. 
 
[421] Arab JP, Arrese M, Trauner M. Recent Insights into the Pathogenesis of 
Nonalcoholic Fatty Liver Disease. Annual review of pathology. 2018;13:321-50. 
 
[422] Marra F, Svegliati-Baroni G. . Lipotoxicity and the gut-liver axis in NASH 
pathogenesis. J Hepatol. 2018;68:280. 
 
[423] Donnelly K, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored 
in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. 
 
267 
J Clin Invest. 2005;115:1343. 
 
[424] Yucun Niu SL, Lixin Na, Rennan Feng, Liyan Liu, Ying Li, Changhao Sun. 
Mangiferin Decreases Plasma Free Fatty Acids through Promoting Its Catabolism 
in Liver by Activation of AMPK. PLoS ONE. 2012;7. 
 
[425] E.D. Muse SO, S. Bhanot, B.P. Monia, R.A. McKay, M.W. Rajala, P.E. 
Scherer, L. Rossetti. Role of resistin in diet-induced hepatic insulin resistance. J 
Clin Invest. 2004;114:232-9. 
 
[426] X. Yu SM, M. Wang, Y. Lee, J. Li, A.K. Saha, R.H. Unger, N.B. Ruderman. 
Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: 
prevention of diabetes and ectopic lipid deposition. Diabetologia. 2004;47:2012-21. 
 
[427] N.B. Ruderman DC, M. Prentki, J.M. Cacicedo. AMPK, insulin resistance, and 
the metabolic syndrome. J Clin Invest. 2013;123:2764-72. 
 
[428] Chakrabarti P, English, T., Karki, S., Qiang, L., Tao, R., Kim, J., Luo, Z., 
Farmer, S.R., Kandror,K.V. SIRT1 controls lipolysis in adipocytes via FOXO1-
mediated expression of ATGL. J Lipid Res. 2011;52:1693–701. 
 
[429] Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, et al. SIRT1 
regulates hepatocyte lipid metabolism through activating AMP-activated protein 
kinase. J Biol Chem. 2008;283:20015-26. 
 
[430] A. Purushotham TTS, Q. Xu, S. Surapureddi, X. Guo, X. Li. Hepatocyte-
specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic 
steatosis and inflammation. Cell Metab. 2009;9:327-38. 
 
[431] Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene 
defective in Peutz-Jeghers syndrome. Nature. 1998;391:184–7. 
 






[433] Shackelford D, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth 
control in tumour suppression. Nat Rev Cancer. 2009;9:563-75. 
 
[434] Bang S, Chen Y, Ahima RS, Kim SF. Convergence of IPMK and LKB1-AMPK 
Signaling Pathways on Metformin Action. Molecular Endocrinology. 2014;28:1186-
93. 
 
[435] Reuben JS, Katja A. Lamia, Debbie Vasquez, Seung-Hoi Koo, Nabeel 
Bardeesy, Ronald A. DePinho, Marc Montminy, and Lewis C. Cantley. The Kinase 
LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of 
Metformin. Science. 2005;310:1642–6. 
 
[436] Hawley SAB, J.; Reid, J.L.; Mustard, K.J.; Udd, L.; Makela, T.P.; Alessi, D.R.; 
Hardie, D.G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta 
and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase 
cascade. J Biol Chem. 2003;2:28. 
 
[437] Niu Y, Li, S., Na, L., Feng, R., Liu, L., Li, Y., Sun, C., . Mangiferin decreases 
plasma free fatty acids through promoting its catabolism in liver by activation of 
AMPK. PLoS One. 2012;7. 
 
[438] SMITH BW, AND LEON A .ADAMS. NON ALCOHOLIC FATY LIVER 
DISEASE. clinical laboratory sciences. 2011;48:97-113. 
 
[439] Glenn Simmons Jr. WMPaKP. Diverse Roles of SIRT1 in Cancer Biology and 
Lipid Metabolism. Int J Mol Sci. 2015;16:950-65. 
 
[440] Park E, Kim YM, Kim HJ, Jang SY, Oh MH, Lee DH, Chang KC. S)YS-51, a 
novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver 
disease in mice by suppressing lipogenesis, inflammation and coagulation. 
 
269 
European journal of pharmacology. 2016;788:200-9. 
 
[441] Doyle K, Bird,D,. Fatty acid ethyl esters are present in human serum after 
ethanol ingestion. Journal of Lipid Research. 1994;35:428–37. 
 
[442] Musso G, Gambino, R., Cassader, M. Recent insights into hepatic lipid 
metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 
2009;48:1–26. 
 
[443] Horton JD, Goldstein, J.L., Brown, M.S. SREBPs: activators of the complete 
program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 
2002;109:1125–31. 
 
[444] Emily AD. AMPK as a Therapeutic Target for Treating Metabolic Diseases. 
2017;28. 
 
[445] Garcia D, Shaw, R.J. AMPK: mechanisms of cellular energy sensing and 
restoration of metabolic balance. Mol Cell. 2017;66:789–800. 
 
[446] Evans A, Mustard KJ, Wyatt CN, Peers C, Dipp M, Kumar P, Kinnear NP, 
Hardie DG. Does AMP-activated protein kinase couple inhibition of mitochondrial 
oxidative phosphorylation by hypoxia to calcium signaling in O2-sensing cells? J 
Biol Chem. 2005;280:41504-11. 
 
[447] Hallows K, Kobinger GP, Wilson JM, Witters LA, Foskett JK. May; . 
Physiological modulation of CFTR activity by AMP-activated protein kinase in 
polarized T84 cells. Am J Physiol Cell Physiol. 2003;284:1297-308. 
 
[448] Viollet B. AMP-activated protein kinase in the regulation of hepatic energy 
metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf). 
2009;196:81–98. 
 





activated protein kinase in mechanism of metformin action. The Journal of clinical 
investigation. 2001;108:1167-74. 
 
[450] Lin CL, Huang HC, Lin JK. Theaflavins attenuate hepatic lipid accumulation 
through activating AMPK in human HepG2 cells. J Lipid Res. 2007;48:2334-43. 
 
[451] Ha et al. JH, S. Daniel, S.S. Broyles, K.H. Kim. Critical phosphorylation sites 
for acetyl-CoA carboxylase activity. J Biol Chem. 1994;269:22162-8. 
 
[452] Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates 
alcoholic fatty liver in mice. American journal of physiology Gastrointestinal and 
liver physiology. 2008;295:G833-G42. 
 
[453] Jose Cacicedo. NR, Yasuo IdoYasuo Ido. SIRT1 Modulation of the 
Acetylation Status, Cytosolic Localization, and Activity of LKB1. Journal of 
Biological Chemistry :. 2008;283:27628-35. 
 
[454] Walker AK. Conserved role of sirt1 orthologs in fasting-dependent inhibition of 
the lipid/cholesterol regulator srebp. Genes Dev. 2010;24:1403-17. 
 
[455] Nogueiras R, Habegger KM, Chaudhary N, Finan B, Banks AS, Dietrich MO, 
Horvath TL, Sinclair DA, Pfluger PT, Tschöp MH. Sirtuin 1 and sirtuin 3: 
physiological modulators of metabolism. Physiol Rev. 2012;92:1479-514. 
 
[456] Yoshino J, et al. . . Nicotinamide mononucleotide, a key NAD(+) 
intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. 
Cell Metab. 2011;14:528–36. 
 
[457] Kim H, et al. Metabolomic analysis of livers and serum from high-fat diet 
induced obese mice. J Proteome Res. 2011;10:722–31. 
 
[458] Min H, et al. Increased hepatic synthesis and dysregulation of cholesterol 





[459] Imai S, Armstrong CM, Kaeberlein M et al: . Transcriptional silencing and 
longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 
2000;403:795–800. 
 
[460] Smith J, Brachmann CB, Celic I et al. A phylogenetically conserved NAD+-
dependent protein deacetylase activity in the Sir2 protein family. Proceedings of the 
National Academy of Sciences of the United States of America. 2000;97:6658–63. 
 
[461] A. Schrivera LS-M, P. Ehrenfreundb, L. d’Hendecourtc. One possible origin of 
 
ethanol in interstellar medium: Photochemistry of mixed CO2–C2H6 films at 11 K. 
A FTIR study. Chemical Physics. 2007;334:128–37. 
 
[462] Yeung F, Hoberg JE, Ramsey CS et al. Modulation of NF-kappaBdependent 
transcription and cell survival by the SIRT1 deacetylase. The EMBO journal. 
2004;23:2369–80. 
 
[463] Ponugoti B. SIRT1 Deacetylates and Inhibits SREBP-1C Activity in 
Regulation of Hepatic Lipid Metabolism. THE JOURNAL OF BIOLOGICAL 
CHEMISTRY. 2010;285:33959 –70. 
 
[464] Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. 
Annu Rev Biochem. 2006;75:137-63. 
 
[465] Loomba RS, A.J. . The global NAFLD epidemic. Nat Rev Gastroenterol 
Hepatol. 2013;10:686–90. 
 
[466] Byrne CDT, G. NAFLD: A multisystem disease. J Hepatol. 2015;62:S47–S64. 
 
[467] Wieckowska AP, B.G.; Li, Z.; Lopez, R.; Zein, N.N.; Feldstein, A.E. Am. 
Increased hepatic and circulating interleukin-6 levels in human nonalcoholic 
steatohepatitis. J Gastroenterol Hepatol. 2008;103:1372–9. 
 
272 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
273 
